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SUMMARY 
This is a combined thesis submitted for MRes in Molecular and Cellular Biology.  
The first project is based on investigating the role of ligand flexibility in the binding of 
myristate to I-FABP. Myristate and palmitate bind the protein I-FABP with affinities orders 
of magnitude higher than similar sized less flexible ligands. This seems to contradict the 
medicinal chemistry textbooks where making a ligand less flexible is an accepted method for 
increasing binding affinity. Here computer simulations were used to investigate myristate 
flexibility and its free energy of binding to I-FABP, to see what role flexibility has in the 
recognition of myristate by I-FABP. 
The second project is based on studying the effect of the bacterial NDK proteins on 
haemapoietic stem cells. Leukaemia patients lack immunity; thus bacterial infections worsen 
leukaemia prognosis. It might be that bacterial invasion can affect leukaemia cells, by 
rendering the latter more aggressive, or even by stimulating cell proliferation. Bacterial and 
eukaryotic NDK proteins are highly conserved indicating that they may also be functionally 
similar. Previously it was shown that additional rNM23-H1 (human NDK protein) indirectly 
promotes leukaemia and healthy stem cell survival and proliferation. Here it was investigated 
if bacterial NDK proteins can show a similar effect. 
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Project 1: 
INVESTIGATING THE ROLE OF LIGAND FLEXIBILITY IN THE 
BINDING OF MYRISTATE TO I-FABP 
  
ABSTRACT 
 Myristate and palmitate bind the protein I-FABP with affinities orders of magnitude 
higher than similarly sized less flexible ligands. This seems to contradict the medicinal 
chemistry textbooks where making a ligand less flexible is an accepted method for increasing 
binding affinity. Here computer simulations were used to investigate myristate flexibility and 
its free energy of binding to I-FABP, to see what role flexibility has in the recognition of 
myristate by I-FABP. 
The difference in the binding free energy between palmitate and myristate on binding 
to I-FABP was calculated using thermodynamic integration. The calculated value of -8.8 
kJ/mol differs from the experimental value of approximately -1.5 kJ/mol. It is unclear whether 
this discrepancy represents a deficiency in the force field; too short a simulation time or 
indeed a problem with the experiment. However, the rough qualitative agreement suggests 
that it is still appropriate to use the system as a model to investigate whether flexibility is 
indeed detrimental for the binding of a myristate-type molecule to I-FABP. 
Further simulations show that, for most of the dihedral angles of myristate, there is a 
minimal change between the I-FABP bound and solution forms. However, there is a high 
increase in rigidity and changes in conformational preference, in the head group of myristate. 
An increase of the flexibility at 6
th
 dihedral is also seen. These results will form the basis for 
investigating the effect of conformationally restricting myristate on its binding to I-FABP in 
silico. 
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1 INTRODUCTION 
The text book view of ligand-protein interactions is that rigid ligands lose less entropy 
whilst binding to a protein than flexible ligands do. Since the loss of entropy is related to the 
strength of the binding, then rigid ligands that lose less entropy are expected to bind to 
proteins in a stronger way than flexible ligands all else being equal (Murray and Verdonk, 
2002, Chang et al., 2007, Searle and Williams, 1992, Mann, 2008). Thus, more flexible ligand 
should have a weaker affinity for the target protein. Nevertheless, flexible fatty acids (FA) 
showed a strong affinity for fatty acid binding proteins (FABPs). It has been reported that 
myristate and palmitate binding constants (Ki) to intestinal-FABP (I-FABP) are 0.041 and 
0.024 µM, but the Ki of more rigid ligands, e.g. nitrazepam and bezafibrate are 2000 and 33 
µM (Velkov et al., 2007). A smaller value of Ki indicates stronger ligand-protein interaction, 
thus, the binding strength to I-FABP can be ranked as: nitrazepam < bezafibrate < myristate < 
palmitate.  
 Based on the common dogma a suitable strategy for drug development is a restriction 
of conformational flexibility (Mann, 2008). Thus, the strong binding of flexible FA to FABPs 
is perplexing and suggests that both the common dogma and the binding of palmitate and 
myristate to FABPs are worthy of further consideration. 
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1.1 FLEXIBILITY AND ENTROPY 
1.1.1 Flexibility 
Molecule flexibility is defined by a molecule‟s ability to adopt a number of different 
shapes or conformations. High molecular movements over time describe very flexible 
molecules, while molecules restricted in intra-molecular movements are rigid. Molecular 
motions can be distinguished into translational, rotational and vibrational motions (Bender, 
2003).  
Translational movement of molecules occurs as a whole molecule movement which 
results in a change of position, in a space (Figure 1.1 (a)). Thus, translational molecular 
movements do not contribute to molecule flexibility. Nevertheless, restriction of translational 
motion does cause a loss of entropy (Murray and Verdonk, 2002). 
Molecular rotation is the rotation of the whole molecule around the principal axis of the 
molecule (Figure 1.1 (b)). It does not have any contribution to the molecular flexibility 
whereas intra-molecular motions cause the biggest conformational change. Intra molecular 
rotations in an atom occur when four or more atoms are joined to each other linearly in the 
molecule, e.g. A-B-C-D, the B-C bond forms an axis of rotation, and there is a circular 
movement of atom D and A bond B-C (Figure 1.1 (c)). Thus, the bond B-C is referred to as a 
rotational bond. 
Intra-molecular rotations in a molecule occur freely if the rotatable bond is single. 
When atom B and C are joined by a double bond movement of atom D is limited. If any 
external force induces movement of atom D, the double bond between atom B and C breaks 
(Housecroft and Constable, 2006). An increase in the number of rotatable bonds in a molecule 
increases the overall motions available to that molecule, i.e. - it becomes more flexible. 
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Vibrational motions consist of bond stretching, angle bending, rocking and libration 
(Figure 1.1 (d)). Vibrational movements occur as small movements of the atoms in the 
molecule, they thus have a small contribution to a molecule‟s conformational change and 
flexibility. Bond stretching is based on atomic vibration, which causes a change of the bond 
length during the interaction between two joined atoms. Vibrational motions of a bond occur 
at low amplitude since larger atomic motions cause the bond to break. Larger motions are 
observed for angle bending. When a molecule consists of three atoms, which are joined to 
each other, e.g. A-B-C, the angle bending occurs as the A and C atoms move toward and 
away from each other (Leach, 2001). Rocking, which is also called asymmetric stretching, is 
when at the same time atom A moves from atom B atom C moves towards atom B and vice 
versa (Housecroft and Constable, 2006). Librations occur as motions in atoms A and C, where 
they oscillate slightly backwards and forwards around the x, y or z axes. 
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(a) 
Translational motions 
 
(b) (c) 
Rotational motions Intra-molecular rotations 
 
 
(d) 
Vibrational motion 
 
 
Figure 1.1 Molecular motions (a) Translational motion, where molecule A-B-C-D move 
from one place in a space to another one (b) Rotational motion around the principal axis of the 
molecule (c) intra-molecular rotations: rotation of atom D around the axis formed by the bond 
B-C (d) Vibrational motions: bond stretching, angle bending, rocking and librating. 
(reproduced from Leach, 1996, Chaplin, 2010) 
 
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 15 of 190 
 
1.1.2 Entropy and flexibility 
Changes in dihedral angles, via rotation of atoms around single bonds, allow structural 
changes in a molecule. Moreover, high structural changes of molecules are characterized by 
their flexibility. Therefore, the number of rotatable bonds in a molecule contribute to the 
entropy change in different processes such as molecular association in solutions and fusion 
(Searle and Williams, 1992) as well as ligand-protein interactions (Searle and Williams, 1992, 
Murray and Verdonk, 2002, Chang et al., 2007).  
During fusion of n-alkanes, n-alkyl carboxylic acids and n-alkyl methyl ketones an 
increase in the number of rotatable bonds increases the fusion entropy of these poly-organic 
compounds. For instance, data for odd n-alkanes fit with the equation ΔS = 15.5 +1.6n (where 
n is the number of rotatable bonds) whereas even n-alkanes fit with the equation ΔS = 10.2 
+3.5n (Searle and Williams, 1992). Therefore, the gain in flexibility contributes to the gain in 
entropy during fusion of poly-organic compounds. Thus, flexible ligands have more entropy 
to lose while binding to a protein. 
1.1.1.1 Ligand flexibility and entropy 
Pharmaceutical drugs act as ligands. They bind to a protein and inhibit or activate cell 
signaling pathways with the aim to cure, treat or prevent a disease. A pharmaceutical drug 
with a low binding affinity to a target protein may be replaced by a competing ligand (Nelson 
and Cox, 2000). Thus, strong protein and ligand binding is relevant in drug design. Therefore, 
drug discovery studies are based on increasing the ligand binding affinity. Ligand binding 
affinity can be improved by making the enthalpy change more negative, the entropy change 
more positive or by a combination of both (Velazquez-Campoy 2001).  
Our project is to investigate why flexible FAs bind strongly to I-FABP. A molecule‟s 
flexibility is based on its ability to adopt a number of conformations. Thus, we are interested 
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in the relation between the conformational entropy change and ligand flexibility. The entropy 
change is based on the changes in solvation entropy and conformational entropy. Thus, an 
increase in the entropy of binding can be provided by an increase in the ligand hydrophobicity 
as well by altering ligand geometry with the aim to minimize the loss of conformational 
entropy upon binding (Velazquez-Campoy 2001). 
Chang et al (2007) studied the relation between the entropy change (-T∆S) and ligand 
flexibility in amprenavir binding to Human immunodeficiency virus (HIV) protease. 
Amprenavir is a flexible ligand and whilst binding to a HIV protease it loses configurational 
entropy (-T∆Sconfig = 26.4 kcal/mol). This loss of entropy is based on the loss of vibrational 
entropy (-T∆Svib = 24.6 kcal/mol) while the loss of conformational entropy (-T∆Sconf) is only 
1.8 kcal/mol. Vibrational entropy includes the entropy associated with rotation and translation 
in space and the motions associated with torsional degrees of freedom, which provides almost 
as much entropy change as the rotation and translational changes while change of 
conformational entropy depends on the number of the stable conformers. 
Chang et al (2007) also calculated the loss of entropy while restricting amprenavir 
bond length and angles. By restricting bond length only the loss of the entropy stayed 
unchanged (-T∆Sconfig = 26.3 kcal/mol) whilst by fixing all bond angles caused it to drop 
down to 24.7 kcal/mol. Conformational restriction of HIV protease strongly affect the loss of 
conformational entropy. The decrease in the loss of total entropy is due the decrease of the 
loss of conformational entropy.   
The common dogma states that rigid ligands that lose less entropy are expected to bind 
to proteins in a stronger way than flexible ligands all else being equal. Thus, ligand binding 
affinity to a protein could be improved by an introduction of the rigidity in the ligand. The 
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introduced rigidity in HIV amprenavir more likely affects the loss of conformational entropy 
not the loss of vibrational entropy. 
It might be that flexible FA loses a negligible amount of conformational and torsional 
entropy upon binding to a FABP. Thus, there is not a large change in the loss of 
conformational entropy between free and artificially restricted FA upon binding to FABP. 
This is what shall be investigated here.  
1.1.1.2 Protein flexibility and entropy 
Proteins are dynamic macromolecules. They may unfold, fold, bind and dissociate 
from a ligand. Entropy change accompanies all of these dynamic processes. Protein and 
ligand binding is usually associated with the loss of their motions. Nevertheless, the complex 
formed may allow for new vibrational modes within it (Boehr et al., 2006). For example the 
dynamics of the ligand-protein topoisomerase I complex are higher than it is for free protein 
(Yu et al., 1996, Boehr et al., 2006). Protein dynamics can stay unchanged as observed in the 
binding of R-lytic protease (Davis and Agard, 1998, Boehr et al., 2006).  
Flexible proteins such as ion channels, nuclear hormones and transporters are able to 
bind a variety of ligands. Thus, protein flexibility may be essential for their functions. 
Moreover, reviewing data about protein and ligand complexes it was found that structurally 
different ligands may bind the same protein in different conformations, e.g. for drug-like 
molecule binding to therapeutically important receptors (Teague, 2003). 
 Flexibility in a protein not only allows the ability to bind a variety of ligands at 
different protein sites, but additionally a protein may be flexible at a binding site. For 
instance, HIV reverse transcriptase can be inhibited by structurally different ligands 
Efavirenz, Nevirapine, UC-781 and Cl-TIBO binding at the same site (Ren et.al, 2000). The 
structure of these ligands is presented in figure 1.2. Thus, it might be that flexibility of a 
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protein is crucial for the strong binding of a rigid ligand, while flexible ligands may better 
adapted for the binding to a rigid protein that do not have the right conformation. 
The hydrogen-bonding network in ileal lipid binding protein (ILBP) is weaker than in 
FABPs indicating that ILBP is more flexible. This unusual flexibility of ILBP allows for the 
binding of the large and rigid bile acid (Lucke et al., 1996). Chemical shifts of protons in the 
ligand and protein complex caused by FA and the more rigid chenodeoxycholic acid binding 
with ILBP were observed using nuclear magnetic resonance (NMR) spectrometry  
A 14% difference in proton chemical shifts was observed when chenodeoxycholic acid 
binds to the protein, but for FA upon its binding to the protein it was just 1%. Bigger chemical 
shifts observed for the chenodeoxycholic acid binding to ILBP may be due to a 
conformational change or due to the presence of ligand atoms next to the protein (Lucke et al., 
1996). Although, the greater interaction between ILBP and chenodeoxycholic acid was 
reported, there was no information on whether it causes stronger binding. However, it might 
be that due to flexibility proteins are likely to bind rigid ligands more strongly than flexible 
ones. 
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Figure 1.2 Structures of ligands able bind to HIV reverse transcriptase at the same 
binding site (reproduced from Ren et.al, 2000). 
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1.2 THE ROLE OF FLEXIBILITY IN THE THERMODYNAMICS OF LIGAND 
AND PROTEIN INTERACTIONS 
1.2.1 Evidence supporting ligand flexibility being detrimental to ligand-protein 
interactions 
Common dogma states that rigid ligands bind more strongly to a protein than a 
flexible ligand does. The flexibility of a ligand can be determined by the number of rotatable 
bonds per molecule. Therefore, common dogma emphasizes the importance of rotatable bonds 
in the control of ligand binding affinity, and this is reflected in Medicinal chemistry text 
books e.g., (Mann, 2008). Mann (2008) reports about the introduction of rigidity in such 
ligands as phenylalanine, histamine and milnacipran analogs, and discussed many examples, 
where an increase of ligand rigidity by the removal of rotatable bonds, contributes to an 
increase in binding affinity of ligands. An example is given in figure 1.3. The restriction of 
compound 1 at the benzyl position increases its rigidity, thereby the newly formed compound 
2 has a higher affinity for the Bradykinin receptor B1 (B-B1). The Ki of compounds 1 and 2 
are 520 nM and 380 nM, respectively. Another example is the increasing of rigidity in 
compound 3 to become compound 4 and subsequently compound 5, where the Ki for binding 
to B-B1 is 382 nM, 0.24 nM and 0.77 nM, respectively (Figure 1.3). Therefore, compounds 4 
and 5 have a greater affinity for B-B1 than does compound 3 (Mann, 2008).  
The removal of rotatable bonds often occurs via the introduction of one or more extra 
heavy atoms (non-hydrogen). The increase in heavy atoms of a ligand up to 15 increases the 
free binding energy by on average 1.5 kcal/mol (6.3 kJ/mol) per heavy atom (Kuntz et al., 
1999), increasing the binding affinity of the ligand. The addition of an extra heavy atom in the 
large ligands (> 15 heavy atoms) gives a small increase in free binding energy. Therefore, it is 
not clear if the improved affinity of a compound with restricted torsions is due to extra heavy 
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atoms added to restrict the torsions, or due to the decreased flexibility. Ligand efficiency is 
the free binding energy per heavy atom (Abad-Zapatero, 2007), thus comparing the ligand 
efficiency of different ligands provides a way to control for the variation in the number of 
heavy atoms.  
Binding free energy is calculated using the formula: ∆G=RTlnKi, where R is the 
universal gas constant, T is the temperature and Ki is the inhibitory constant, a measure of 
binding affinity. Ligand efficiency is obtained by dividing the calculated ∆G value by the 
number of heavy atoms. Binding free energy increases with each heavy atom introduced in a 
molecule. Thus, similar ligand efficiencies would mean that ligands bind stronger due to 
heavy atom introduction. While a higher value of ligand efficiency would indicate that an 
increase in ligand binding affinity is not likely to be just due to the introduction of a heavy 
atom, but to some other effect such as the molecule becoming more rigid as well.  
The number of rotatable bonds is decreased by 2 when compound 1 is restricted to 
form compound 2. Nevertheless, compounds 1 and 2 have similar ligand efficiencies 1.24 
kJ/mol and 1.20 kJ/mol, respectively (Figure 1.3). Although, the decrease in the binding 
constant supports the dogma when compound 1 becomes restricted to form compound 2, 
compound 2 may bind more strongly to B-B1 due to an increase in heavy atoms in the 
molecule, not due to the increase in rigidity. Ligand efficiencies for compound 4 and 5 are 
approximately 1.2 times greater than it is for compound 3 (Figure 1.3). Therefore, stronger 
binding of 4 and 5 to B-B1 is likely to be due to the reduction in the number of rotatable 
bonds.  
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Figure 1.3 Drug design making ligands more rigid by the introduction of extra bonds (a) 
Design of new Bradykinin ligands. (b) Calculated Bradykinin ligand efficiencies (Ligand 
structures are reproduced and Ki values are taken from Mann, 2008). 
  
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 23 of 190 
 
A fragment-based drug discovery approach was introduced in the mid-1990s. 
However the technique first time was described earlier by Page and Jenks (1971). This 
technique is based on the joining two fragments which have an affinity to bind a protein in 
different but adjacent binding sites. Two fragment joining result in entropy gain because when 
joined fragment binds to a protein it loses less entropy than individual fragments do. Thus, it 
was reported that the affinity of the joined fragment will usually be greater than the sum of 
two fragment affinities (Murray and Verdonk, 2002). An example is given in figure 1.4; 
compounds 6 and 7 are joined to form compound 8, while compounds 9 and 10 are joined to 
form compound 11. The Ki of joined compounds 8 and 11 is much greater than it is for the 
individual fragments. 
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Compound 6 75 17000 -9.92 5 1.98 2 0.40 
Compound 7 195 20 -26.34 15 1.76 2 0.13 
Compound 8 282 0.025 -42.62 21 22.03 6 0.29 
Compound 9 100 34 -25.05 7 3.58 0 0.00 
Compound 10 116 260 -20.10 8 2.51 4 0.50 
Compound 11 214 0.00000041 -69.45 15 4.63 6 0.40 
 
Figure 1.4 Drug design making ligands more rigid by joining two fragments together (a) 
Joining compound 6 and 7 is formed new ligand – compound 8. Compound 6, 7 and 8 binds 
to stromelysin. (b) Joining compound 9 and 10 is formed new ligand – compound 11. 
Compound 9, 10 and 11 binds to avidin. (c) Calculated ligand efficiencies. (Ligand structures 
are reproduced and Ki are taken from Murray and Verdonk, 2002) 
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1.2.2 Ligand flexibility may be favorable  
Ligand conformational restriction is a basic principle in drug-design. Nevertheless, it 
was reported that ligand flexibility may be favorable as flexible ligand can adapt and bind to 
mutated proteins.  
Protein mutation can cause binding site conformational changes making a protein 
become drug resistant (Cai and Schiffer, 2010). Thus, a mutated protein may not bind a rigid 
ligand that has a high affinity for the wild type protein (Velazquez-Campoy et al., 2001). 
Moreover, multiple mutations often affect the binding of ligands even when the mutations are 
distant from the binding site (Lassila, 2010, Genoni et al., 2010). Therefore, flexible ligands 
are thought to be more favorable as they are able to adapt their conformation so as to bind the 
mutated protein. As an example, KNI-272 has a high affinity for HIV-1 protease. The Ki is 16 
pM. Since KNI-272 is rigid, it is not able to adapt to the protein mutation and the binding 
affinity to the HIV-1 protease mutant V82F/I84V is 550 times smaller. Flexible KNI-764 
ligand has a slightly lower affinity than KNI-272 for HIV-1 protease; the Ki is 36 pM. Due to 
its flexibility it can adapt to the conformational change in the binding site of mutant 
V82F/I84V. The affinity of ligand KNI-764 for V82F/I84V is decreased just 26 times 
(Velazquez-Campoy et al., 2001). KNI-272 and KNI-764 structures are represented in figure 
1.5.  
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Figure 1.5 Structures of ligands able bind to HIV-1 protease (reproduced from Velazquez-
Campoy et al., 2001). 
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1.2.3 Evidence for exceptions, where flexible ligands bind stronger to a protein than 
rigid and larger ligands do 
Common dogma states that larger and more rigid ligands bind more strongly to a 
protein. The evidence supporting the dogma described above showed that it is enough to make 
a ligand larger or more rigid to increase its binding affinity. Thus, drug-design is based on the 
introduction of extra rigidity. Nevertheless, in review Teague (2003) reported that there are a 
large number of flexible ligands used as drugs. For example, flexible zopolrestat and tolrestat 
bind to aldose reductase, while flexible tamoxifen and raloxifen bind to oestrogen receptor. 
It was experimentally determined that flexible FAs bind stronger to I-FABP than 
larger and more rigid ligands do (Velkov et al., 2005, Velkov et al., 2007). The Ki for 
palmitate and myristate are ≥ 1000 times higher than Ki of rigid nitrazepam and bezafibrate. 
Calculated ligand efficiencies for palmitate, myristate, nitrazepam and bezafibrate bound to I-
FABP show that flexible FAs have higher ligand efficiency as well as the count of rotatable 
bonds per heavy atom. Thus, it might be that flexibility of FA is relevant for strong binding to 
I-FABP and it is an exception to the common dogma. 
Palmitate differs from myristate by two extra heavy atoms. Thus, it has extra rotatable 
bonds and is more flexible than myristate. Ki values indicate that flexible palmitate binds 
more strongly to I-FABP than myristate. Nevertheless, the calculated ligand efficiencies show 
that the two additional heavy atoms decrease the free binding energy per heavy atom. 
Therefore, the two additional heavy atoms are likely to be the reason for the palmitate 
stronger binding to I-FABP, not increase in flexibility.  
Another example is the strong binding of oleate to liver-FABP (L-FABP) (Chuang et 
al., 2008). The difference between Ki values for oleate and the more rigid and larger ligands is 
not as significant as it was in the case of myristate and palmitate binding to I-FABP. For 
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example, the Kis of oleate, ibuprofen and fenofibric acid are 0.18 µM, 47.6 µM and 0.334 
µM, respectively.  
Intriguingly there are larger and more rigid ligands that bind to L-FABP stronger than 
oleate. They are progesterone and fenofibrate, whose structures are represented in figure 1.6. 
The calculated ligand efficiencies for oleate, progesterone and fenofibrate are very similar 
while the count of rotatable bonds in oleate is much bigger (Figure 1.7).  
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Figure 1.6 Structures of ligands (reproduced from Chuang et al., 2008). 
 
  
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 30 of 190 
 
 
(a) 
L
ig
a
n
d
 
K
i, 
µ
M
 
∆
G
, 
k
J
/m
o
l 
T
h
e
 c
o
u
n
t 
 
o
f 
h
e
a
v
y
 a
to
m
s 
L
ig
a
n
d
 e
ff
ic
ie
n
c
y
 
 (
G
/t
h
e
 c
o
u
n
t 
o
f 
 
h
e
a
v
y
 a
to
m
s)
, 
k
J
/m
o
l 
T
h
e
 c
o
u
n
t 
o
f 
r
o
ta
ta
b
le
 b
o
n
d
s 
T
h
e
 c
o
u
n
t 
o
f 
R
o
ta
ta
b
le
 
b
o
n
d
s/
th
e
 c
o
u
n
t 
o
f 
h
e
a
v
y
 a
to
m
s 
Nitrazepam 2000 -15.13 21 0.72 2 0.10 
Bezafibrate 33 -25.13 25 1.01 8 0.32 
Myristate 0.041 -41.42 16 2.59 12 0.75 
Palmitate 0.024 -42.72 18 2.37 14 0.78 
 
 
(b) 
L
ig
a
n
d
 
K
i, 
µ
M
 
∆
G
, 
k
J
/m
o
l 
T
h
e
 c
o
u
n
t 
 
o
f 
h
e
a
v
y
 a
to
m
s 
L
ig
a
n
d
 e
ff
ic
ie
n
c
y
 
 (
G
/t
h
e
 c
o
u
n
t 
o
f 
 
h
e
a
v
y
 a
to
m
s)
, 
k
J
/m
o
l 
T
h
e
 c
o
u
n
t 
o
f 
r
o
ta
ta
b
le
 b
o
n
d
s 
T
h
e
 c
o
u
n
t 
o
f 
R
o
ta
ta
b
le
 
b
o
n
d
s/
th
e
 c
o
u
n
t 
o
f 
h
e
a
v
y
 a
to
m
s 
Oleate 0.18 -37.82 20 1.89 15 0.75 
Progesterone 0.027 -42.43 23 1.84 1 0.04 
Fenofibrate 0.024 -42.72 25 1.71 7 0.28 
Fenofibric acid 0.334 -24.23 22 1.15 5 0.23 
Ibuprofen 47.6 -36.31 21 1.65 3 0.14 
 
Figure 1.7 Ligand efficiency (a) Calculated ligand efficiency, when they bind to I-FABP. (b) 
Calculated ligand efficiency, when they bind to L-FABP (Ki are taken from Velkov et al, 
2007, Chuang et al, 2008). 
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1.3 I-FABP: A MODEL SYSTEM FOR EXPLORING THE ROLE OF 
FLEXIBILITY IN LIGAND BINDING 
Common dogma states that rigid ligands have a higher affinity when binding to a 
protein, due to a smaller loss of entropy. Calculated efficiencies for Bradykinin ligands show 
that increase in ligand binding affinity may be due to the increase in the number of heavy 
atoms. Thus, it is questionable if the ligands‟ strong binding is due to their rigidity. Moreover, 
some flexible ligands appear to bind to protein more strongly than rigid ligands, something 
seen in the I-FABP system. Therefore, it is relevant to investigate the role of ligand flexibility 
during the binding of flexible FAs to I-FABP.  
FAs are small size (150-450 Da) structural components of the cell‟s phospholipid 
membrane and undertake an important part in the cell‟s metabolic processes. Nevertheless, 
the presence of free FAs in the cytoplasm is unwanted due to their detergent-like properties 
(Tsfadia et al., 2007, Levin et al., 2010, Levin et al., 2009, Friedman et al., 2006, Woolf and 
Tychko, 1998). Therefore, efficient transfer of free FAs in the cytoplasm to the cell‟s 
structural elements is needed. This is performed by FABPs, which have a high affinity to bind 
FAs. FABPs are classified by their tissue of origin, e.g. I-FABP, L-FABP and muscle-FABP 
(M-FABP) (Friedman et al., 2006, Levin et al., 2009, Tsfadia et al., 2007, Velkov et al., 
2005). 
The most important finding is to be stressed here is that FAs such as myristate and 
palmitate bind more strongly to I-FABPs than more rigid ligands do (Velkov et al., 2005).  
This observation is opposite to the dogma. Palmitate is more flexible than myristate, due to its 
higher number of rotatable bonds. However, the calculated ligand efficiencies show that the 
stronger binding of palmitate is due to the increase in the number of heavy atoms. Thus, it 
seems that flexibility of FA is neither advantage nor disadvantage for their strong binding to 
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 32 of 190 
 
FABP. Therefore, it is questionable what kind of role plays FA flexibility in their strong 
binding to I-FABP. 
The effect of ligand flexibility whilst binding to proteins can be determined by an 
investigation of myristate binding to I-FABP by computational modeling of the binding. As 
flexibility is related to the conformational change of a molecule, it is important to observe 
conformational contribution of myristate while binding to I-FABP. It could be true that 
common dogma does not have any exemptions and the strong binding of flexible FAs to 
FABPs is putative. On the other, hand it could be that ligand flexibility is somehow critical 
for binding. 
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1.4 COMPUTATIONAL APPROACH 
Computationally it is possible to change parameters that define the flexibility of a 
molecule without changing the number of heavy atoms or its geometry. A computational 
approach requires the choice of an appropriate force field, one that demonstrates the 
appropriate behavior for the bind of myristate to I-FABP (i.e. similar to the known 
experimental behavior of the system). To determine if the force field is correctly chosen, a 
calculation of the difference between the ∆G of myristate and palmitate (∆∆G) on binding to 
I-FABP can be made and compared to experiment. Further, the conformational preference of 
myristate in solution and bound to I-FABP can be calculated by molecular dynamic (MD) 
simulations. This allows the determination of which myristate rotatable bonds become 
restricted when it binds to I-FABP. Furthermore, by calculating ∆∆G both when myristate is 
flexible and artificially rigid, the effect of flexibility on the binding energy can be quantified.  
1.4.1 Force fields and molecular dynamics 
Molecular dynamic simulation is the computational simulation of atom and molecule 
movements (Alder and Wainwright, 1959). Various protein motions occur over a broad 
timescale (Figure 1.8) (Boehr et al., 2006).. The time to simulate these motions can last from 
hours to several years. For example, whilst simulating ligand and protein binding, it is 
important to take into account the timescale of the molecule‟s vibrational motions (in 
picoseconds (ps) and nanoseconds (ns) time) and larger configurational changes (in 
microseconds (µs) and milliseconds (ms) time). Protein simulations of timescales of µs 
unusual but becoming more common and ms simulations are not currently practical for 
anything but short peptides. According to the computational time used for our project to 
simulate 1 µs of ligand motions on an eight core processor in real time is the equivalent of 0.5 
years, whilst ligand and protein interactions will take around a year of computational time. 
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Nevertheless, MD simulations can be performed for a short computational time and 
subsequently extended in length to check for convergence of the simulated motions or 
thermodynamic properties, e.g. an initial simulation of 10 ns, with the behavior observed in 
this simulation confirmed by extension of the simulation to 20 ns, 50 ns etc... 
To perform MD, a topology, a co-ordinate and a simulation input file are needed. The 
topology file contains information about the atom connectivity in a molecule, their potential 
energy and the interaction forces. The potential energy and interaction forces are defined by 
the force field. The co-ordinate file defines the initial atom positions. It will include the 
position of the solvent atoms if they are present in the system. The simulation input file 
defines simulation parameters such as temperature and pressure. Following minimization of 
the energy of the initial coordinates, to remove high energy strains from the system and an 
initial equilibration only then is the simulation system ready for productive MD. Energy 
minimization allows for the initial structure to adjust to the constrains of the force field, but 
equilibration equilibrates kinetic and potential energies through the simulation system.  
In a molecular modeling context a force field is a mathematical function, which 
evaluates the potential energy of the atoms in the system. Force fields for computational 
simulations are derived from quantum mechanical calculations and from experimental data. 
Based on the required representation and an available amount of computational time, force 
fields can be divided into three categories. Firstly, “all atom” force fields, where energetic 
interactions are represented for all atoms. Secondly, “united atom” force fields, where all 
atoms in a terminal methyl group are represented in the force field as if they were one atom. 
Thirdly, “coarse grained” force fields that provide a much cruder representations, e.g. an 
amino acid represented by a spherical particle for the backbone and a spherical particle for the 
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side chain (Ponder and Case, 2003). Moreover, by simplifying the contribution of some atoms 
this makes the computation of system‟s energy less time-consuming.  
The first force fields for the study of macromolecule dynamics were developed and 
designated as AMBER (Cornell et al., 1995), CHARMM (Brooks et al., 1983) and GROMOS 
(Scott et al., 1999). AMBER force field was originally developed for protein and DNA study. 
CHARMM, besides being used in macromolecule research, was also developed in small 
molecule research. However, GROMOS is used for the study of biomolecular systems and 
has two versions – A and B. The A version is intended for the simulation of aqueous or apolar 
solutions of proteins, nucleotides and sugars. The B version is intended for the simulation of 
isolated molecules in their gas phase. Besides these three, there are many more varieties of 
force field with varied applications, i.e. more or less specific (Ponder and Case, 2003).  
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Figure 1.8 Timescale of typical protein motions A – bond vibration and B – surface side chain rotations (reproduced from Boehr et al., 
2006).
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1.4.2 Calculation of binding free energy  
The calculation of free energy is based on the thermodynamic cycle of the binding of 
proteins and ligands. Computationally we calculate the conversion for the solvated free ligand 
X into the solvated free ligand Y and for the conversion of ligand X into ligand Y while they 
are bound to the solvated protein P. Water is usually used as a solvent for these simulations. 
Computational mutation of the ligand gives two changes of free energy, which are calculated 
for the unbound state (ΔGU) and for the bound state (ΔGB). The difference in free energy of 
the ligands (ΔΔGbind) is calculated by the formula shown in figure 1.9 (Michel et al., 2010). 
For free energy computational calculations, several methods have been presented: free 
energy perturbation (FEP), thermodynamic integration (TI), linear interaction energy (LIE), 
molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) and molecular mechanics 
generalized Born surface area (MM-GBSA) (reviewed in Michel et al., 2010, Hayes et al., 
2012). Considering about which method to use there is a need to make a choice between 
expenses and accuracy. Such methods as LIE, MM-PBSA and MM-GBSA were reported as 
trade-off and are successfully used. FEP and TI calculation methods are most accurate of 
these methods, although they are time consuming. Of these two TI has the advantage that it is 
easier to parallelize since, as described below, each lambda point used in the calculation is 
completely independent of every other lambda point. 
The computational approach of FEP allows the calculation of the potential energy 
difference UY - UX between two complexes during the conversion of the ligand X into the 
ligand Y. The conversion in the ligands is maintained throughout one or more intermediate 
states defined by a coupling parameter λ. The coupling parameter λ is used for the acquisition 
of free energy from intermediate states. Therefore, λ = 0 represents the ligand X, but λ = 1 
represents the ligand Y. When λ is any value between 0 and 1, it represents an intermediate 
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state of ligand X changing to ligand Y (Michel et al., 2010). A simplified model is present in 
figure 1.9 (b). Stars X and Y represent two structurally different ligands. Those differences 
are illustrated by color changes in the figure. Therefore, stars A to F represent intermediate 
states in the ligand X mutation to Y. Moreover, those intermediate states do not represent any 
different molecule. Depending on λ value, they illustrate whether they are structurally more 
similar to ligand X or Y, but their structure does not have any real physical meaning in the 
calculation of binding free energy. The ΔG calculation is more accurate when a higher 
number of chosen intermediate states are used. Each state gives free energy ΔG, which is an 
averaged value of Uλ-Uλ-1 (where λ – 1 denotes the lambda value before the one under 
consideration) over numerous snapshots for given lambda value). The total value of all ΔG 
gives ΔGB. 
TI has a similar principle for calculating free energy ΔGB, using the intermediate 
states. However, this method integrates the derivate of the potential energy for with respect to 
lambda point in the conversion of the ligand X into Y using equation: 
    ∫ 〈
     
  
〉   
 
 
 
In the equation ΔGB is the total free energy during ligand X conversion into Y for the 
ligand-protein complex, where 〈
     
  
〉  is the ensemble average in the ensemble 
corresponding to U(λ) (formula is adapted from Steinbrecher et al, 2007). TI has the 
advantage over FEP that it is easy to add additional lambda points, since the derivative 
depends only on the lambda value at hand, not on the preceding lambda value, which is the 
case in FEP. 
 FEP and TI are limited in usage due to ligand X cannot be converted into any different 
ligand Y. The ligands need to have similar structures to each other. The most accurate results 
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are obtained when X and Y ligands have small differences, of particular concern is that the 
ligands‟ difference in shape and size can cause different preferred locations at the binding site, 
which would represent very large perturbations to the system. FEP and TI give highly 
accurate results; however obtained results may differ from the experimental data (Michel et 
al., 2010, Steinbrecher et al., 2007, Cai and Schiffer, Michel et al., 2010). This can be 
overcome by altering the force field. 
When investigating the gain or loss of atoms TIs are performed as a three-step 
simulation. In the first, the charge removal from the atoms to be lost is simulated. In the 
second the chosen atoms are transformed, so the ligand X became ligand Y. In the last step 
the new charge is added to the newly formed atoms. This three step procedure avoids the 
possibility that as the van der Waals forces are decreased with lambda, the charges on the 
atoms may become unrealistically close leading to excessively high interaction energies and 
thus problems with the simulation. 
  
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 40 of 190 
 
(a) 
  
 
(b) 
 
 
 
Figure 1.9 TI and free binding energy calculation (a) TI cycle to compute free energies of 
binding. P is a protein, X and Y are two different ligands, ∆GU and ∆GB are free binding 
energies for mutation of ligand at unbound and bound state, respectively. ∆Gbind(X) and 
∆Gbind(Y) are free binding energies for ligand X and Y binding to a protein. ∆∆Gbind is the 
difference between ligand Y and X free binding energy. (b) Representative figure of λ value 
meaning. X and Y are ligands, A, B, C, D, E are intermediate states between ligand X and Y. 
Color difference between two stars identify how different or similar are two intermediate 
states between each other or from ligand X and Y. (Figures are reproduced from Michel et al, 
2010). 
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1.4.3 Clustering  
The conformational states of myristate can be observed by molecular dynamics (MD) 
simulations, which “produce trajectories of atomic positions (and optionally velocities and 
energy) as a function of time” (Shao et al., 2007). Data-mining techniques such as clustering 
sorts and groups the data enclosed in MD trajectories into similar clusters allowing investigate 
the preferable molecule‟s conformations. 
 There exist a couple of different clustering methods. Shao et al (2007) tested and 
compared clustering algorithms for single-stranded DNA molecules or DNA hairpin 
interactions with the minor groove binding drug DB226. The clustering algorithms tested 
include hierarchical, single-linkage edge joining, centroid-linkage, average-linkage, complete-
linkage, centripetal and centripetal-complete, means, Bayesian, self-organizing maps and tree 
(COBWEB). The authors refer to each algorithm as having its own unique clustering abilities 
and none of the algorithms presented all possible abilities. Moreover, each algorithm is based 
on a comparison of different sets of results for the same molecule, but at different simulation 
times. Each algorithm has a different way of comparing the molecule. Therefore, each one 
gives varied result clusters. Shao et al (2007) found that grouping DNA molecules into 5 
clusters to be the best for the observation of conformational change of DNA molecules, due to 
tendency to form single molecule clusters when molecules are grouped into > 5 clusters.  
 The average-linkage and hierarchical algorithms have an advantage as they can be 
used when the number of clusters required is not known. However, the hierarchical algorithm 
is highly sensitive to outliers and the average-linkage algorithm tends to produce small 
clusters. This tendency for the average-linkage algorithm can be minimized by performing 
clustering with different numbers of clusters. Myristate clustering into distinct sets will be 
performed using the average-linkage algorithm. Clustering by the average link algorithm can 
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give some information about the increase in rigidity of myristate while it binds to I-FABP.
 The dihedral angle is the angle or torsion between two planes. Thus, the dihedral angle 
for a sequence A-B-C-D is formed by planes ABCAP and DPBCD, where AP-C is the 
projection of bond A-B and DP-B is the projection of bond D-C (Figure 1.10 (a.1)). The 
dihedral clustering principle is based on dividing a dihedral angle into bins (Case et al., 2010). 
For instance, if grouped in bins of eight, each bin differentiates the position of the atom D per 
40º. Figure 1.10 (a.3) shows that atom D appears in the first bin. Therefore, the dihedral angle 
is between 0º and 40º. 180º is the maximum possible angle between bonds A-B and C-D 
(Figure 1.10 (b)). However, a dihedral angle between 320º and 360º would place it in the 
highest bin, bin 8. This bin is equivalent to 0º to -40º which we use later (Figure 1.10 (b)). 
 In the case of free myristate, it is expected to observe different occupancies of the bins 
representing different angles as myristate is not restricted and can, therefore, freely change its 
conformation. Occupancy of all the bins would represent the potential ability of free myristate 
to access all possible dihedral angle values for every aliphatic carbon torsion. Myristate bound 
to I-FABP might be expected to be more rigid than myristate free in solution. Therefore, 
fewer bins are likely to be occupied i.e. there is a more restricted number of dihedral angle 
values that are observed.  
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(a)   
(a.1) (a.2) (a.3) 
 
  
(b)  
 
 
Figure 1.10 Dihedral angle (a) Dihedral angle and clustering bins, where (a.1) is the 3D 
structure of a chain A-B-C-D, atoms B and C are drawn as circles. The dihedral angle for a 
sequence A-B-C-D is formed by planes ABCAP and DPBCD, where AP-C is A-B bond 
projection and DP-B is D-C bond projection. Dihedral angle is shown as an arrow. (a.2) 
Newman projection for the chain A-B-C-D. Atom C is behind atom B. Dihedral angle is 
shown as an arrow. (a.3) Clustering by dihedral angle into 8 bins (numbered in grey) (b) 
Newman projection of dihedral angles and their values.  
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1.4.4 The investigation system 
Our computational model of myristate binding to I-FABP will be studied using the 
AMBER force field. TI simulations for the myristate change to palmitate will allow the 
calculation of the difference in the protein binding free energy of the two ligands. The data 
recorded during the MD simulation will be used for the comparison of the conformations of 
myristate that exist in its free and protein bound states. The comparison will be performed by 
the clustering of myristate conformational states using average-linkage and also by dihedral 
angle.  
Combining MD simulations with clustering of myristate conformations, it can be 
determined whether myristate possesses any favored conformational state in solution or when 
it is bound to I-FABP. With the information about the conformational state of the free 
myristate and the bound myristate to I-FABP, it can be ascertained which bond torsions show 
changes of behavior upon binding with the protein. Further, using TI simulations, the free 
binding energy of myristate can be calculated, when myristate is both flexible and artificially 
rigid. This will give data to support whether flexibility of myristate plays an important role in 
its stronger binding to I-FABP than it was seen for rigid ligands. 
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1.5 THE AIM OF THE RESEARCH 
 Common dogma predicts that rigid ligands lose less entropy during binding, thus 
binding more strongly to protein than otherwise equivalent flexible ligands do. Nevertheless, 
experimentally it was found that flexible myristate and palmitate bind more strongly to I-
FABP that rigid ligands do. Therefore in our research we examined I-FABP and myristate 
interaction using before described model with the aim of understanding the basis of stronger 
binding between flexible ligands and proteins.  
 An investigation of FABP and FA interactions is necessary as it is not clear is the 
flexibility of FA plays a role in the strong binding of FA and FABP. Moreover, this 
mechanism might work in other biological systems which include a high degree of 
conformational freedom. Thus, the aim of the research is to test if flexibility of myristate 
plays a role in myristate strong binding to I-FABP.  
From a comparison of the calculated ligand efficiencies, it can be assumed that 
flexible palmitate binds stronger to I-FABP than less flexible myristate due to an increase in 
the number of heavy atoms. Therefore, it could be true that common dogma does not have any 
exemptions and flexible FA binding to FABP is just putative. Nevertheless, we are expecting 
that the flexibility of FA has a crucial effect on binding to FABP and their interaction can be 
an entire binding mechanism, which allows for recognition of the ligands by the protein.  
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2 METHODS 
2.1 SETTING UP SIMULATIONS 
 TI and MD simulations where performed using the AMBER suite of programs with 
the amber ff99SBildn force field (Hornak et al., 2010). The I-FABP structure was taken from 
the Protein Data Bank. Palmitate and I-FABP complex was created by superimposing the 
coordinate files of palmitate and I-FABP. The hydrogen bond network of the palmitate and I-
FABP complex, including crystallographic water molecules was optimized and hydrogen 
atoms added with Whatif (Vriend, 1990), and a topology and starting co-ordinate file was 
created with  xleap. The coordinate files of myristate and complex of myristate with I-FABP 
were created manually by deleting extra carbon and hydrogen atoms of palmitate and then by 
adding missing hydrogen atoms. A TIP3P water 12 Å truncated octahedron water box and a 
sodium anion was added to the all coordinate files (Jorgensen et al., 1983).  
The created set of coordinates was used in the replicate study (Durrant, 2012). For the 
current study a different set of coordinates was created by a 100 ps long run of TI simulation 
(van der Waals creation step) of the myristate conversion into palmitate at 310 K, when λ = 
0.6, using soft core potential. The same simulation was done for the complex of myristate and 
I-FABP (complexmyr) conversion into the complex of palmitate and I-FABP (complexpalm). 
The created systems were used in further TI and MD simulation.  
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2.2 THERMODYNAMIC INTEGRATION 
 TI was preformed based on Steinbrecher et al (2007). It consists of three steps. In the 
first step charge from H28 of myristate was removed, in the second step H28 was changed 
into–CH2CH3 group by adding the van der Waals interactions of the atoms C15, H28, H29, 
C16, H30, H31, H32, in the third step charge was added on the created atoms.  
Each of the steps consists of consecutive minimization, equilibration and production 
processes using a non-bonded cutoff of 9 Å, i.e. all non-bonded interactions between atoms 
separated by > 9 Å away are ignored. All steps were performed by using coupling parameters 
λ from 0.1 till 0.9 with difference 0.1 and λ = 0.025 and 0.975, where λ = 0 has the more 
myristate like parameters for the ligand, λ = 1 the more palmitate like parameters. TI 
simulations are run only for the intermediates (0 < λ <1) as the way TI is coded in AMBER 
leads to divide by zero error for λ = 0 and λ = 1. 
All three minimization processes were run for 500 cycles starting with 10 cycles of 
steepest descent minimization followed by conjugate gradient minimization, in constant 
volume. Equilibration and production processes were run in T = 293 K, using Langevin 
dynamics with the collision frequency γ = 5 given by gamma_ln (in the case of equilibration) 
and γ = 2 (in the case of production), pressure was kept constant 1 bar, with pressure 
relaxation time 0.2 ps.  Equilibration processes were run 1 ns long using dt = 0.002 in the first 
(myristate hydrogen‟s charge removal) and third step (palmitate additional atoms charge 
creation) and dt = 0.001 in the second step, while the production process was run as 10 ns, in 
the case of myristate conversion into palmitate in water, and 14 ns, in the case of complexmyr 
conversion into complexpalm, following steps 1 ns long using dt = 0.002 in the first and third 
step and dt = 0.001 in the second step. Convergence of the TI processes was observed by 
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plotting <dU/dλ> against time for the simulation at each lambda value. <dU/dλ> data was 
extracted from TI production steps.  
In the first and third steps in systems during equilibration and production processes 
used the SHAKE algorithm, bonds which involved hydrogen atoms were kept constrained, 
while in the second step systems “shaking” was off.  SHAKE usage limits molecular bond 
stretching, thus it cannot be used in the simulation where atoms are disappearing and 
appearing. Due to the SHAKE usage equilibration and production processes in step 1 and 3 
proceed faster than in step 2. 
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2.3 FREE ENERGY CALCULATIONS 
Calculation of the difference in free energy of binding to I-FABP of palmitate 
compared to myristate (ΔΔGbinding) is based on the thermodynamic cycle of the binding of the 
myristate to I-FABP and of the palmitate binding to I-FABP (Figure 2.1), and it can be 
explained by the equation ΔGsolution + ΔGP = ΔGM + ΔGcomplex, where ΔGP and ΔGM are, 
respectively, the free energy of binding of palmitate and to I-FABP, ΔGsolution and ΔGcomplex 
are, respectively, the free energy for the conversion of myristate into palmitate and 
complexmyr conversion into complexpalm (Figure 2.1). Therefore, the difference between free 
binding energy (ΔΔG) of palmitate and myristate binding to I-FABP can be calculated by the 
equation: ΔΔG = ΔGP – ΔGM = ΔGcomlex – ΔGsolution. 
The free energy difference is the integral of <dU/dλ> with respect to λ, i.e. the area 
under the curve, which is determined using the trapezium rule. Firstly, the <dU/dλ> values for 
λ = 0 and λ = 1 were extrapolated from the other λ values. The graphs of the <dU/dλ> against 
λ value were prepared for myristate changed to palmitate after 10 ns of simulation time per 
lambda value and of the complexmyr conversion into complexpalm after 14 ns of simulation per 
lambda value. The graphs for the <dU/dλ> difference between complexmyr conversion into 
complexpalm and myristate conversion into palmitate was determined by subtracting 
appropriate graphs (see Results). 
Calculation of ΔΔG was done in two ways. For one method, firstly area was calculated 
under the curves of the <dU/dλ> vs λ value plot for the conversion of myristate into palmitate 
and for the conversion of complexmyr into complexpalm. Further, the difference between the 
area for the conversion of complexmyr into complexpalm and conversion of solvated myristate 
into solvated palmitate was calculated by subtraction of these two areas (see Results). In the 
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second method, the curves from the TI simulations for converting myristate into palmitate in 
solution and in the I-FABP complex were subtracted prior to integration (see Results).  
 
 
 
 
 
 
Figure 2.1 Thermodynamic cycle to compute the difference in the free binding energy 
between myristate and palmitate, while they are binding to I-FABP. Complexpalm and 
Complexmyr indicate I-FABP bound respectively to palmitate and myristate, each complex 
being solvated in water 
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2.4 MOLECULAR DYNAMICS 
MD simulations were performed for myristate in the solution and for the complex of 
myristate and I-FABP in the solution with a non-bonded cutoff of 9 Å, the temperature was 
kept at 293 K, with a Langevin thermostat ntt = 3 and collision frequency γ = 5 given by 
gamma_ln = 5, pressure was kept constant 1.0 bar with pressure relaxation time 1.0 ps. MD 
simulations were run for 1ns with dt = 0.002, and were written in output files as 10 
consecutive steps. In total a 10 ns long MD simulation was performed. SHAKE was used to 
keep the positions of hydrogen constrained.  
The atomic coordinates were written to a trajectory file every 0.01 ps creating 100 data 
frames per 1 ns and were used for subsequent analysis of conformations of myristate. In total 
1000 data frames containing the information about the atomic coordinates were obtained from 
10 ns long MD simulation. Each frame has information about the myristate conformational 
state. 
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2.5 CLUSTERING 
Myristate clustering was performed by extracting information written in each frame of 
the trajectory file. Before myristate clustering water molecules and the sodium ion were 
removed. Two methods for the conformation clustering of free and bound myristate were used 
– clustering into by the average link algorithm and clustering by dihedral angles, using the 
program ptraj, supplied with AMBER software. 
2.5.1 Clustering by the average link algorithm 
Myristate conformations were clustered for co-ordinates from both MD trajectories with 1) 
just myristate in solution and 2) myristate in the complex with i-FABP, using average-linkage 
algorithm by comparison of the root mean squared deviation (RMSD) of all atoms myristate 
molecules were grouped by changing number of clusters from 1 to 10. In both cases myristate 
clustering was observed by changing MD simulation time from 1ns to 10 ns. Hierarchic 
arrangement representing the percentage of each cluster was arranged in the figures. 
2.5.2 Analysis of the dihedral angles 
 The value of each distinct dihedral angle of myristate was assigned into one of 36 
bins of 10º each, for each recorded snapshot of the simulation. The results were used for 
calculating the Shannon entropy and also the correlation coefficients comparing the dihedral 
distribution between protein bound and free myristate. 
2.5.2.1 Shannon entropy 
The dihedral clustering results were used to calculate the ratio Shannon entropy/the 
maximum Shannon entropy (H/Hmax) for each dihedral of free and bound myristate. From the 
clustering results the probability of each bin for each dihedral was calculated. Each dihedral 
angle was divided into 36 bins. The maximal entropy is when each bin has equal probability, 
i.e. p(x) for each bin is 1/36. For each dihedral for each bin -p(x)ln(p(x)) was calculated. The 
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sum of -p(x)ln(p(x)) for all 36 bin is the Shannon entropy (H) for a dihedral. The maximum 
Shannon (Hmax) entropy for one bin is -(1/36)ln(1/36). Thus, Hmax entropy for a dihedral is -
ln(1/36). 
2.5.2.2 Correlation coefficient 
For each dihedral angle the correlation between the distributions of values observed 
for the free and bound myristate was calculated. For this purpose data obtained from dihedral 
angle clustering were used. The Pearson correlation coefficient was calculated using the 
equation:  
rx,y = 
∑               
 
   
√∑                
 
In the equation xi and yi are the number of occurrences in that angle bin for the free 
and bound fatty acid and xa and ya are the mean average occurrence in all angle bins for the 
free and bound fatty acid.  
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3 RESULTS 
3.1 THERMODYNAMIC INTEGRATION (TI) SIMULATIONS 
 TI simulations were run for the conversion of sodium myristate into sodium palmitate 
(here sodium myristate and sodium palmitate will be referred to as myristate and palmitate) in 
water and when bound to the solvated I-. Three different steps were taken for both 
conversions. During the first, the charge is removed from the 28
th
 hydrogen of myristate. The 
second step changes the 28
th
 hydrogen of myristate to the ethyl group of palmitate. The third 
step adds a charge on the ethyl group. 
The time required to perform these simulations is unknown, since the simulation 
length depends on the system studied and how long it takes to sample the accessible 
conformations for each intermediate lambda state. Therefore, during the production step for 
each TI simulation, the change in <dU/dλ> over time was followed, i.e. <dU/dλ> needs to 
converge to a constant value. As it was mentioned before λ value shows the degree of 
mutation of the sampled ligand. Thus, λ = 0 has the more myristate like parameters for the 
ligand, λ = 1 the more palmitate like parameters. Within the AMBER force field TI is coded 
to record <dU/dλ>. However, when λ = 0 and λ = 1, the analytical expression for <dU/dλ> in 
the softcore simulations contains a divided by 0 in its implementation in AMBER and thus 
gives an error. Therefore, TI simulations are run only for intermediate λ values between 0 and 
1. 
 At first, TI simulation production steps for myristate conversion into palmitate and 
complexmyr conversion into complexpalm were run as 10 consecutive simulations, each 1ns 
long. Data from TI simulations, where myristate was converted to palmitate show that the 
processes have been run long enough, all curves are observed as almost straight lines (Figure 
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3.1). For the TI simulations, where the charge was removed from the 28
th
 hydrogen of 
myristate, there were no high changes observed in <dU/dλ> for all λ values (Figure 3.1), 
which indicates likely convergence. 
At the beginning of the TI simulations for myristate conversion into palmitate, when 
the 28
th
 hydrogen of myristate was converted into the ethyl group, for some λ values there 
was a fluctuation in <dU/dλ> (Figure 3.1). The most notable change in <dU/dλ> was 
observed for λ = 0.8. Nevertheless, for all expected convergence is observed after 5 ns. 
For TI simulations when a charge was added on the ethyl group, after 2 ns there was observed 
a small fluctuation of <dU/dλ> was observed for some λ values (Figure 3.1). However, 
similar to the TI simulation, when the charge was removed from the 28
th
 hydrogen, all curves 
quickly become almost straight lines. Thus, the TI simulations for the conversion of myristate 
into palmitate in water indicate appropriate convergence within 6 ns or less.   
For TI simulations where the charge was removed from the 28
th
 hydrogen of myristate 
for the conversion of complexmyr into complexpalm high fluctuations of <dU/dλ> were 
observed for all λ values for the first 10 ns (Figure 3.2). Therefore, TI production steps for all 
λ values were continued for a further 4 ns. When TI simulations were continued for the next 4 
ns, a stabilization of <dU/dλ> was observed. Moreover, for λ values except λ = 0.1 <dU/dλ> 
are almost constant after 12 ns of TI simulations. For λ = 0.1 <dU/dλ> is constant from 9 to 
12 ns. When the TI simulation for λ = 0.1 was run for >12 ns another increase in <dU/dλ> 
was observed (Figure 3.2 (a)), suggesting that this simulation should be continued for a longer 
time.  
In the second step of TI simulations for complexmyr conversion into complexpalm, when 
the hydrogen of myristate was mutated into the additional ethyl group found in palmitate, the 
fluctuation of <dU/dλ> is much higher than was observed in the first production step. A small 
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<dU/dλ> fluctuation was observed for λ = 0.4 and 0.9, but for λ = 0.1, 0.8 and 0.975, 
<dU/dλ> remains almost constant (Figure 3.2 (b)) after 10 ns of TI simulations. While some 
of the curves observed in Figure 3.2 (b) show that after 10 ns of TI simulations the fluctuation 
of <dU/dλ> for λ = 0.025, 0.2, 0.3, 0.5, 0.6 and 0.7, is relatively high. Therefore, TI 
production steps for all λ values were continued for a further 4 ns. When TI simulations were 
run for a further 4 ns <dU/dλ> became almost constant for most values of λ. Nevertheless, for 
λ = 0.2, there was observed an increase in <dU/dλ> during the last ns. The curve for λ = 0.3, 
which was observed as a constant from 5 to 9 ns, shows a decrease in <dU/dλ> from 11 to 13 
ns (Figure 3.2 (b)). Therefore, to verify that, in further simulations, there is no significant 
change in <dU/dλ> and to stabilize the change in <dU/dλ> for the processes where λ = 0.2 
and 0.3, all TI simulations should be run for at least 5 ns longer.  
In the third step of TI simulations of complexmyr conversion to complexpalm when a 
charge was added to the ethyl group, fluctuations in <dU/dλ> were seen for λ = 0.025, 0.3, 
0.5, 0.7 and 0.8 for the first 10 ns, but <dU/dλ> converged to a stable value for λ = 0.4, 0.9 
and 0.975 from 8 to 10 ns and for λ = 0.1 and 0.2 from 6 to 10 ns (Figure 3.2 (c)). After a 
further 4 ns of TI simulations the almost constant lines observed for λ = 0.1 and 0.2 indicated 
a convergence in the value of <dU/dλ>, which was also seen from 11ns for λ = 0.025 and 
from 12 ns for λ = 0.5. Nevertheless, <dU/dλ> for λ = 0.4, 0.7, 0.9 and 0.975, which became 
almost constant by 10 ns, slightly decreased when TI was run for a longer time. 
A TI production step of 1 ns for a simulation of a ligand free in solution takes about 30 
hours, but for ligand and protein complex 40-60 hours of computational time. Within the time 
limitations of this project it was not possible to continue the TI simulation for longer and thus 
the results here were used for the calculation of free binding energy, although it is desirable to 
run the simulations for longer.  
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Figure 3.1 The change in <dU/dλ> over time for the conversion of sodium myristate to 
sodium palmitate in water solution. (a) 1
st
 TI step - charge removal from the 28
th
 hydrogen 
atom, (b) 2
nd
 TI step – the hydrogen atom is changed into an ethyl group, (c) 3rd TI step - 
charge add on the ethyl group.   
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Figure 3.2 The change of <dU/dλ> over time for complexmyr conversion to complexpalm in 
water. (a) 1
st
 TI step - charge removal from the 28
th
 hydrogen atom, (b) 2
nd
 TI step – the 
hydrogen atom is changed into an ethyl group, (c) 3
rd
 TI step - charge add on the ethyl group.  
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3.2 CALCULATION OF THE DIFFERENCE BETWEEN THE FREE ENERGY OF 
MYRISTATE AND PALMITATE BIND TO I-FABP 
In the Introduction section it was explained that from TI simulations can be calculated 
only the difference of free binding energy (∆∆G) between two very similar ligands. To 
calculate ∆∆G, graphs of <dU/dλ> with respect to λ were plotted. As mention before, TI 
simulations cannot be run for λ = 0, and 1. Therefore, <dU/dλ> values for λ = 0 and 1 were 
extrapolated from the other λ values. For myristate converted to palmitate in solution, the 
graphs were plotted after 10 ns of TI simulations (Figure 3.3 (a)). In the case of complexmyr 
conversion into complexpalm the graphs were prepared after 14 ns of simulation (Figure 3.3 
(b)). The difference between <dU/dλ> for these two process, i.e. between the conversion of 
complexmyr into complexpalm and the conversion of myristate into palmitate are plotted against 
lambda in figure 3.3 (c) and were calculated by simply subtracting the lines in 3.3 (a) from 3.3 
(b), e.g. figure 3.3 (c) column 1 is a subtraction of figure 3.3 (a) column 1 from figure 3.3 (b) 
column 1.  
The change in <dU/dλ> with respect to λ for the TI simulations where myristate was 
converted into palmitate is smooth (Figure 3.3 (a)). A relatively smooth change in <dU/dλ> 
with respect to λ was also observed in the case of complexmyr changing into complexpalm, 
where a charge was added to the ethyl group (Figure 3.3 (b) column 3). For the removal of the 
charge from the 28
th
 hydrogen of the myristate the change of <dU/dλ> with λ is smooth, 
except λ = 0.1 and 0.7, which deviate from the general trend of the curves (Figure 3.3 (b) 
column 1). For the conversion of complexmyr into complexpalm, when the 28
th
 hydrogen was 
changed into an ethyl group the change in <dU/dλ> with respect to λ does not form a smooth 
curve (Figure 3.3 (b) column 2). The lack of smooth <dU/dλ> versus λ curves could arise due 
to insufficient conformational sampling at a given λ point, i.e. the point is erroneous or from 
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not having enough λ points. Either way it is likely to contribute to errors in the calculation, 
and continuation of this aspect the project should investigate this.  
Comparing graphs plotted for the conversion of myristate into palmitate and 
complexmyr into complexpalm the graphs for similar production steps of the change in <dU/dλ> 
with respect to λ are mapping similar curves. For example, for the charge removal from the 
28
th
 hydrogen of myristate, curves for the conversion of myristate into palmitate and 
complexmyr into complexpalm both have a negative gradient. Therefore, the graphs for the 
subtraction of <dU/dλ> in figure 3.3 (a) from the <dU/dλ> in figure 3.3 (b) are expected to 
form straight lines with slight or no slope. Although, the tendency to form these straight lines 
is observed in plotted graphs (Figure 3.3 (c)), fluctuation of the change in <dU/dλ> with 
respect to λ is observed.  
Both graphs of <dU/dλ> over time and graphs of <dU/dλ> with respect to λ show that 
TI simulations for complexmyr conversion into complexpalm were not run long enough. 
Therefore, two ΔΔG values were calculated, ΔΔG* was calculated from TI simulations of 
myristate conversion into palmitate and from complexmyr conversion to complexpalm run for 10 
ns, and ΔΔG** was calculated, when TI simulations for the conversion of myristate into 
palmitate was run for 10ns, but TI simulation of complexmyr conversion to complexpalm for 14 
ns. Comparison of these values should give some indication of the likely effects on ΔΔG 
arising from possibly not having been able to run the simulations for long enough. 
The ΔΔG calculation is based on integration of <dU/dλ> with respect to λ. An integral 
of <dU/dλ> is determined by calculation of the area under curves in the prepared graphs of 
<dU/dλ> with respect to λ. The area under the curves, thus integral of <dU/dλ> is determined 
using the trapezium rule. 
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Calculation of ΔΔG was done in two ways. For one method, firstly by calculating the 
areas (A) under the curves of <dU/dλ> with respect to λ for myristate change into palmitate 
(Figure 3.3 (a)) and under the curves of <dU/dλ> with respect to λ for complexmyr conversion 
to complexpalm (Figure 3.3 (b)) for all three TI steps. Next, the difference between the areas 
(ΔA) of complexmyr conversion to complexpalm and myristate conversion to palmitate by 
subtraction was calculated, e.g. ΔA1 (the difference between the areas for the first TI step) is a 
subtraction of A (Figure 3.3 (a) column 1) from A (Figure 3.3 (b) column 1). In the same way 
a calculation was made for the difference in area for the second (ΔA2) and third (ΔA3) TI 
simulation step. ΔΔG is a sum of the ΔA1, ΔA2 and ΔA3 (Figure 3.4 (a)). 
The second ΔΔG calculation used only one integration step since the curves for 
simulations in solution and in the I-FABP complex were subtracted prior to integration, e.g. 
<dU/dλi> (Figure 3.3 (c)) = <dU/dλi> (Figure 3.3 (b)) - <dU/dλi> (Figure 3.3 (a)) for λi.  
Our calculated ΔΔG shows that ΔGM > than ΔGP, i.e. palmitate binds the strongest. To 
verify the obtained ΔΔG and how accurate is our simulation system, ΔΔG was calculated 
from experimentally obtained data. Velkov et al. (2005 and 2007) obtained dissociation 
constants (Kd) of palmitate (KdP) and myristate (KdM) during 1-anilinonaphthalene-8-sulfonic 
acid (ANS) displacement by the ligands in the complex of ANS and I-FABP. Velkov et al. 
(2005 and 2007) performed experiments using three different buffers.  The difference of the 
palmitate and myristate binding energy (ΔΔG) was calculated using equation:  
ΔΔG = ΔGP - ΔGM = RTlnKdP - RTlnKdM = RTln(KdP/KdM) 
In the equation Kd = [L][P]/[PL], where [L] is the concentration of the ligand, [P] is 
the concentration of the protein and [PL] is the concentration of the complex. ΔGdissociation = - 
RTlnKd for the reaction PL → P + L. The ΔGbinding goes in the opposite direction so ΔGbinding 
= RTlnKd; ΔGP = RTlnKdP; ΔGM = RTlnKdM. Calculated ΔΔG from experimental data shows 
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that ΔΔG is dependent on the buffer conditions used. Nevertheless, the calculated ΔΔG are 
similar (Figure 3.4 (c)).Comparing our obtained ΔΔG with the ΔΔG calculated from 
experimental data it is clear that our results overestimate the magnitude of the ΔΔG value, 
although the simulations performed here are in “pure water” compared to the different buffer 
conditions used in the experiments and are thus not directly comparable. Nevertheless, ΔΔG 
calculated from experimental data as well as our calculated ΔΔG show that ΔGM > than ΔGP, 
i.e. palmitate binds the strongest.  
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Myristate conversion into palmitate 
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Figure 3.3 The change of <dU/dλ> with respect to λ (a) TI simulations for the conversion 
of myristate into palmitate, (b) TI simulations for the conversion of complexmyr into 
complexpalm, (c) graphs of <dU/dλ> with respect to λ calculated by subtraction of <dU/dλ> in 
(a) graphs from <dU/dλ> in (b) graphs. Column 1 is 1st TI step - charge removal from the 28th 
hydrogen atom, column 2 is 2
nd
 TI step - the hydrogen atom change into an ethyl group and 
column 3 is 3
rd
 TI step - charge was added onto the ethyl group. In each graph λ = 0 has the 
more myristate like parameters for the ligand, λ = 1 the more palmitate like parameters.  
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(a) 
 
Obtained ΔΔG from TI simulations 
Method ΔΔG
 *
, kJ/mol ΔΔG
 **
, kJ/mol 
1. -9.080 -8.816 
2. -7.573 -8.795 
 
(b) 
 
Calculated ΔΔG from reported experimental Kd data 
No 
Buffer 
ΔΔG, 
kJ/mol 
1. 50 mM Tris-HCl, 150 mM NaCl, 1 ml dithiothreitol, 0.5 mM EDTA
 
-1.747
 
2. 50 mM Tris-HCl, 150 mM NaCl
 
-1.220
 
3. 20 mM Tris-HCl
 
-1.380
 
 
Figure 3.4 The difference of the myristate and palmitate free binding energy (ΔΔG), 
while they bind to I-FABP. (a) obtained ΔΔG from TI simulations, where ΔΔG* is calculated 
from TI simulations run for 10 ns, ΔΔG** is calculated from TI simulations of myristate 
conversion to palmitate run for 10 ns and from TI simulations of complexmyr conversion to 
complexpalm, run for 14 ns  (b) Calculated ΔΔG from reported experimental Kd data using 
different buffers. Kd for No 1 ΔΔG calculation is taken from Velkov et al. (2005). While for 
Kd for No 2 and 3 ΔΔG calculation is taken from Velkov et al. (2007). 
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3.3 INVESTIGATING THE FLEXIBILITY OF FREE MYRISTATE IN SOLUTION 
AND OF BOUND MYRISTATE TO I-FABP 
MD simulations of myristate in water and complexmyr in water were run as 10 
consecutive steps, each 1ns long with 1000 frames (co-ordinate sets) written to file. Each 
frame has information about the myristate conformational state. Before clustering the 
myristate co-ordinate sets water molecules and the sodium ion was removed. Two methods 
for conformational analysis of free and I-FABP bound myristate data were used – clustering 
by the average link algorithm and classification by the value of the dihedral angles. Clustering 
by the average link algorithm was performed by atom distance comparison using RMSD. 
Classification by dihedral angles was performed to for each dihedral angle, allocating each 
dihedral angle to a given bin for each given simulation frame, dependent upon the value of the 
dihedral angles. 
Myristate consists of 14 carbon atoms as represented in figure 3.5. Thus, the dihedral 
angle for the 1
st
 dihedral is angle between bond O- C1 and C2-C3 in a chain O-C1-C2-C3.  
 
 
 
 
 
 
Figure 3.5 Formula of myristate, with carbons and dihedral angles labeled the latter in red. 
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3.3.1 Clustering by the average link algorithm 
Conformations of free myristate and bound myristate to I-FABP were grouped into 
clusters from one to five according to their structural similarities. Clustering data is presented 
in figure 3.6.  
Free myristate has one dominant conformation, when conformations are grouped into 
two to five clusters. Grouping myristate conformation into five clusters, the dominant cluster 
consists of 65.2%, whilst the second largest of 29.3% from the total count of myristate 
conformations. Moreover, when myristate conformations were grouped into three clusters 
these two clusters were grouped as one. Therefore, the biggest two clusters, when myristate 
conformations are grouped into five clusters, consist of similar myristate conformations 
(Figure 3.6 (a)). The average RMSD distance of all cluster members from the average 
structure of the cluster is set by default as < 0.6 Å indicating that each representative cluster is 
compact.  
Grouping free myristate conformations into two clusters, the dominant cluster consists 
of 96.5%. Clusters from simulations with myristate bound to I-FABP consist of 54.2% and 
45.8% from the total count of myristate conformations. When the number of clusters grouping 
conformations of bound myristate was increased from two to five the percentage of the 
biggest cluster decreases from 54.2% to 32.5%, while the percentage of the second biggest 
cluster stays unchanged – 45.8% (Figure 3.6 (b)). 
Representative structures of clusters, when conformations of free and bound myristate 
are grouped into five clusters, were observed using pymol (Figure 3.7). For both free and 
bound myristate comparing cluster representative structures by their dihedral angles, the high 
similarity between the two biggest clusters was confirmed. The difference in the angle higher 
than 5ᵒ was observed at the 1st, 2nd, 6th and 7th dihedrals for free myristate - 60ᵒ, 90ᵒ, 100ᵒ and 
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100ᵒ, respectively (Figure 3.7 (a)). For bound myristate the difference in angle higher than 5ᵒ 
was observed for 3
rd
, 4
th
, 6
th
 and 7
th
 dihedrals, it is about 60ᵒ, 30ᵒ, 90ᵒ and 100ᵒ, respectively 
(Figure 3.7 (b) and (c)).  
Comparing cluster representative structures for the biggest clusters of free and bound 
myristate with the third cluster, respectively,  six and seven dihedrals from the total of twelve 
were found to form a similar angle (maximal angle difference is within 5ᵒ). Five dihedrals 
from the total of twelve were found to form a similar angle comparing the biggest cluster of 
free myristate with either the fourth or the fifth cluster of free myristate. In the case of bound 
myristate six dihedrals were found to form a similar angle comparing the biggest cluster with 
either the fourth or the fifth cluster. 
. Therefore, clusters of bound myristate look like being more similar, than free 
myristate clusters are. However, the sum of conformation of two biggest clusters for free and 
bound myristate is 945 and 783 from total 1000 myristate conformations.  
An important observation was that, when the conformations are grouped into five 
clusters, the biggest clusters of free and bound myristate have extremely high structural 
similarity (Figure 3.8), i.e. the dominant conformation myristate found in the I_FABP bound 
structure is almost identical to the dominant conformation found for myristate free in solution. 
A difference was observed only at the 1
st
 and 2
nd
 dihedral angles. 
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(a) 
Free myristate clusters 
 
(b) 
Bound myristate clusters  
 
Figure 3.6 The clustering of myristate into distinct clusters. The clusters were divided 
from the linkage algorithm based on RMSD between structures from 1000 snapshots saved 
from a 10 ns simulation, with the algorithm being set to return from one to five clusters. (a) 
The diagram represents the cluster connection and the percentage of free myristate 
conformations in each cluster. (b) The diagram represents the cluster connection and the 
percentage of bound myristate conformations in each cluster.  
5 clusters 
4 clusters 
3 clusters 
2 clusters 
1 cluster 100% 
96.5% 
96.2% 
66.9% 
65.2% 1.7% 
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29.3% 
0.3% 
0.3% 
0.3% 
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3.5% 
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1 cluster 100% 
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(a)  
 Myristate in solution 
 
  
(b)  
 Myristate bound to I-FABP (front view) 
 
  
(c)  
 Myristate bound to I-FABP (90º rotation ) 
 
  
Figure 3.7 Representative structures for five clusters that represent the dominant 
conformations in simulations of myristate free in solution and bound to I-FABP. The 
clusters were derived from the linkage algorithm based on RMSD between structures from 
1000 snapshots saved from 10 ns simulations. (a) Conformational clustering of free myristate 
in solution. Myristate is represented in green, red, black, blue and purple respectively consist 
of 65.2%, 29.3%, 3.5%, 1.7% and 0.3% recorded myristate conformations. (b) 
Conformational clustering of bound myristate to I-FABP (front view). Myristate is 
represented in blue, red, green, purple and black respectively consist of 45.8%, 32.5%, 18.3%, 
3.2% and 0.2% recorded myristate conformations. (c) Conformational clustering of bound 
myristate to I-FABP (90º rotation). Myristate is represented in blue, red, green, purple and 
black respectively consist of 45.8%, 32.5%, 18.3%, 3.2% and 0.2% recorded myristate 
conformations. 
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Front view 90º rotation  
  
 
Figure 3.8 Comparison of the representative conformations for the dominant cluster for 
free and bound myristate. Free myristate is represented in green, bound myristate in blue. 
Five clusters were derived from the linkage algorithm based on RMSD between structures 
from 1000 snapshots saved from 10 ns simulations. 
 
.  
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3.3.2 Clustering by dihedral angles 
 Clustering by dihedral angles was performed for free myristate in solution and for 
bound myristate for each dihedral of myristate, using 36 bins. The distribution of the formed 
angles for each dihedral is represented in graphs (Figure 3.9 and 3.10).  
 The angle distribution at the 1
st
 dihedral for free myristate  was observed as four 
preferred angle ranges centered at 80º, 90º, -120º and -80º. Where first two and last two 
overlap forming two broad bands. At the 2
nd
 to 12
th
 dihedrals free myristate has three 
preferred angle ranges centered at 60º, 175º and -70º. The dominantly preferred angle is 
centered at 175º. 
 The angle distribution at the 1
st
 dihedral for bound myristate was observed as two 
preferred angle ranges. The dominantly preferred angle range is centered at -120º, the second 
preferred angle at -70º. The angle distribution at the 2
nd
, 3
rd
 and 5
th
 dihedrals also was 
observed as two preferred angle ranges. The dominantly preferred angle and the second 
preferred angle are centered at 55º and -70º for the 2
nd
 dihedral, at 175º and -100º for the 3
rd
 
dihedral and at 175º and -70º for the 5
th
 dihedral, respectively. At the 4
th
 and 6
th
 to 12
th
 
dihedrals three preferred angle ranges centered at 65º, 175º and -70º was observed, where the 
dominantly preferred angle is centered at 175º. 
Shannon entropy divided by the maximum possible Shannon entropy (H/Hmax) was 
calculated for each dihedral from the data shown in figures 3.9 and 3.10. H/Hmax values for 
each dihedral are shown in figure 3.11 (a). H/Hmax = 1 refers to the maximal dihedral 
flexibility, while H/Hmax = 0 to the maximal rigidity. Dihedrals of free myristate were 
arranged in order with increasing in flexibility: 5
th
 ≈ 9th < 6th = 10th ≈ 7th = 3rd ≈ 8th ≈ 11th ≈ 4th 
= 12
th
 ≈ 2nd < 1st, where H/Hmax increases from 0.60 to 0.88. While dihedrals of bound 
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myristate were arranged in order with increasing in flexibility: 10
th
 < 8
th
 ≈ 5th = 2nd = 12th ≈ 9th 
= 1
st
 ≈ 3rd < 11th < 7th < 4th < 6th. H/Hmax for bound myristate increases from 0.54 to 0.76.  
Comparing H/Hmax values at the same dihedral between free and bound myristate was 
confirmed that myristate became more rigid, when it binds to I-FABP. Dihedrals of myristate 
were arranged in order of the decreasing change of flexibility: 11
th
 ≈ 3rd < 10th = 8th ≈12th ≈ 
2
nd
 < 1
st
. It is intriguing that myristate became more flexible at the 6
th
 dihedral, when it binds 
to I-FABP. No change in flexibility at the 4
th
, 5
th
, 7
th
 and 9
th
 dihedrals was observed as the 
change in H/Hmax ≤ 0.3. 
The correlation coefficient of each dihedral angle was calculated to compare the angle 
distribution between free and bound myristate (Figure 3.11 (b)). The correlation coefficient = 
1 refers to the identical angle distribution. Dihedrals were arranged in order with increasing 
similarity between free and bound myristate angle distribution: 2
nd
 < 1
st
 < 6
th
 < 4
th
 < 3
rd
 ≈ 7th = 
12
th
 ≈ 5th = 8th ≈ 9th = 11th ≈ 10th. The smallest correlation coefficient < 0.25 was observed at 
the 1
st
 and 2
nd
 dihedrals. Thus, at this dihedrals angle distribution difference is the highest. 
The correlation coefficient for the 6
th
 dihedral is 0.88, for the 3
rd
 to 5
th
 and 7
th
 to 12
th
 is > 0.90, 
which indicates that free and bound myristate have very similar angle distribution at these 
dihedrals. 
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Figure 3.9 Myristate clustering by dihedral angles using 36 bins of 10º (dihedrals 1
st
 to 6
th
). The angle distribution at dihedrals for free 
myristate is presented in blue, for bound myristate in red.   
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Figure 3.10 Myristate clustering by dihedral angles using 36 bins of 10º (dihedrals 7
th
 to 12
th
). The angle distribution at dihedrals for 
free myristate is presented in blue, for bound myristate in red. 
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(a) 
Dihedral 
number 
H/Hmax 
Myristate in 
solution 
Myristate 
bound to I-
FABP 
Palmitate in 
solution 
Palmitate bound to 
I-FABP 
1
st
 0.88 0.60 0.89 0.47 
2
nd
 0.71 0.58 0.73 0.40 
3
rd
 0.67 0.61 0.61 0.49 
4
th
 0.70 0.73 0.67 0.43 
5
th
 0.60 0.58 0.58 0.60 
6
th
 0.65 0.76 0.58 0.49 
7
th
 0.67 0.70 0.71 0.59 
8
th
 0.68 0.57 0.65 0.64 
9
th
 0.61 0.60 0.67 0.51 
10
th
 0.65 0.54 0.71 0.70 
11
th
 0.69 0.64 0.65 0.51 
12
th
 0.70 0.58 0.62 0.61 
13
th
 - - 0.67 0.63 
14
th
 - - 0.65 0.73 
 
(b) 
Dihedral number 
Correlation coefficient 
Myristate Palmitate 
1
st
 0.24 0.55 
2
nd
 0.11 0.01 
3
rd
 0.94 0.96 
4
th
 0.91 0.90 
5
th
 0.96 0.05 
6
th
 0.88 0.98 
7
th
 0.95 0.85 
8
th
 0.96 0.96 
9
th
 0.98 0.92 
10
th
 0.99 0.77 
11
th
 0.98 0.98 
12
th
 0.95 0.98 
13
th
 - 0.81 
14
th
 - 0.97 
 
Figure 3.11 The determination of the change in myristate and palmitate flexibility, when 
myristate and palmitate binds to I-FABP. (a) Shannon entropy divided by the maximal 
possible Shannon entropy (H/Hmax), where H/Hmax = 1 refers to the maximal possible 
flexibility and H/Hmax = 0 to the minimal possible flexibility (maximal rigidity). (b) The 
correlation coefficient for the angle distribution each dihedral between free and bound 
myristate and palmitate (H/Hmax and correlation coefficient values for palmitate are taken 
from Durrant, 2012).  
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4 DISCUSSION 
4.1 CONVERGENCE OF TI SIMULATIONS 
The graphs recording the change in <dU/dλ> over time for the conversion of myristate 
into palmitate show that the processes for all λ and all production steps have been run long 
enough, all curves are observed as almost straight lines.  
In the case of the conversion of complexmyr into complexpalm, convergence was 
observed only for some λ values after being run for 14 ns. However, for most λ values 
complexmyr has higher energy changes and needs to be simulated for a longer time for the 
energy to converge to a stable value compared to the free myristate simulation. Slow 
convergence of ensemble averages and high energy changes indicate greater conformational 
changes within the system and highlight the importance of protein flexibility. Within the time 
limitations of this project it was not possible to continue the TI simulation for longer and thus 
the results here were used for the calculation of free binding energy, although it is desirable to 
run the simulations for longer. 
The convergence of our TI simulations was compared with a replicate study (Durrant 
2012). Most conditions of TI simulations for both projects were set up as the same. The 
difference between the projects is set up of pressure relaxation time 0.2 ns and 1 ns, in this 
project and Durrant‟s project, respectively.  
Expected convergence of TI simulation for myristate conversion into palmitate was 
observed only for production step 1 and step 3 after 10 ns (Durrant 2012). Despite observed 
convergence, the fluctuation of <dU/dλ> over time is higher than it was observed in our TI 
simulation for the same steps. Moreover, for the conversion of myristate into palmitate when 
the 28
th
 hydrogen was changed into an ethyl group, and for the some step for the conversion 
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of complexmyr into complexpalm, high fluctuation of <dU/dλ> over time after was observed in 
the 10 ns length TI simulations. The change of 28
th
 hydrogen into an ethyl group causes 
higher conformational changes than the removal and addition of charge. Thus, for the TI 
simulation for the conversion of myristate into palmitate, production step 2 requires a longer 
simulation time (Durrant 2012). The fluctuation of <dU/dλ> over time in Durrant‟s project 
was observed as greater in all three TI simulation steps. Thus, stabilization of energy changes 
within the system proceeds faster when a smaller pressure relaxation time is used.  
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4.2 THE DIFFERENCE BETWEEN THE BINDING FREE ENERGY OF 
MYRISTATE AND PALMITATE  
To calculate ∆∆G, graphs of <dU/dλ> with respect to λ were prepared. For the TI 
simulations, where myristate was converted into palmitate, curves for the change in <dU/dλ> 
with respect to λ are smooth. A relatively smooth change in <dU/dλ> with respect to λ was 
observed in the case of the conversion of complexmyr into complexpalm, where a charge was 
added to the ethyl group, the step 3. While the change in <dU/dλ> with respect to λ for the 
removal of the charge from the 28
th
 hydrogen of myristate in the conversion of complexmyr 
into complexpalm is smooth excluding λ values of 0.1 and 0.7. The reason for λ values of 0.1 
and 0.7 not following the rest of the curve could be that there was not appropriate 
convergence to a constant value of the <dU/dλ> over time, or it may indicate that more λ 
points are needed around these values to map the curve properly. For the conversion of 
complexmyr into complexpalm, when the 28
th
 hydrogen was changed into an ethyl group the 
change in <dU/dλ> with respect to λ does not form a smooth curve, therefore, it is likely to 
give a bigger error in the ΔΔG calculation.  
In our study smooth curves of <dU/dλ> with respect to λ were observed for the 
conversion of myristate into palmitate for all three production steps. It is intriguing that TI 
simulations for the conversion of myristate into palmitate for production step 2 do not have 
the expected convergence; nevertheless the change of <dU/dλ> with respect to λ is 
represented as smooth curves. In the Durrant‟s replicate study the change of <dU/dλ> with 
respect to λ for the conversion of complexmyr into complexpalm does not form smooth curves 
(Durrant, 2012). Moreover, the change of <dU/dλ> with respect to λ for the conversion of 
complexmyr into complexpalm in the replicate study is more chaotic than was observed in our 
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study. Therefore, in this study the calculated ΔΔG should be more close to the ΔΔG value that 
could be obtained if the TI simulations could be run for longer.  
Both my study and Durrant‟s study graphs of <dU/dλ> over time and graphs of 
<dU/dλ> with respect to λ show that the TI simulations for the conversion of complexmyr into 
complexpalm were probably not run for long enough. Therefore, two ΔΔG values with the aim 
to predict ΔΔG value, which could be obtained when TI simulations run long enough, were 
calculated. The calculated ΔΔG values using the first method (described on page 61) after 10 
ns and 14 ns TI simulations are -9.090 kJ/mol and -8.816 kJ/mol, respectively. Using the 
second method (described on page 61) ΔΔG values are -7.573 kJ/mol and -8.795 kJ/mol. The 
difference between both methods after 10 ns and 14 ns is about 18.1% and 0.2%, respectively. 
The second method for ΔΔG calculation uses fewer integration steps, thus making it more 
precise. Moreover, in the complexmyr system greater energy changes were observed after 
production step 2 for 10 ns TI simulations. Thus, the first method can have higher calculation 
error and differs more.  
Our results show that ΔΔG is about -9 kJ/mol. Therefore, even whilst the 14 ns long 
TI simulations of complexmyr conversion into complexpalm do not indicate appropriate 
convergence; the calculated ΔΔG values vary little as the simulation is extended. 
In the replicate study, ΔΔG calculated using the second method was -9.164 kJ/mol 
after 10 ns TI simulation. As was mentioned above ΔΔG calculated by Durrant (2012) will a 
have higher uncertainty than our calculated ΔΔG due to higher energy fluctuation. 
Our calculated ΔΔG shows that ΔGM > ΔGP. Thus, palmitate binds stronger to I-FABP 
than myristate does. This was reported by Velkov et al. (2005 and 2007). Therefore, our 
calculated ΔΔG shows that our system is qualitatively comparable with experimental data. 
Nevertheless, ΔΔG is about five to seven times smaller than the ΔΔG calculated from the 
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experimental Kd values. These Kd values were obtained in experiments under varied 
conditions (Velkov et al., 2005, Velkov et al., 2007), resulting in varied experimental ΔΔG 
values. Thus, it could be assumed that the difference between our ΔΔG value and 
experimental ΔΔG values is due to different conditions. However, the difference between 
experimental ΔΔG values is small, while the difference between our calculated and 
experimental ΔΔG is about 5-7 times higher. Thus, it is likely that this difference is due to 
insufficient sampling or inadequate force fields within our simulated system. Therefore, our 
system is not quantitatively adequate and requires optimization. In further research an 
improvement in the system is required so that ΔΔG is close to experimental values.  
When the simulated system is optimized, TI simulations for artificially restricted 
myristate can be run. . The optimized system and TI integration data for genuinely flexible 
and artificially restricted myristate can be further used to calculate ΔΔG. The difference 
between the values can give an idea as to whether flexibility of FAs is important for stronger 
binding to FABP proteins. 
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4.3 INVESTIGATING THE FLEXIBILITY OF FREE MYRISTATE IN SOLUTION 
AND OF MYRISTATE BOUND TO I-FABP 
As our system is qualitatively comparable to the experimental data, MD simulations 
were performed, and conformations of myristate were grouped into clusters. Clustering results 
allowed suggestions to be made about potential bond and angle restrictions that can be used in 
further investigation. 
4.3.1 Clustering by the average link algorithm 
Grouping conformations of myristate by RMSD (set by default as < 0.6 Å) into 
distinct sets from one two five it was observed that myristate free in solution has one 
dominant conformation, while bound myristate forms two large clusters. Grouping myristate 
conformations into five clusters the biggest cluster of free myristate consists of 65.2% while 
two biggest clusters of bound myristate consist of 45.8% and 32.5% from the total count of 
myristate conformations (Figure 3.6). It could be true that the formation of a dominant cluster 
while myristate is free in solution is essential for myristate binding to I-FABP. Moreover, the 
dominant conformation of free myristate was found as highly similar to the myristate 
conformation when it binds to I-FABP (Figure 3.8). Therefore, the formation of a dominant 
conformation might be a driving force for myristate‟s strong binding to I-FABP. 
Although, higher similarity was observed comparing five bound myristate clusters 
between them (described on pages 66 and 67), the sum of conformation of two biggest 
clusters for free myristate is bigger than it is for bound myristate, respectively, 945 and 783 
from total 1000 myristate conformations. From this comparison it is hard to justify whether 
conformations of bound myristate are   more similar than conformations of free myristate. 
Moreover, the higher similarity could suggest, but cannot indicate whether free or bound 
myristate is more rigid, thus clustering by dihedral angles was performed. 
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4.3.2 Clustering by dihedral angles 
Clustering by dihedral angles was performed for each dihedral of free myristate in 
solution and bound myristate, using 36 bins. The angle distribution for each dihedral is 
represented in graphs (Figure 3.9 – 3.10). This dihedral analysis confirms that free myristate 
differs in angle range from bound myristate only at the 1
st
, 2
nd
 and 3
rd
 dihedrals (Figure 3.9 – 
3.10).  The 1
st
, 2
nd
 and 3
rd
 dihedrals are positioned at the head group of myristate. It was 
reported that FAs binds to FABP protein with their head groups while their aliphatic tail 
group moves freely (Woolf and Tychko, 1998). The same was observed in our clustering 
results. 
 The preferred angle range at the 1
st
, 2
nd
 and 3
rd
 dihedrals of myristate becomes more 
concise upon myristate binding to I-FABP indicating that free myristate is more flexible at 
these dihedrals than bound myristate. Important to note that myristate binding to I-FABP as 
well leads to a change in the angle distribution at the 2
nd
 dihedral angle.  
In the replicate study, MD simulations using the same simulation conditions were 
performed for palmitate. Clustering by dihedral angles was performed for each dihedral of 
free palmitate in solution and bound palmitate, using 36 bins (Durrant, 2012). The structure of 
palmitate differs from myristate by an additional ethyl group instead of the myristate‟s 28th 
hydrogen.  
Comparing the angle distribution for free myristate and free palmitate (Durrant, 2012) 
no high differences in the preferred angle ranges were observed. However, comparing the 
angle distribution for bound myristate and bound palmitate different preferred angle ranges at 
the 2
nd
, 4
th
 to 6
th
 dihedrals were observed. At the 4
th
 and 6
th
 dihedrals bound palmitate has 
only one preferred angle range while bound myristate has three preferred angle ranges. The 
dominantly preferred angle range for bound myristate and the only angle range for bound 
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palmitate are centred at 175º. The additional angle ranges for bound myristate indicate that at 
the 4
th
 and 6
th
 dihedrals bound myristate is more flexible than bound palmitate.   
At the 2
nd
 and 5
th
 dihedrals the preferred angle ranges are shifted differently for bound 
myristate and bound palmitate. At the 2
nd
 dihedral bound palmitate has only one dominate 
preferred angle range centred  at -70º, while bound myristate forms two, the dominantly 
preferred angle range is centred at 55º and the second preferred angle range at -70º. At the 5
th
 
dihedral, bound palmitate has three preferred angle ranges, the dominant at -75º, and the other 
two at 50º and 180º. While bound myristate forms two preferred angle ranges, the dominant at 
175º and the second at -70º.  
Crystal structures of FA interaction with FABPs show that the crystal structure of the 
protein-ligand complex indicated that FA may penetrate FABP with either aliphatic tail 
(Stewart, 2000, Zimmerman and Veerkamp, 2002, Thompson et al., 1997) or carboxylate 
(Stewart, 2000, Zimmerman and Veerkamp, 2002, Wolfrum and Spener, 2000, Haunerland 
and Spener, 2004, Sacchettini et al., 1989). In the most cases when FA penetrates FABP 
either with aliphatic tail or carboxylate FA are half buried in the FABP, but it can be buried in 
the FABP fully. For example, Tsfadia et al. (2007) showed that palmitate penetrates Toad-
liver FABP with the carboxylate group.  At the first palmitate is half buried into Toad-liver 
FABP, the carboxylate group is interacts only with Q56. Further, the carboxylate penetrates 
deeper into the Toad-liver FABP cavity there it becomes stabilized by Q56 and H58 (Tsfadia 
et al., 2007).  
Palmitate is longer than myristate by an additional ethyl group. As was mentioned 
above there is a difference in preferred dihedral angle ranges for myristate and palmitate. 
Thus, an additional ethyl group in palmitate should play a role in this difference.  It might be 
that due to the additional group the tail of palmitate interacting with the I-FABP and is forced 
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to penetrate I-FABP deeper than myristate does. Although this has not been investigated, 
higher restriction and difference in the angle distribution comparing to myristate might be 
explained by the deeper palmitate penetration into I-FABP. Thus, it could be, due to this 
palmitate binds stronger to I-FABP than myristate does. However, the extra carbon atoms 
should increase the van der Waals interaction and the hydrophobic effect to enhance binding, 
which should improve the binding affinity. Thus, it might be that the bigger flexibility of free 
palmitate in comparison to free myristate does not play a role in the stronger binding to I-
FABP. 
4.3.2.1 The change in myristate flexibility during its binding to I-FABP  
H/Hmax was used as a measure of dihedral flexibility. Dihedrals of free myristate were 
arranged in order with increasing flexibility: 5
th
 ≈ 9th < 6th = 10th ≈ 7th = 3rd ≈ 8th ≈ 11th ≈ 4th = 
12
th
 ≈ 2nd < 1st, while dihedrals of bound myristate were arranged in order with increasing 
flexibility: 10
th
 < 8
th
 ≈ 2nd = 5th = 12th ≈ 1st = 9th ≈ 3rd < 11th < 7th < 4th < 6th. H/Hmax for free 
myristate ranges from 0.60 to 0.88 at different dihedrals. Similar H/Hmax values from 0.58 to 
0.89 were calculated for free palmitate in the replicate study (Figure 3.11 (a)); indicating that 
flexibility of myristate at each dihedral is different. The most flexible free myristate and free 
palmitate are at the 1
st
 dihedral. This was expected, as the 1
st
 dihedral angle is formed 
between O-C1 and C2-C3, where C1 is bound to two oxygens which rotate freely around C1-C2 
bond.  
Myristate and palmitate binds to I-FABP with the head group. Thus, it was expected 
the head group will be the most rigid, when FAs binds to I-FABP. However, bound myristate 
is the most rigid at the 10
th
 dihedral, where H/Hmax is 0.54. H/Hmax for the 1
st
 and 2
nd
 and 3
rd
 
dihedrals is just a bit lower than the average H/Hmax = 0.62. In comparison bound palmitate is 
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the most rigid at the first four dihedrals (Figure 3.11 (a)), indicating that palmitate movements 
are restricted at these dihedrals by the interaction with the protein.  
Although, the bound myristate is the most rigid at the 10
th
 dihedral, the decrease in 
flexibility when myristate binds to I-FABP is at the first dihedral. Dihedrals of myristate were 
arranged of the decreasing change of flexibility: 11
th
 ≈ 3rd < 10th = 8th ≈12th ≈ 2nd < 1st. It is 
intriguing that when myristate binds to I-FABP it becomes more flexible at the 6
th
 dihedral. 
At the 4
th
, 5
th
, 7
th
 and 9
th
 dihedrals no change in flexibility was observed. In the replicate study 
palmitate had the largest decrease in flexibility at the 1
st
, 2
nd
 and 4
th
 dihedrals, the largest 
increase in flexibility at the 14
th
 and no change was observed at 5
th
, 8
th
, 10
th
, 12
th
 and 13
th
. 
4.3.2.2 Correlation coefficient 
Correlation coefficients for each dihedral angle were calculated to compare the 
similarity of the angle distribution between free and bound myristate. Dihedrals were arranged 
in order of increasing similarity between their free and bound myristate angle distribution is: 
2
nd
 < 1
st
 < 6
th
 < 4
th
 < 3
rd
 ≈ 7th = 12th ≈ 5th = 8th ≈ 9th = 11th ≈ 10th. The highest difference 
between the free and bound myristate angle distribution was observed at the 1
st
 and 2
nd
 
dihedrals, with correlation coefficients of 0.24 and 0.11, respectively, reflecting that myristate 
changes its preferred angle range for these dihedrals when it binds to I-FABP. At the other 
dihedrals, high similarity between free and bound myristate angle distribution was observed. 
The correlation coefficient at these dihedrals is > 0.94; except for the 4
th
 and 6
th
 it is 0.91 and 
0.88, respectively.  
During binding to I-FABP myristate adapts to the most energetically favorable 
conformation. An important fact is that the conformation of free myristate is very similar to 
the conformation when it is bound to I-FABP. The biggest differences between the free and 
bound myristate angle distribution and the biggest increase in the flexibility was observed at 
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the 6
th
 dihedral, excepting the 1
st
 and 2
nd
 dihedrals which have already been discussed. The 
correlation coefficients calculated for palmitate dihedrals in the replicate study were reported 
as 0 for the 2
nd
 and 5
th
 and as 0.55 for the 1
st
 indicating that there were no similarities between 
free and bound palmitate angle distribution  at these dihedrals. For the other dihedrals the 
correlation coefficients were < 0.85, except the 10
th
 and 13
th
 dihedrals, where it was 0.77 and 
0.81, respectively (Figure 3.11 (b)).  
Comparing the correlation coefficients for myristate and palmitate, myristate has half 
smaller correlation coefficient at the 1
st
 dihedral, indicating that the 1
st
 dihedral of myristate 
undergoes higher conformational changes than it does in palmitate. The correlation coefficient 
for myristate and palmitate at the 2
nd
 dihedral is 0.11 and 0.01, respectively (Figure 3.11 (b)). 
However, at the 2
nd
 dihedral palmitate has a smaller correlation coefficient, a shift in the 
preferred angle range been observed for both FAs upon their binding to I-FABP. The 
correlation coefficient at the 5
th
 dihedral for myristate indicates that the conformations of 
bound and free myristate are very similar at this dihedral. While the correlation coefficient at 
the 5
th
 dihedral for palmitate indicates that they have no similarities. It might be that the 
changes at the 5
th
 dihedral of palmitate are required to maintain an energetically favorable 
conformation for binding to I-FABP. At the 10
th
 dihedral, the correlation coefficients for 
myristate and palmitate are 0.99 and 0.77, indicating that palmitate undergoes bigger 
conformational changes at this dihedral. However, the changes between conformation of free 
and bound palmitate are small. The correlation coefficients at the other dihedrals of myristate 
and palmitate are similar.  
4.3.2.3 Is flexible FA stronger binding to I-FABP putative?  
Comparing our myristate dihedral clustering and palmitate clustering by Durrant (2012) 
was suggested that  due to two extra carbon atoms palmitate penetrates might penetrate I-
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FABP deeper resulting in the higher torsion restriction and difference in the angle distribution 
Palmitate becomes more rigid at the first four dihedrals, while myristate only at the first two. 
It might be that palmitate restriction at these four dihedrals causes the increase in the rigidity 
in the remaining molecule. As well it might be that the dihedral changes are due to the 
different binding conformations of myristate and palmitate. 
Myristate does not penetrate I-FABP as deep. Thus, the dynamics of the torsions in the 
head group of the bound myristate and bound palmitate might be different causing the 
palmitate to bind stronger to I-FABP. . As well it might be that palmitate binds stronger to I-
FABP due to additional ethyl group allows palmitate to penetrate I-FABP deeper and not due 
to an increase in rotatable bonds. Thus, it might indicate that flexible FA strong binding to I-
FABP is putative. It is assumed that FAs may have the best fit in the I-FABP cavity, which 
allows them to bind stronger to the protein than rigid ligands do. 
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4.4 FURTHER STUDIES 
Our clustering results by dihedral angle show that during myristate binding to I-FABP 
myristate became more rigid at the 1
st
 and 2
nd
 dihedrals and more flexible at the 6
th
. 
Therefore, the restriction of myristate should be considered at these dihedrals for the purpose 
to calculate the free energy effect of restriction. In the further studies TI simulations for 
conversion of artificially rigid myristate into flexible myristate should be performed and the 
difference of the free binding energy between artificially rigid and flexible myristate should 
be calculated (ΔΔGR-F). 
The restriction of free myristate at the 1
st
 dihedral to imitate the dominant 
conformation of bound myristate is expected to affect the loss of entropy. Artificially rigid 
myristate may lose less entropy as common dogma states and thus bind better. Therefore, a 
decrease in ΔΔGR-F would show that introduced rigidity improves myristate binding to I-
FABP. While, a positive ΔΔGR-F value would indicate that genuinely flexible myristate binds 
to I-FABP stronger than artificially rigid myristate does.  
As it was discussed before when myristate binds to I-FABP at most of the dihedrals it 
becomes rigid. However, the bound myristate is more flexible at the 6
th
 dihedral than when it 
is free in solution. Thus, a restriction of bound myristate at the 6
th
 dihedral to imitate the 
dominant conformation of free myristate could show if an increase in the flexibility at this 
dihedral supports bound myristate formed conformation similar to the conformation when it is 
free in solution. The importance of flexibility would be confirmed by a decrease in ΔΔGR-F 
value. 
The 2
nd
 dihedral as well should be considered for a restriction. When myristate binds 
to I-FABP, at this dihedral a shift in the preferred angle range was observed and myristate 
became more rigid around this torsion. . The restriction of bound myristate at this dihedral to 
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imitate the dominant conformation of free myristate by making the 2
nd
 dihedral angle of free 
myristate 180ᵒ big could give us evidence of how the conformation of myristate affects its 
binding to I-FABP. It could be true that the dominant conformation of free myristate is 
important for its interactions with the protein. Nevertheless, the restriction may not lead to 
binding. The binding to I-FABP of the artificially restricted myristate can be simulated even if 
the restriction would not lead to the myristate and I-FABP binding in an experimental system. 
Therefore, the change in ΔΔGR-F would show how big the effect of the conformational 
restriction on the binding of myristate and I-FABP is.  
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4.5 SUMMARY 
TI simulations of the conversion of myristate into palmitate in solution indicate a rapid 
convergence of <dU/dλ>. TI simulations of the conversion of complexmyr into complexpalm 
proceeded with greater conformational changes within the system. Therefore, these TI 
simulations need to continue until the energy of the system becomes constant for all λ. In 
comparison to the Durrant‟s study, where pressure relaxation time was 1 ns, pressure 
relaxation time 0.2 ns used in our studies allows for faster convergence of TI simulations. 
The calculated ΔΔG is around -9 kJ/mol for TI simulations run for 10 ns and 14 ns. 
Although the curves of <dU/dλ> for individual λ do not appear to completely converge, the 
calculated ΔΔG values vary little as the simulation is extended.  Subsequently minimal ΔΔG 
changes are expected after further TI simulations are continuation.  
 Our ΔΔG is quantitatively different from the experimental data (Velkov et.al. 2005, 
Velkov et.al. 2007). This could be due to incomplete sampling (particularly of the slower 
protein motions), due to inadequacies in the force field or indeed inadequacies in the 
conditions used, although the first two reasons are more likely. Nevertheless, the negative 
value of ΔΔG, calculated from both ours and the Velkov et al. (2005 and 2007) data shows 
that palmitate binds to I-FABP stronger than myristate does. Therefore, the system can be 
used as a qualitative model in the investigation of the role of ligand flexibility in the binding 
of myristate to I-FABP. Nevertheless, optimization of the system would be advisable to make 
it match the experimental data more closely. 
 Clustering by the average link algorithm showed that both free myristate and bound 
myristate have a dominant conformation. Whilst binding to I-FABP, myristate becomes more 
rigid close to the head group. Change in conformation was also observed in the head group 
accompanied by a change in conformational preference.  
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At the 6
th
 dihedral bound myristate is the most flexible, but at the 10
th
 dihedral it is the 
most rigid. However, the 1
st
 and 2
nd
 dihedrals experience the biggest decrease in flexibility, 
upon binding I-FABP compared to the others dihedrals.  
It is assumed that the more flexible palmitate may bind stronger to I-FABP due to its 
ability to penetrate I-FABP more than myristate can. Thus, it might indicate that flexible FA 
strong binding to I-FABP is putative. Thus, it might be that the structure of I-FABP and the 
structure of the protein cavity are favorable for FAs penetration and strong binding to I-
FABP. 
The restriction of the rotation around a dihedral in silico will lead to a measurable 
change in ΔΔGR-F. If we work on the assumption that flexibility could somehow be beneficial 
in the thermodynamics of myristate binding to I-FABP, then restricting myristate at the 1
st
 
dihedral should make ΔΔGR-F more negative, but at the 6
th
 dihedral should make ΔΔGR-F less 
negative.  
Thus, the simulations presented here provide a good basis for system optimization to 
qualitatively and quantitatively understand the role of flexibility in myristate binding to I-
FABP, thereby resolving the potential anomaly that was described in the introduction.  
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Project 2:  
STUDYING THE EFFECT OF THE BACTERIAL NDK PROTEINS ON 
HAEMOPOIETIC STEM CELLS 
  
ABSTRACT 
Leukaemia patients lack immunity, thus they are more responsive to bacterial 
infections. Moreover, infections are likely to worsen the leukaemia prognosis. It might be that 
bacterial invasion can affect leukaemia cells, by rendering the latter more aggressive, or even 
by stimulating cell proliferation. 
Previous research has indicated that overexpression of NM23-H1 is related with poor 
prognosis of leukaemia patients. Moreover, additional rNM23-H1 is able to bind to more 
mature cells and indirectly promote leukaemia and healthy stem cell survival and 
proliferation. High structural similarity in NDK proteins may lead to functional similarity. 
Thus, additional bacterial NDK protein may indirectly promote leukaemia, healthy stem cell 
survival and proliferation as it was shown using rNM23-H1.  
In our project we optimized purification of CD34
+ve 
reaching 75.8 - 85.7% high purity. 
The positive control (rNM23-H1) failed to work; hence no suggestions can be made about 
rNDK effect on cord blood stem cells. The fail of positive control can be explained by 
possible rNM23-H1 activity loss due to protein aggregation after purification. Furthermore, 
the protocol of cord blood storage used for CB samples from previous studies was altered in 
our study. This change could affect CD34
-ve
 and/or CD34
+ve
 cell activity. Based on the latter, 
our study aimed to explore valuable directions for future research.
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CD34
+ve
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+ve
 cells treated with conditioned media collected from treated  
CD34
-ve
 cells with S.aureus rNDK protein 
CD34
+ve
/CM-SP CD34
+ve
 cells treated with conditioned media collected from treated  
CD34
-ve
 cells with S.pneumoniae rNDK protein 
CFU Colony forming unit 
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CM Conditioned media 
CMdep Recombinant NDK protein depleted conditioned media 
CM-EB Conditioned media collected from CD34
-ve
 cells treated with elution buffer 
CM-EC conditioned media collected from CD34
-ve
 cells treated with E.coli rNDK 
protein 
CM-KP Conditioned media collected from CD34
-ve
 cells treated with 
K.pneumoniae rNDK protein 
CML Chronic myeloid leukaemia 
CM-NM Conditioned media collected from CD34
-ve
 cells treated with rNM23-H1 
protein 
CM-SA Conditioned media collected from CD34
-ve
 cells treated with S.aureus 
rNDK protein 
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CM-SP Conditioned media collected from CD34
-ve
 cells treated with S.pneumoniae 
rNDK protein 
EB Elution buffer 
EBV Epstein-Barr virus 
GEC Gingival epithelial cell 
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1 INTRODUCTION 
 The immune system is an important biological system which acts with the aim to 
protect the body against infections caused by bacteria, parasites, fungi and viruses. Blood 
cells such as macrophages, neutrophils, mast cells, eosinophils, basophils, and natural killer 
cells are involved in defense of the body (Janeway et al., 2005). 
 Formation of normal haemopoietic cells is disrupted in leukaemia patients; thus 
leukaemia patients lack immunity (Wang and Dick, 2005) and are more responsive to 
bacterial infections (Bucaneve et al., 2007). Moreover, infections are likely to worsen 
leukaemia prognosis. It might be that bacterial invasion can affect leukaemia cells making 
them more aggressive or somehow the bacteria may support leukaemia cell proliferation. 
The nucleoside diphosphate kinase (NDK) protein family includes is highly conserved 
and includes bacterial and eukaryotic proteins such as human non-metastatic protein 23 
(NM23) group. Most of the work on human NDK protein (NM23 protein) in leukaemia has 
been carried out in a recent past by Okabe-Kado and Willems, who focused mainly on 
expression of human non-metastatic protein 23 (NM23) by haemapoietic cells and 
investigated the effect of additional NM23 proteins on healthy haemapoietic and leukemia 
cells. Since then has been shown that overexpression of NM23 homologue 1 (NM23-H1) is 
related with patient poor prognosis (Steeg et al., 1988, Yokoyama et al., 1996, Willems et al., 
1998, Niitsu et al., 2000, Okabe-Kado et al., 2002, Okabe-Kado et al., 2009). Additional 
NM23 proteins can inhibit differentiation of healthy and leukaemia cells (Okabe-Kado et al., 
1988, Okabe-Kado et al., 1992, Okabe-Kado et al., 1995) or alter cytokine induced 
differentiation (Willems et al., 2002), and promote acute myeloid leukaemia (AML) cell 
survival (Okabe-Kado et al., 2009). Lilly et al (2011) showed the most important finding in 
NM23 protein investigation, where additional recombinant (rNM23-H1) protein can bind to 
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more mature CD34
lo
/CD11b
+ve
 cells and indirectly promote survival and proliferation of 
healthy and leukaemia stem cells (CD34
+ve
). Because bacterial and eukaryotic NDK proteins 
are highly conserved, we hypothesize that bacterial NDK proteins will act on leukaemia cells 
as it was observed by Lilly et al (2011) using the NM23-H1 protein.  
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1.1 HAEMOPOIESIS 
The process of blood cell formation from haemopoietic stem cells (HSCs) is called 
haemopoiesis. Differentiation of HSCs promotes formation of various blood cell lineages 
(Figure 1.1). Blood cells are divided into red and white cells, where red cells incorporate the 
erythroid lineage. White cells are divided into myeloid and lymphoid cells (Hoffbrand et al., 
2008).  
1.1.1 Haemopoietic stem cells (HSCs) 
HSCs have multipotent stem cell capacity, as they are able to differentiate into 
haemopoietic progenitor cells, which can further differentiate and maturate into various 
haemopoietic cells (Figure 1.1). Moreover, HSCs are capable of self-renewal. Thus, HSCs 
produce transit amplifying cells and then split into differentiated lineages (Hoffman et al., 
2009). Progenitor cells differentiate and forms colony forming units (CFUs) (Figure 1.1). 
Further differentiation lead to mature blood cells. Despite progenitor cell ability to 
differentiate, they and their successors do not have self-renewal potential. Therefore, all blood 
cells can only be derived by HSC differentiation (Hoffbrand et al., 2008).  
In murine bone marrow, the ratio of HSCs to the total amount of blood cells is one in 
10,000 to 100,000. HSCs can be distinguished into long-term and short-term HSCs (LT-HSCs 
and ST-HSCs, respectively). Most of the HSCs are LT-HSCs that are. When LT-HSCs leave 
the steady state they become ST-HSCs that have the potential to differentiate into mature 
blood cells. LT-HSCs have the highest self-renewal potential. Moreover, in vivo studies have 
shown that ST-HSCs have limited self-renewal potential as they disappeared after 4-6 weeks 
(Coulombel, 2004). 
  
MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 109 of 190 
 
 
 
Figure 1.1 Formation of blood cell lines. LT-HSC and ST-HSC - long term and short term 
haemopoietic stem cells, BFU – burst forming unit, CFU – colony forming unit, Baso – 
basophil, E – erythroid, Eo – eosinophil, G – granulocyte, GEMM – granulocyte, erythroid, 
monocyte and megakaryocyte, GM – granulocyte, monocyte, GMEo – granulocyte, monocyte 
and eosinophil, M – monocyte, Meg – megakaryocyte. (Reproduced from Hoffman et al, 2009 
and Hoffbrand et al, 2006) 
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The main site of haemopoiesis in adults is bone marrow. HSCs and progenitor cells 
differentiate here and usually do not leave the bone marrow. Nevertheless, they are able to 
exit the bone marrow as they are found in peripheral blood in low numbers. High migration of 
HSCs occurs in haematological malignancies (Hoffbrand et al., 2008, Hoffman et al., 2009). 
Bone marrow is distinguished into two niches – endosteal and vascular (Figure 1.2). 
The endosteal niche is formed by osteoblasts, stromal fibroblasts and CXCL12-abundant 
reticular cells. These cells are involved in the regulation of HSC number and their function. 
HSCs found in endosteal niche are quiescent. Osteoblasts are maintaining HSC self-renewal. 
Migration of HSCs to a vascular niche leads HSCs to become active. Thus, in the vascular 
niche HSCs proliferate and differentiate (Buske et al., 2002, Wilson and Trumpp, 2006, Lilly, 
2011). 
 
 
 
Figure 1.2 Bone marrow niches. (Reproduced from Wilson and Trumpp, 2006) 
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1.1.2 Leukaemia stem cells (LSCs) 
Mutations within HSCs may lead HSCs to become cancer stem cells called leukaemia 
stem cells (LSCs). The important fact is that any cancer is a heterogenic cell population. Thus, 
within a cancer there are cancer stem cells and more mature cancer cells (Heppner and Miller, 
1993, Dick, 2008). Cytotoxic chemotherapy is one cancer treatment where chemotherapeutic 
agents kill rapidly dividing cells. As quiescent LSCs do not divide, they may survive 
chemotherapy and restore depleted leukaemia cell heterogeneity (Dick, 2008, Sehl et al., 
2009). Bacteria may invade leukaemia patients and can affect LSCs making them more 
aggressive and more resistant to chemotherapeutic agents, thus causing leukaemia to reoccur. 
However, bacteria can invade leukaemia patient after chemotherapy. Thus, bacteria may 
support LSC proliferation and relapse of leukaemia.  
1.1.3 Haemopoietic cell molecular markers  
Cell molecular markers are antigens of which the expression changes with cell 
differentiation (Dick, 2008). Therefore, molecular markers allow us to distinguish 
haemopoietic cells at the various development stages. Unfortunately, there is no unique 
marker for HSCs, progenitor cells or even mature haemopoietic cells. To distinguish these 
cells combination markers can be used (Hoffman et al., 2009).  
Some of the cell molecular markers are expressed only in immature cells, whilst the 
others are found only in the more mature cells. For example, human HSCs and multipotent 
progenitor (MPP) cells express CD34. It is highly expressed in the most immature HSCs, its 
expression lowers with stem cell maturation (Shizuru et al., 2005). While CD38 marker is 
absent in an early stage of heamopoiesis and its expression is observed on common myeloid 
progenitor cells (CMPs) (Wang et al., 2012).   
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Cell molecular markers are species dependent. The markers that are commonly used to 
identify mouse and human HSCs are shown in the Figure 1.3 (a). LSCs, as well as HSCs, 
express CD34 marker and lacks CD38. However, there is a difference in expressed markers 
by LSCs and HSCs (Figure 1.3). LSCs lack CD90 and CD117 cell markers, which are 
expressed by HSCs. Moreover, CD123 known as well as interleukin-3 receptor α (IL-3Rα) is 
expressed only by LSCs (Wang and Dick, 2005). It might be that receptor IL-3Rα is required 
for LSCs abnormal behavior and life cycle maintenance. 
Different types of mature haemopoietic cells may express the same markers such as 
CD11b as well as an individual marker for the cell lineage. CD11b is expressed by monocyte-
macrophage lineage (Grigoriadis et al., 2010) as well by natural killer cells and T-cells 
(Moreau et al., 2009).  
(a) 
 
Mouse haemapoietic cell markers 
HSC/LT-HSC CD34
-ve
 Lin
-ve
 c-Kit
+ve
 Sca1
+ve
 CD150
+ve 
ST-HSC/MPP CD34
+ve
 Lin
-ve
 c-Kit
+ve
 Sca1
lo
 CD150
-ve
 
  
Human haemapoietic cell markers 
HSC CD34
+ve
 CD38
-ve
 Lin
-ve
 CD90
+ve
 CD45RA
-ve
 CD49f
+ve 
MPP CD34
+ve
 CD38
-ve
 Lin
-ve
 CD90
-ve
 CD45RA
-ve
 CD49f
-ve
 
CMP CD34
+ve
 CD38
+ve
 Lin
-ve
 CD45RA
-ve
 CD123
med
 CD135
+ve 
CLP CD34
+ve
 CD7
+ve
 CD10
+ve 
  
(b)  
  
Haemapoietic and leukaemia stem cell markers 
HSC Lin
-ve
 CD34
+ve
 CD38
-ve
 CD90
+ve
 CD117
+ve
 CD123
-ve
 
LSC Lin
-ve
 CD34
+ve
 CD38
-ve
 CD90
-ve
 CD117
-ve
 CD123
+ve
 
 
Figure 1.3 Expression of haemopoietic cell markers, where LT-HSC and ST-HSC - long 
term and short term haemopoietic stem cells, MPP - multipotent progenitors, LSC – 
leukaemia stem cells, CMP = common myeloid progenitor cells and CLP – common 
lymphoid progenitor cells (a) Mouse (adapted from Wognum and Szilvassy (2013)) and 
human haemopoietic cell markers (adapted from Wang et al, 2012 (b) comparison of cell 
markers between LSCs and HSCs (cell molecular markers are adapted from Wang and Dick, 
2005) 
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1.2 LEUKAEMIA 
Leukaemia is cancer of the blood cells, which manifests itself by an increase in 
functionally immature blood cells (Wang and Dick, 2005). Accumulation of the immature 
cells in the bone marrow causes a decrease in the healthy cell development. Thus, leukaemia 
patients are immunocompromised. Moreover, the excess of leukaemia cells may exit the bone 
marrow, and they spread to the other organs.  
There are four main types of leukaemia: acute and chronic lymphocytic leukaemia 
(ALL and CLL, respectively), and acute and chronic myeloid leukaemia (AML and CML, 
respectively). Other rarer leukaemias also exist, e.g. hairy cell leukaemia, T-cell 
prolymphocytic, large granular lymphocytic, adult T-cell leukaemia, etc. (Hoffbrand et al., 
2008). 
1.2.1 Acute myeloid leukaemia (AML) and its treatments  
AML is a cancer of myeloid blood lineages. It proceeds as abnormal white blood cell 
growth. Primary AML occurs in previously healthy patients whilst secondary AML develops 
from myelodysplastic syndromes (MDS) or other haemopoietic diseases. AML patients are 
assigned to the secondary AML group if they had any exposure to carcinogens, radiation or 
they have reoccurring AML (Rowe, 2002). 
Common treatments for leukaemia including AML are chemotherapy, radiotherapy, 
blood transfusion, bone marrow transplants or other drug treatments. Treatment method 
depends on the type of AML as well on the age of a patient (Burnett et al., 1998))  
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1.2.2 Bacterial infections in the AML patients 
Human beings are continuously exposed to harmful microbiological organisms. In a 
healthy person, the immune system controls the extent and duration of the infection. As the 
immune system of AML patients is depleted, they are at a high risk of bacterial, viral or 
fungal infections (Janeway et al., 2005). Moreover, infections are likely to worsen the AML 
prognosis. From clinical data in the period from 1980 until 2005, Buncaneve et al (2007) 
quantified that bacterial infections are responsible for 30-40% of all febrile episodes in acute 
leukaemia and haemopoietic stem cell transplantation (HSCT) patients. Moreover, 30% of all 
infections were caused by infection of the bloodstream (Bucaneve et al., 2007). 
Bacterial infection can be caused by gram-negative and gram-positive bacteria. These 
were accounted as 10% and 15%, respectively, of total febrile episodes in acute leukaemia 
and HSCT patients, respectively. The most common gram-negative bacteria causing an 
infection in leukaemia patients are Escherichia coli (Kern et al., 2005, Gomez et al., 2003, 
Buncaneve et al., 2007), Pseudomonas spp such as Pseudomonas aeruginosa (Kang et al., 
2003), Enterobacter cloacae (Tancrede and Andremont, 1985) and Salmonella typhimurium 
(Helms et al., 2002, Tancrede and Andremont, 1985). Most common gram-positive bacteria 
are Staphylococcus spp such as Staphylococcus aureus (Madani, 2000, Marty et al, 2006, 
Buncaneve et al., 2005) and Streptococcus spp such as Streptococcus pneumonia (Madani, 
2000, Bucaneve et al., 2007). E.coli and Staphylococcus strains such as Staphylococcus 
epidermidis are not pathogenic to healthy humans, yet may cause infection in immune-
suppressed patients.  
Prophylaxis of bacterial infection in the AML patient treatment includes antibiotics, 
antiseptics for bathing, mouthwashes and a “clean diet”. Patients with neutropenia, on anti-
cancer chemotherapy, and severely immunocompromised patients to prevent bacterial and 
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viral infections are usually kept in a reverse-barrier room. The amount of protection required 
varies with the patient (Hoffbrand et al., 2008, Schimpff et al., 1975).  
Prophylaxis is very important, but it does not protect leukaemia patient from bacterial 
infection 100%, and it does not cure leukaemia. Nevertheless, it improves patient prognosis, 
for example, prophylaxis of acute leukaemia and HSCT patients using fluoroquinolone was 
associated with a reduction in mortality of 48% in causes, and a reduction in infection-related 
mortalities of 68% (Bucaneve et al., 2007).  
In conclusion, bacterial infections are likely to occur in leukaemia patients as their 
immune system is suppressed. Bacterial infection prophylaxis using antibiotics has been 
shown to reduce mortality in leukaemia patients. Therefore, a number of questions arise; do 
bacterial infections affect or support the development of leukaemia? Is there a united 
mechanism for different bacterial strains to affect leukaemia?  
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1.3 NUCLEOSIDE DIPHOSPHATE KINASE (NDK) PROTEINS 
NDK proteins are enzymes (phosphotransferases), which reversibly catalyze the 
exchange of terminal phosphate groups between nucleoside diphosphate and nucleoside 
triphosphate (Berg et al., 2002).  
NDK proteins are highly conserved. Human NDK proteins are named as non-
metastatic proteins 23 (NM23) because at their discovery; the time expression of NM23-H1 
protein was found related to the suppression of metastasis (Steeg et al., 1988). Ten 
homologues of NM23 have been identified, and named as NM23-H1, NM23-H2, NM23-H3, 
NM23-H4, NM23-H5, NM23-H6, NM23-H7, NM23-H8, NM23-H9 and NM23-H10 (Bilitou 
et al., 2009). The sequence of NM23 homologues is shown in figures 1.4. The biggest 
sequence similarity (88.2%) is between NM23-H1 and NM-23-H2, while 65.8% and 55.3% of 
the NM23-H1 sequence is identical to the sequence of NM23-H3 and NM23-H4, respectively 
(Figure 1.4).  
Not only human NDK homologues have high sequence identity. Eukaryotic and 
bacterial NDK proteins are also highly conserved. For example, E.coli NDK protein has 57% 
sequence identity with its homologue in Myxococcus xanthus, 45% with Dictyostelium 
discoideum (Hama et al., 1991) and 95% with K.pneumoniae NDK protein (Figure 1.5). 
NM23-H2 possess 45% and 67% sequence identity with Mycobacterium tuberculosis (Chen 
et al., 2002) and Dictyostelium NDK protein (Dumas et al., 1992), respectively. NM23-H1 
has 43%, 44%, 47% and 53% sequence identity with E.coli, K.pneumoniae, S.pneumoniae, 
S.aureus NDK proteins, respectively (Figure 1.5).  
Eukaryotic and bacterial NDK proteins are structurally very similar. The Killer of 
prune (Knp) loop, α helixes and β sheets are distinguished in the NDK protein tertiary 
structure. In figure 1.6, they are matched on to the E.coli, K.pneumoniae, S.pneumoniae, 
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S.aureus NDK protein and NM23-H1 sequences. The most conserved regions are the Knp 
loop, β1 and α5. The Kpn loop has an important role in kinase activity of the NDK protein 
(Bilitou et al., 2009). Thus, structural similarities in-between bacterial and human NDK 
proteins may also mean that bacterial and human NDK proteins have functional similarity. 
Thus, bacteria may affect leukaemia cells in a similar way. 
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                                        1    5       
H3                                        M I C L V L T I    
  10     15     20     25     30     35     40     45     50     55    
H1          M A N C E R T - F I A I K P D G V Q R G L V - G E I I K R F E Q K G F R L V G L K 
H2          • • • L • • • - • • • • • • • • • • • • • • - • • • • • • • • • • • • • • • A M • 
H3 F A N L F P A A C T G A H • • • - • L • V • • • • • • • R • • - • • • V R • • • R • • • K • • ∆ • • 
H4  V R H G S G G P S W T R • • • - L V • ○ • • • • • • • ○ • • - • D V • Q • • • ○ R • • T • • • ∆ • 
H5  M E I S M P P □ Q I Y V • K • - □ A I • • • • I • D K E - - - E • • Q D I I L ○ S • • □ I • Q R R 
H6   M A ◊ I L R S P Q ○ ∆ Q L • - □ ◊ L • • • • A • A H P • I L ◊ A □ H □ Q ◊ ◊ S N K • L ◊ • R ∆ ◊ 
H7          • N H S • • F V • • • E W Y • P N ⌂ S L • R R Y • L L - - • - Y P • D G S • E ∆ H 
H8   ⌂ ⌂ ◊ K K ⌂ E V ⌂ L Q T V I - N N Q S L W • E M L Q N K - - • L T ○ I D V Y • A W C ӿ P C ⌂ A M 
H9   ⌂ ○ ◊ □ # □ L ○ V V D V Q G - W C G P C K P V • S F Q # M ӿ I • □ G L # L ◊ H F A L A E A D ◊ L 
H10 M G C F ○ A # ⌂ R K • D K • S R - P E N ӿ E E R ӿ K • Y S W D Q R • K ○ ◊ P K D ӿ M F S ӿ • K × E T 
  60     65     70     75     80     85     90     95     100     105    
H1 F M Q A S E D L L K E H Y V D L K D R P F F A G L V K Y M H S G P V V A M V W E G L N V V K T G R V 
H2 • L R • • • E H • • Q • • I • • • • • • • • P • • • • • • N • • • • • • • • • • • • • • • • • • • • 
H3 L V • • • • ∆ • • R • • • A E • R E • • • Y G R • • • • • A • • • • • • • • • Q • • D • • R • A • A 
H4 M ∆ • • P • S V • A • • • Q • • ○ R K • • ○ ∆ A • I R • • S • • • • • • • • • • • Y • • • ○ A S • ○ 
H5 K ∆ ∆ L • P ∆ Q C S N F • • ○ K Y G □ M • • ∆ N • T A • • □ • • • L • • • I L A R H K A I S Y W L E 
H6 E ∆ L W R K ∆ D ◊ Q R ◊ • R ○ H E ◊ • F • ○ Q ○ • • E F • ○ • • • I R • Y ◊ ◊ ◊ H K ○ ◊ ◊ Q L ◊ • T 
H7 D ○ K N H R T F • • ⌂ T K Y • N L H I E D L F I G N • V N V F S R Q L V L ◊ D Y • D Q Y T A R Q ◊ G 
H8 Q P ⌂ F ⌂ ⌂ L K N E L N E D ○ I ӿ ӿ F A V A E □ D ӿ I ӿ T L Q P F R D K C E P V F • F S • N G K I I 
H9 ӿ ○ ⌂ E K Y R G K C • P T F L F ◊ A ӿ K ӿ E • L S D ⌂ D E C V ӿ H G K N N G E D E ӿ M • S ◊ E R T C 
H10 V G ∆ ◊ □ G ӿ □ A G ∆ Q - × × # Q • C ӿ N C N ӿ Y □ F × - • • A T V T I D D C T N C I I F L P V K ӿ 
  110     115     120     125     130     135     140     145     150     155    
H1 M L G E T N P A D S - - - K P G T I R G D F C I Q V G R N I I H G S D S V E S A E K E I G L W F H P 
H2 • • • • • • • • • • - - - • • • • • • • • • • • • • • • • • • • • • • • • K • • • • • • S • • • K • 
H3 L I • A • • • • • A - - - P • • • • • • • • • • E • • K • L • • • • • • • • • • R R • • A • • • R A 
H4 • ○ • H • D S • E ○ - - - A • • • • • • • • S V H I S • • V • • A • • • • • G • Q ○ • • Q • • • Q S 
H5 ○ • • P N • □ L V ○ K E T H • D S L • A I Y G T D D L • • A L • • • N D F A A • • ○ • • R F M • P E 
H6 ○ M • ◊ • R V F R ○ R H V □ • ◊ ◊ • • • S • ◊ L T ◊ T • • T T • • • • • • V • • S ○ • • ○ A F • ◊ D 
H7 S R K • K T I • L I - - - • • ◊ A • S K A G E • I E I I • K A G F T I T K L K M M M L S P K E A L ⌂ 
H8 E K I Q G A N • P L - - - V N K K V I N L I D E ○ R K ӿ A ◊ G E M A R P Q Y P E I P ӿ V D S D S E V 
H9 T • A I I K • D A V - - - □ H • # T D E ◊ # M K ӿ Q E A G F E I L ӿ ◊ E E R T ӿ T E A E V R L • Y G 
H10 ӿ V F F R • C R • C - - - • C T L A C Q Q • R □ R ◊ C • K L × V ӿ L C C A T Q P # I • ӿ ∆ # N I ∆ F 
  160     165     170     175     180     185     190     195     200     205    
H1 - - E E L V D Y T S C A Q N W I Y E                                 
H2 - - • • • • • • K • • • H D • V • •                                 
H3 - - D • • L C W E D S • G H • L • •                                 
H4 - - S • • • S ○ A ○ G G • ○ S S I H P A                               
H5 V I V • P I P I G Q A • K ∆ Y ○ N L H I M P T L L E G L T E L C K Q K P A D - P L I W L A D W L L K 
H6 - F □ • Q R W • ○ E E E P Q L R C G ◊ V C Y S P E G ◊ V H Y V A G T G G L G - ◊ A          
H7 - ⌂ H V D H Q S R P F F N E ⌂ • Q F I T T G P I I A M E I L R D D A I C E W K R ◊ ◊ G P ◊ N S G V A 
H8 - - □ • E S ◊ C ○ • V Q E L ◊ □ □ A ӿ ◊ K ◊ D A V I S K K V ◊ E ◊ R ◊ I - T ӿ A G F I I E A E H K I 
H9 - - ӿ K A G E E □ F ⌂ K L V H H M C C G S S H E ◊ # L T # T E G F E D V V # - T W R T V M G P R D D 
H10 - - G C F Q ⌂ • Y ӿ ⌂ L A F Q F K D A × L × I F N N T W S N I H ӿ F T ◊ × S - G E L N W S L L P E × 
  210     215     220     225     230     235     240     245     250     255    
H5 N N P                                                
H6                                                   
H7 R I D A S A S I R A I F G T D G I R N A A H G P D S F A S A A R E M E L F F P S S G G C G P A N T A 
H8 V L T E E Q V V N F Y S R I A D Q C D F E E F V S F M T ӿ G L S Y I L V V S Q G ӿ K H N P ӿ S E E T 
H9 P ◊ V ӿ R R E Q - P E # L R # Q Y G T E M P # N A V H G ӿ R D ӿ ӿ D A D R E L A L L F P S L K F S D 
H10 A V × Q D Y # P I × T T E E L K A V R V S T E A N R S I V P I # R G Q R Q K S ӿ D E S ӿ L V V L F ӿ 
  260                                                 
H5                                                   
H6       265     270     275     280     285     290     295     300     305    
H7 K F T N C T C C I V K P H A V S E G L L G K I L M A I R D A G F E I S A M Q M F N M D R V N V E E F 
H8 E P Q T D ӿ E P N E R S E D Q P ӿ V E A Q V T P G M M N K Q D S L Q E Y L E R Q H L A Q L C D I ӿ E 
H9 ӿ D ӿ E A P Q G E S S T Q P R L K I T D L D                             
H10 G × Y # I A N A R K L I D E M V G K G F F L V Q T K E V S M K A ӿ D A Q R V F R E K # P D F L P L L 
  310     315     320     325     330     335     340     345     350     355    
H7 Y E V Y K G V V T E Y H D M V T E M Y S G P C V A M E I Q Q N N A T K T F R E F C G P A D P E I A R 
H8 D A A N V A K F M D A F F P D F K K M K S M K L E K T L A L L R P N L F H E R K D D V L R I I K D E 
H9                                                   
H10 N K G P # I A L E F N G D G A V ӿ V C Q L I V N # I F N G T K M F V S E S K ӿ T A S G D V D S F Y N 
  360     365     370     375     380     385     390     395     400     405    
H7 H L R P G T L R A I F G K T K I Q N A V H C T D L P E D G L L E V Q Y F F K I L D N         
H8 D F K I L E Q ӿ Q V V L S E ӿ E A Q ӿ L C K E Y E N ӿ ӿ Y F N K L I E N M T S G P S L A L V L L R D 
H9                                                   
H10 F A D # Q M G I                                           
  410     415     420     425     430     435     440     445     450     455    
H8 N G L Q Y W K Q L L G P R T V E E A I E Y F P E S L C A Q F A M D S L P V N Q L Y G S D S L E T A E 
                                                   
  460     465     470     475     480     485     490     495     500     505    
H8 R E I Q H F F P L Q S T L G L I K P H A T S E Q R E Q I L K I V K E A G F D L T Q V K K M F L T P E 
  510     515     520     525     530     535     540     545     550     555    
H8 Q I E K I Y P K V T G K D F Y K D L L E M L S V G P S M V M I L T K W N A V A E W R R L M G P T D P 
  560     565     570     575     580     585     590     595     600     605    
H8 E E A K L L S P D S I R A Q F G I S K L K N I V H G A S N A Y E A K E V V N R L F E D P E E N    
                                                   
     • The same AA as in H1   ○ The same AA as in H3   ◊ The same AA as in H5   ӿ The same AA as in H7   × The same AA as in H9    
     ∆ The same AA as in H2   □ The same AA as in H4   ⌂ The same AA as in H6   # The same AA as in H8        
Figure 1.4 Alignment of NM23 homologous protein sequences, where H1 to H10 are NM23-H1 to NM23-H10, AA – amino acid (Reproduced from Mehus et al., 1999, PubMed protein database)
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 1    5     10     15     20     25     30   
NM23-H1 M A N C E R T F I A I K P D G V Q R G L V G E I I K R F E Q K G 
E.coli ● ● I - ● ● ● ● S I ● ● ● N A ● A K N V I ● N ● F A ● ● ● A A ● 
K.Pneumoniae ● ● ○ - ● ● ● ● ○ ○ ● ● ● ○ ○ ● ○ ○ ○ ○ ○ ● S ● ○ S ● ● ● ○ ○ ● 
S.aureus ● - - - ● ● ● ● L M ● ● ● ● ○ ● ● ● ○ ● ○ ● ● V ● S ● I ● R ● ● 
S.pneumonia ● - - - ● Q ● ● F ○ ● ● ● ● ● ● K ● ● ● ● ● ● V L ● ● I ● ● R ● 
   35     40      45     50     55     60    
NM23-H1 F R L V G L K F M - Q A S E D L L K E H Y V D L K D R P F F A G 
E.coli ● K I ● ● T ● - ● L H L T V E Q A R G F ● A E H D G K ● ● ● D ● 
K.Pneumoniae ● ○ - ● ● ○ ● - ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ E ○ ● ● ● ● ○ ● 
S.aureus L ○ ● ● ● G ● L ● - ● V P M ○ ● ○ E T ● ● G ○ ○ Q ○ ○ ● ● Y N D 
S.pneumonia ● T ○ E K ● E ● R S ● V ● ● ○ ● I D Q ● ● Q ● ● V ○ Q S ● Y P P 
  65     70     75     80     85     90     95 
NM23-H1 L V K Y M H S G P V V A M V W E G L N V V K T G R V M L G E T N 
E.coli ● ● E F ● T ● ● ● I ● V S ● L ● ● E ● A ● Q R H ● D L ● ● A ● ● 
K.Pneumoniae ● ● ○ ● ● ○ ● ● ● ○ ● ○ ○ ● ○ ● ● ○ ● ○ ● ○ ○ ○ ● ○ ○ ● ● ○ ● ● 
S.aureus ● I S ● I ○ ● A ● ● F ● ● ● V ● ● ○ D ○ ● N V S ● H I I ● S ● ● 
S.pneumonia I R ○ ● ● ○ ● ● ● ● L ○ G ● I S ● P K ● I E ● W ● T ● M ● ○ ● R 
     100     105 
 
   110     115 
 
        120   
NM23-H1 P A D S K P G T I R G D F C I Q V G R N - I I - - - - H G S D S 
E.coli ● ● N A L A ● ● L ● A ● Y A D S L T E ● - G T - - - - ● ● ● ● ● 
K.Pneumoniae ● ● ○ ○ ○ ○ ● ● ○ ● ○ ● ○ ○ ○ ○ F ○ ○ ● - ○ ○ - - - - ● ● ● ● ● 
S.aureus ● S E ○ S ● ● S ● ● ● ● L G L T ● ● ● ● - ● ● - - - - ● ● ● ● ● 
S.pneumonia ● E E ○ ○ ● ● T ● ● ● ● ● ○ K A A ● ○ ● E ● ● Q N V V ● ● ● ● ● 
   125    130     135     140     145     150      
NM23-H1 V E S A E K E I G L W F H P E E L V D Y T S C A Q N W I Y E   
E.coli ● ● ● ● A R ● ● A Y F ● G E G ● V C P R ● R           
K.Pneumoniae ● ● ● ● ○ ○ ● ● ○ F ○ ● A ○ ○ ● ○ ○ ○ ○ ● ○           
S.aureus L ● ● ● ● ○ ● ● N ● ● ● N ○ N ● I T S ● A ● P R D A ● L ● ●   
S.pneumonia E ● ● ● K ○ ● ● ○ ● ●                      
                                 
 ●  The same amino acids as in NM23-H1 protein    The same amino acids found in K.Pneumoniae and S.aureus NDK proteins 
                                 
 ○  The same amino acids as in NDK protein from E.coli  
 
 The same amino acids found in S.aureus and S.Pneumoniae NDK proteins 
 
Figure 1.5 Alignment of E.coli, K. pneumoniae, S.pneumonia, S.aureus NDK protein and NM23-H1 sequences.    
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       β1         α0         α1        
NM23-H1 M A N C E R T F I A I K P D G V Q R G L V G E I I K R F E Q K G 
E.coli ● ● I - ● ● ● ● S I ● ● ● N A ● A K N V I ● N ● F A ● ● ● A A ● 
K.Pneumoniae ● ● ○ - ● ● ● ● ○ ○ ● ● ● ○ ○ ● ○ ○ ○ ○ ○ ● S ● ○ S ● ● ● ○ ○ ● 
S.aureus ● - - - ● ● ● ● L M ● ● ● ● ○ ● ● ● ○ ● ○ ● ● V ● S ● I ● R ● ● 
S.pneumonia ● - - - ● Q ● ● F ○ ● ● ● ● ● ● K ● ● ● ● ● ● V L ● ● I ● ● R ● 
    β2                α2           αA  
NM23-H1 F R L V G L K F M - Q A S E D L L K E H Y V D L K D R P F F A G 
E.coli ● K I ● ● T ● - ● L H L T V E Q A R G F ● A E H D G K ● ● ● D ● 
K.Pneumoniae ● ○ - ● ● ○ ● - ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ E ○ ● ● ● ● ○ ● 
S.aureus L ○ ● ● ● G ● L ● - ● V P M ○ ● ○ E T ● ● G ○ ○ Q ○ ○ ● ● Y N D 
S.pneumonia ● T ○ E K ● E ● R S ● V ● ● ○ ● I D Q ● ● Q ● ● V ○ Q S ● Y P P 
             β3           α3         
NM23-H1 L V K Y M H S G P V V A M V W E G L N V V K T G R V M L G E T N 
E.coli ● ● E F ● T ● ● ● I ● V S ● L ● ● E ● A ● Q R H ● D L ● ● A ● ● 
K.Pneumoniae ● ● ○ ● ● ○ ● ● ● ○ ● ○ ○ ● ○ ● ● ○ ● ○ ● ○ ○ ○ ● ○ ○ ● ● ○ ● ● 
S.aureus ● I S ● I ○ ● A ● ● F ● ● ● V ● ● ○ D ○ ● N V S ● H I I ● S ● ● 
S.pneumonia I R ○ ● ● ○ ● ● ● ● L ○ G ● I S ● P K ● I E ● W ● T ● M ● ○ ● R 
   Knp loop      α4                β4      
NM23-H1 P A D S K P G T I R G D F C I Q V G R N - I I - - - - H G S D S 
E.coli ● ● N A L A ● ● L ● A ● Y A D S L T E ● - G T - - - - ● ● ● ● ● 
K.Pneumoniae ● ● ○ ○ ○ ○ ● ● ○ ● ○ ● ○ ○ ○ ○ F ○ ○ ● - ○ ○ - - - - ● ● ● ● ● 
S.aureus ● S E ○ S ● ● S ● ● ● ● L G L T ● ● ● ● - ● ● - - - - ● ● ● ● ● 
S.pneumonia ● E E ○ ○ ● ● T ● ● ● ● ● ○ K A A ● ○ ● E ● ● Q N V V ● ● ● ● ● 
       α5                          
NM23-H1 V E S A E K E I G L W F H P E E L V D Y T S C A Q N W I Y E   
E.coli ● ● ● ● A R ● ● A Y F ● G E G ● V C P R ● R           
K.Pneumoniae ● ● ● ● ○ ○ ● ● ○ F ○ ● A ○ ○ ● ○ ○ ○ ○ ● ○           
S.aureus L ● ● ● ● ○ ● ● N ● ● ● N ○ N ● I T S ● A ● P R D A ● L ● ●   
S.pneumonia E ● ● ● K ○ ● ● ○ ● ●                      
                                 
 ●  The same amino acids as in NM23-H1 protein    The same amino acids found in K.Pneumoniae and S.aureus NDK proteins 
                                 
 ○  The same amino acids as in NDK protein from E.coli  
 
 The same amino acids found in S.aureus and S.Pneumoniae NDK proteins 
Figure 1.6 α helixes, β sheets and Knp loop matching to the E.coli, K.pneumoniae, S.pneumonia, S.aureus NDK proteins and  
NM23-H1 sequences. 
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1.3.1 Human NDK proteins and their function 
The relationship of NM23-H1 protein expression to the suppression of metastasis 
firstly was reported by Steeg et al (1988). This relationship was found in such cancer types as 
cervical, gastric, breast, melanomas (Okabe-Kado et al., 2009) and hepatocellular carcinoma 
(Yamaguchi et al., 1994). Nevertheless, in some cancer types such as colon cancer (Martinez 
et al., 1995), neuroblastoma (Chang et al., 1994), leukaemia and other haematological 
malignancies (Steeg et al., 1988, Yokoyama et al., 1996, Willems et al., 1998, Niitsu et al., 
2000, Okabe-Kado et al., 2002, Okabe-Kado et al., 2009) and neoplasms (Okabe-Kado et al., 
2009) researchers found a relationship between an overexpression of the NM23-H1 and poor 
prognosis of the patients. Expression levels of NM23-H1 protein in ovarian cancer was 
suggested as contradictory (Okabe-Kado et al., 2009, Mandai et al., 1994). 
NM23-H1 and NM23-H2 protein expressing genes are located near the breast cancer 
susceptibility gene 1 (BRCA1) locus at chromosome 17q21.3. BRCA is associated with 
development of breast and ovarian cancer (Backer et al., 1993, Saha and Robertson, 2011). 
Moreover, NM23-H2 was identified as a transcription factor (TF) PuF, which regulates 
activity of proto-oncogene c-myc (Postel et al., 1993) suggesting that changes in expression 
level or mutation in NM23-H2 may activate or inhibit proto-oncogene c-myc activity (Postel 
and Ferrone, 1994). Overexpression of c-myc plays an important role in cancer development 
(Miller et al., 2011), thus changes in NM23-H2 expression levels may affect cancer 
development. Nevertheless, Yokoyama et al (1996) observed that expression of c-myc 
remains unchanged in AML cells, whereas NM23-H1 and NM23-H2 are elevated.  
The relationship of the other NM23 homologues with cancer development has not 
been reported. They play important roles in other processes and may have some effect in cell 
metastatic activity or its inhibition. For example, NM23-H3 is able to inhibit granulocyte 
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differentiation and induce their apoptosis (Mehus et al., 1999). NM23-H4 possibly is related 
to intramictohondrial GTP metabolism, whilst NM23-H5 may be involved in spermatogenesis 
(Mehus et al., 1999). 
Viral pathogens such as the Epstein-Barr virus (EBV) (Murakami et al., 2009), Human 
Papillomavirus (HPV) (Mileo et al., 2006) and Kaposi‟s sarcoma associated herpesvirus 
(KSHV) (Qin et al., 2011) indirectly interact with NM23-H1 resulting in its suppression. EBV 
nuclear antigens (EBNA) 3C and 1, latency associated nuclear antigen (LANA) and E7 
protein are tumour virus encoded oncoproteins for EBV, KSHV and HPV, respectively. These 
oncoproteins are mediators in the interaction between virus and NM23-H1. The virus triggers 
an expression of the oncoprotein, which binds to NM23-H1 protein, causing its translocation 
from cytoplasm into nucleus where it forms a stable complex with the oncoprotein. Therefore 
the host cell becomes transformed, resulting as a range of human cancers, for example, 
Burkitt‟s lymphoma (from EBV) (Murakami et al., 2009), cervical and ano-genital cancers 
(from HPV) (Mileo et al., 2006) and Kaposi‟s sarcoma (from KSHV) (Qin et al., 2011).  
1.3.1.1 Human NM23 protein role in normal haemopoiesis and leukaemia 
It is important to understand the role of human NM23 proteins in normal haemopoiesis 
and leukaemia. NM23-H1 and NM23-H2 proteins are expressed by normal haemopoietic and 
leukaemia cells. However, in leukaemia patients, the levels of both proteins are elevated. 
Thus, NM23 proteins may play an important role in normal haemopoiesis. Elevated NM23 in 
leukaemia patients may play an extra role.  
Expressed NM23 proteins can be found in the cell cytoplasm, transported to the outer 
cell membrane where they can be secreted. The highest expression of NM23-H1 and NM23-
H2 has been found in bone marrow CD34
+ve
 cells. Expression levels in mature cells are lower. 
Moreover, levels of NM23-H1 and NM23-H2 were lineage dependent. The highest expression 
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levels of NM23-H1 were observed in polymorphonuclear cells, but NM23-H2 was expressed 
more in lymphocytes (Willems et al., 1998). 
In AML patient samples elevated levels of NM23-H1 and NM23-H2 was found 
intracellularly (Yokoyama et al., 1996) and extracellularly (Niitsu et al., 2000). Thus, it was 
suggested that the elevated levels of NM23-H1 and NM23-H2 proteins are related with poor 
patient prognosis.  
Extracellular and intracellular expression of the NM23 protein has been tested in 
various cell lines from different cancers. Lymphoid cell lines such as HSB2, SupT1, Jurkat 
(Willems et al., 1998), MOLT3, MOLT4 (Okabe-Kado et al., 2002, Willems et al., 1998), 
BALL-1, BALM-1, HT, DB, BALM-3, SKW-4, SU-DHL-4, U-698-M, MOLT16 and HPB-
ALL (Okabe-Kado et al., 2002) did not show extracellular expression of the NM23-H1 and 
NM23-H2. Minor extracellular expression of NM23-H1 was observed only in Raji lymphoid 
cells (Okabe-Kado et al., 2002). 
Extracellular expression of NM23-H1 was observed on myeloid cell lines such as 
KG1, U937t (Willems et al., 1998), HL-60 (Okabe-Kado et al., 2002, Willems et al., 1998), 
NB4, HT93, ML-1, THP-1 and U937 (Okabe-Kado et al., 2002). Expression of both of these 
proteins was observed as well on erythroid cell lines such as K562, KU812F, HEL and M6 
(Okabe-Kado et al., 2002). Therefore, extracellular expression of NM23 is dependent on the 
cell type.  
An important observation was the decrease of extracellular NM23 protein after K562, 
HEL and NB4 cell differentiation initiation using All Trans-Retinoic Acid (ATRA) (Okabe-
Kado et al., 2002). Thus, extracellular NM23 levels decreases with cell maturation. Moreover, 
it was shown that targeting NM23 proteins with monoclonal antibody specific for NM23-H1 
(H1-229, immunoglobulin class IgG2a) and NM23-H2 (H2-206, immunoglobulin class IgG2b) 
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HL60 and HEL cell cytolysis can be induced. Therefore, Okabe-Kado et al (2002) suggested 
that NM23 proteins can be a potential target in leukaemia therapy. 
1.3.1.2 Effect of additional NM23 proteins on healthy haemopoietic and leukaemia cells 
NM23-M2 is able to inhibit normal mouse bone marrow growth and maturation in the 
presence of GM-CSF or M-CSF and to induce differentiation of myeloid leukaemia M1 cells 
(Okabe-Kado et al., 1988). Therefore it is also known as inhibitor factor (I-factor). It 
possesses 98% sequence identity with NM23-H2, 91% with NM23-M1 and 89% with NM23-
H1 (Okabe-Kado et al., 1992). Thus, all NM23 family members are potentially involved in 
inhibition of normal haemopoietic cell growth and differentiation.  
Abilities of I-factor to inhibit induced differentiation of in human cell lines such as 
HL-60, ML-1 and K562 and mouse cell line Friend were tested. Cell differentiation in HL-60 
and ML-1 was induced using 12-O-tetradecanoylphorbol-13-acetate and retinoic acid, in 
K562 using hemin, 1-β-D-arabinofuranosylcytosine or sodium butyrate, but in Friend using 
dimethyl sulfoxide or actinomycin D. I-factor did not inhibit initiated differentiation (Okabe-
Kado J. et.al., 1988). In the later study Okabe-Kado et al (1995) tested the inhibition 
properties of human NM23 protein family members. It was found that proteins NM23-H1, 
NM23-H2, NM23-M1 and NM23-M2 (I-factor) inhibit the TGF-β initiated erythroid 
differentiation of HEL, KU812F and K562 cell lines. Moreover, Cys
118
 mutant NM23-H2 and 
truncated at C terminal (has only 60 amino acids) NM23-H2 protein despite of lack of NDK 
activity showed similar inhibition ability as rNM23 proteins. Therefore, NM23 proteins do 
not require NDK activity for inhibition of cell differentiation. It was also suggested that 
inhibition of initiated cell differentiation is cell-line dependent (Okabe-Kado et al., 1995). 
Important to note that only TGF-β initiated differentiation was inhibited by I-factor. It might 
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be that inducing agents: hemin, 1-β-D-arabinofuranosylcytosine or sodium butyrate reduces I-
factor inhibitor. 
Additional NM23 protein effect was studied as well on a specific cell marker sorted 
cells. Normal bone marrow cells were sorted for CD34
+ve
/CD38
-ve
 and CD34
+ve
/CD38
+ve
 
cells. Additional extracellular NM23-H1, NM23-H2 and NM23-H3 did not affect 
CD34
+ve
/CD38
-ve
 primary cell differentiation, whilst more mature CD34
+ve
/CD38
+ve
 cell 
differentiation was altered. In the presence of all NM23 isoforms CD34
+ve
/CD38
+ve
 cells 
differentiation more into BFUE, while differentiation into CFUM was inhibited (Willems et al., 
2002). Thus, it might be that bacterial NDK proteins are also able to alter haemopoietic cell 
differentiation. Moreover, it might be that bacterial NDK proteins affect healthy and 
leukaemia cells in different ways.  
Recombinant NM23-H1 and NM23-H2 proteins promote growth and survival of 
mononuclear AML cells. Moreover, additional rNM23-H1 causes release of GM-CSF, IL-1β, 
IL-6 cytokines in physiologically effective levels. Using anti-TNFα, anti-IL-1β, GM-CSF 
and/or anti-IL-1 antibodies alone or in varied combination, partial inhibition of AML cell 
survival promoted by additional rNM23-H1 could be observed. An important fact is that used 
antibodies inhibits p38 mitogen-activated protein kinase (MAPK) cell signaling pathway. 
Hence, it was proposed that through the cytokine release rNM23-H1 is able activate MAPK 
signaling pathway and promote AML cell survival (Okabe-Kado et al., 2009).  
Lilly et al (2011) and Lilly (2012) showed that additional rNM23-H1 is able to bind to 
the surface of CD34
+ve
 and CD34
lo
/CD11b
+ve
 cells and promote their survival. Although 
rNM23-H1 promoted survival of both populations, rNM23-H1 binds better to more mature 
cells CD34
lo
/CD11b
+ve
 then to immature CD34
+ve
. Lilly et al (2011) suggested that additional 
rNM23-H1 indirectly promotes immature cell survival.  
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Lilly et al (2011) showed for the first time that rNM23-H1 indirectly promotes stem 
cell survival and proliferation. The authors performed an experiment where mononuclear 
AML cells were sorted for CD34
-ve
/CD117
-ve
 and CD34
+ve
/CD117
+ve
 cells. Then recombinant 
NM23-H1 was added to more mature CD34
-ve
/CD117
-ve
 cell population. CD34
-ve
/CD117
-ve
 
cells incubated with additional rNM23-H1 secreted a combination of cytokines, 
predominantly IL1β and IL6. CD34+ve/CD117+ve cells were resuspended in CMdep collected 
from CD34
-ve
/CD117
-ve
 treated cell cultures. Hence, it was proposed that cytokines found in 
CM are promoting survival and proliferation of stem cells (CD34
+ve
/CD117
+ve
 cells).  
As mentioned above, expression levels of rNM23-H1 drop with blood cell maturation. 
Moreover, the increased levels of rNM23-H1 were observed in AML patients. Recombinant 
NM23-H1 express by stem cells may bind to more mature cells and promote the release of 
cytokines that stimulate the proliferation of stem cells. LSCs express higher levels of rNM23-
H1. The levels of cytokines released by more mature leukaemia cells may be higher than 
healthy cells release them. Thus, it might be that through the secretion of NM23-H1 LSCs 
affect more mature cells to release LSC survival promoting cytokines. We assume that rNDK 
proteins may act in the same way as rNM23-H1, observed by Lilly et al (2011). It might be 
that leukaemia patient prognosis worsens due to bacterial NDK proteins that indirectly 
promote leukaemia stem cell proliferation.  
1.3.2 Bacterial NDK protein role in bacteria 
Structural similarity between human and bacterial proteins may also mean that 
bacterial NDK proteins play a similar role in healthy and leukaemia patients as NM23-H1 
does. Thus, in this paragraph we will discuss bacterial NDK protein role in host invasion. 
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1.3.2.1 Bacterial NDK secretion  
Zaborina et al (1999) reported that Pseudomonas aeruginosa secretes enzymes 
involved in ATP synthesis, including NDK protein (Zaborina et al., 1999). In later studies, it 
was suggested that DXXX (X is predominantly hydrophobic amino acid) motif in the 
carboxyl-terminal region (C-terminal) of NDK protein is essential for their secretion by the 
type I mechanism (Kamath et al., 2000). For example, the motif in the NDK of P.aeruginosa 
it is DTEV. Secretion of NDK was observed as well in such bacteria as Porphyromonas 
gingivalis (Yilmaz et al., 2008), Leishmania amazonensis (Kolli et al., 2008), M.tuberculosis 
(Zhao et al., 2007), P.aeruginosa (Zaborina et al., 1999), Vibrio cholera, and S.typhimurium 
(Dar et al., 2011). 
No information is available if bacteria can secrete NDK protein. There is a possibility 
that some bacteria do not secrete it. Moreover, the exact mechanism of NDK protein secretion 
in above mentioned bacteria is not determined. It remains uncertain if common bacteria such 
as E.coli (Kern et al., 2005, Gomez et al., 2003, Buncaneve et al., 2007), Pseudomonas 
aeruginosa (Kang et al., 2003), Staphylococcus aureus (Madani, 2000, Marty et al., 2006, 
Buncaneve et al., 2005) and Streptococcus pneumonia (Madani, 2000, Bucaneve et al., 2007) 
invading leukaemia patients are able to secrete NDK proteins. 
1.3.2.2 Bacterial NDK effect on the host cells 
Human beings are continuously exposed to harmful microbiological organisms. The 
largest number of bacterial species is harmless and few species are beneficial or pathogenic. 
Leukaemia patients lack immunity so even bacteria that are harmless to healthy humans may 
invade leukaemia patients (Bucaneve et al., 2007). As varied pathogenic bacteria and host 
interactions are extensively investigated, in this paragraph we will concentrate on pathogenic 
bacteria and their effects on the host cells. 
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The location of pathogenic bacteria in the host determines processes within bacteria 
and their effects on a host. Based on their location, harmful bacteria are divided into 
extracellular and intracellular pathogens. Pathogenic extracellular bacteria do not enter host 
cells; thus they usually promote host cell death. Intracellular bacteria grow and reproduce 
within host cells (Spooner and Yilmaz, 2012, Nazareth et al., 2007, Lau et al., 2007, Martner 
et al., 2008, Lowy, 2000). Such bacteria, like Chlamydophila spp, Ehrlichia spp and 
Rickettsia spp are obligate intracellular parasites (Fritsche et al., 1999), which need to prevent 
host cell induced apoptosis. Bacteria such as P.gingivalis, S.typhimurium, Chlamidia 
trachimatis, Bacillus anthracis, Mycobacteria spp and L. amazonensis are usually 
intracellular (Spooner and Yilmaz, 2012). On the other hand, P.aeruginosa, V.cholerae 
(Spooner and Yilmaz, 2012), E.coli (Nazareth et al., 2007), K.pneumoniae (Lau et al., 2007), 
S.pneumonia (Martner et al., 2008) and S.aureus (Lowy, 2000) are extracellular bacteria. It 
might be that extracellular and intracellular pathogen NDK proteins act in leukaemia patients 
in different ways. We will further observe how these pathogens affect non leukaemia patients, 
and what the role of NDK in the bacterial invasion is. 
Yilmaz et al. (2008) reported that NDK of P.gingivalis prevents host cell apoptosis 
through the inhibition of P2X7 receptor of gingival epithelial cells (GECs). P2X7 receptor 
mediates immune processes such as cell motility and microbial phagocytosis (Bours et al., 
2006) and the release of proinflammatory cytokines such as IL-1β and IL-18 in response to 
microbial invasion (Pedra et al., 2009). P2X7 receptors are found in macrophages, monocytes 
and microglia (Lister et al., 2007). It might be that NDK of intracellular bacteria may affect 
leukaemia cells through the inhibition of P2X7 receptors, causing them to release cytokines 
IL-1β and IL-18. The released cytokines observed in more mature haemapoietic cells treated 
with rNM23-H1 by Lilly et al (2011) may promote leukaemia stem cells to enhance survival 
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and proliferation of LSCs. However, P.gingivalis invades GECs, but not blood cells. Bacterial 
NDK proteins can be secreted by bacteria in this case P.gingivalis and transported out of host 
cells. Pedra et al (2009) made a conjecture that NDK protein of P.gingivalis may be 
transported from the invaded GEC to the neighboring cells. The latter suggestion, however, 
remains unproven. 
Dar et al (2011) tested how S.typhimurium and V.cholerae bacteria secretion products 
containing NDK proteins, affect ATP-induced J774 mouse macrophage cell lysis. Through 
sets of experiments, the authors determined that secreted NDK proteins by extracellular and 
intracellular bacteria have similar functional properties. Secretion products of intracellular 
pathogen S.typhimurium containing either own NDK protein or NDK protein of extracellular 
pathogen V.cholerae inhibited ATP-induced J774 cell lysis. Moreover, lack of NDK in the 
secretion products of S.typhimurium did not protect J774 cells against induced cell lysis. 
Secretion products of the extracellular pathogen V.cholerae had a cytotoxic effect on ATP-
non-induced and ATP-induced J774 cells and even when secretion products were collected 
from NDK knockdown V.cholerae strains.  
The functional similarity of NDK proteins of extracellular and intracellular pathogens 
may mean that any bacterial NDK may act in a similar way in leukaemia patients. The 
difference between the pathogen types is that NDK proteins of intracellular pathogens require 
to be secreted by bacteria and transported out of the cell. 
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1.4 THE AIM OF THE RESEARCH 
The main aim of this research is to test if E.coli, K.pneumoniae, S.pneumoniae and 
S.aureus rNDK proteins promote the survival of leukaemia stem cells in the same way as it 
was shown by Lilly et al (2011) using rNM23-H1. We hypothesized that when bacteria invade 
leukaemia patients secreted bacterial NDK proteins indirectly promote survival and 
proliferation of leukaemia stem cell through binding to more mature cells.  
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2 METHODS 
2.1 PRODUCTION OF HIS-TAGGED RECOMBINANT NDK (rNDK) PROTEINS 
2.1.1 rNDK protein production system 
Glycerol stocks (available in our laboratory) of E.coli BL21 (DE3) (Bioline, London, 
UK) cultures containing the E.coli, S.aureus, S.pneumoniae or K.pneumoniae rNDK gene 
coded in the pET-15b expression vector (Novagen, Merk Chemicals Ltd, Nottingham, UK) 
were used. The pET-15b expression vector contains an ampicillin resistance marker, T7 
promoter, Lac operator and 6×His-tag sequence coding gene (Figure 2.1). NDK protein 
coding gene is ligated in-between Nde1 and BamH1 restriction sites of pET-15b expression 
vector (Figure 2.1) 
 
 
 
(a) (b) 
pET-15b vector 
pET-15b vector containing NDK protein 
coding gene 
 
Figure 2.1 Commercial pET-15b vector and pET-15b vector containing NDK protein 
coding gene. (a) pET-15b vector purchased from Novagen. (b) pET-15b vector containing 
NDK protein coding gene. 
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2.1.2 rNDK protein expression 
BL21 (DE3) bacteria glycerol stocks were streaked out on LB agar plates supplemented 
with 100 µg/ml ampicillin (see Appendix) and grown overnight at 37°C. Three different 
cultures of BL21 (DE3) for each rNDK were picked and inoculated in 5 ml LB media 
supplemented with 100 µg/ml ampicillin (see Appendix) and incubated overnight at 37°C 
with shaking at 220 rpm. The integrity of overnight cultures was checked by colony PCR. 
Overnight cultures were diluted 1:50 in 150 ml LB media supplemented with 100 µg/ml 
ampicillin and incubated for 4 hours at 37°C with shaking at 220 rpm. After 4 hours 1mM an 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich Ltd., Gillingham, UK) was 
added to induce rNDK protein expression. IPTG induced cultures were left incubating for 24 
hours at 37°C with shaking at 220 rpm.  
2.1.3 rNDK protein purification 
After 24 hour incubation IPTG induced cultures were centrifuged at 6000×g at 4°C for 
10 minutes. Supernatant was removed, and wet mass weighed. To lyse bacteria pellets were 
resuspended in 5 ml of BugBuster
TM
 (Novagen) per 1 g of wet weight and 1 μl/ml benzonase 
nuclease (Novagen). Cell lysis was performed at room temperature for 40 minutes, following 
incubation at 4°C for 20 minutes. Lysate was centrifuged at 14000 rpm for 20 min. 
Supernatant was collected, whilst pellets were discarded. rNDK proteins were purified from 
supernatant using the His-Bind Purification kit (Novagen) following manufacturer‟s 
instructions. Each column was filled with 2 ml Ni-NTA His-Bind resin, where resin settled 
bed volume was 1 ml. When liquid stopped dripping, equilibration and charge of the resin was 
performed following 3 steps:  
1) 3 ml sterile dH2O 
2) 5 ml 1×Charge Buffer 
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3) 3 ml 1×Binding Buffer  
Supernatants containing rNDK proteins were loaded onto the columns and allowed to 
drip through. Columns were washed with 10 ml 1×Binding Buffer, then with 6 ml 1×Wash 
buffer. Proteins were eluted with 6 ml 1×Elute Buffer and collected in 6 separate 1 ml 
fractions. 
Protein elution was verified by sodium dodecyl sulphate (SDS) polyacrylamide gel 
staining with Coomassie blue and Western blot analysis. rNDK protein concentration was 
determined for the first three fractions. Only pure fractions were used for further experiments. 
2.2 MEASURING SECRETION OF rNDK PROTEINS FROM BL21 (DE3) 
BACTERIA  
Overnight cultures (described above) were used for the time course experiment. 
Overnight cultures were diluted 1:50 in 10 ml LB media supplemented with 100 µg/ml 
ampicillin and incubated for 4 hours at 37°C with shaking at 220 rpm. After 4 hours, 1mM 
IPTG was added to induce expression of rNDK proteins. IPTG non-induced cultures were 
used as controls. IPTG induced and non-induced cultures were left incubating at 37°C with 
shaking at 220 rpm for the next 6 days. Zero time point samples (1 ml) were collected shortly 
before IPTG induction. The next samples were collected as 1 ml every 24 hours.  
Samples were centrifuged at 14,000 rpm for 5 minutes and pellets were discarded. 
Supernatants were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
12.5% gels and stained with Coomassie blue. Secreted rNDK proteins were verified by 
calculation of their masses and comparison to the expected masses. 
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2.3 CELL PURIFICATION AND CELL CULTURE 
Umbilical cord blood (CB) samples were provided by tissue bank under ethical 
approval following informed consent. CB samples were received in plastic bags supplemented 
with anti-coagulants. Cell purification was performed as described in Figure 2.2. 
2.3.1 The purification of mononuclear cells from umbilical cord blood (CB) 
Mononuclear cell separation was performed using 50 ml tubes and spin filter tubes 
(PPA, London, UK). 15 ml Ficoll-Paque
TM
 PLUS (G.E.Healthcare, Amersham, UK) was 
pipette on the top of filter in spin filter tubes. To move the Ficoll-Paque
TM
 PLUS through the 
filter, tubes were centrifuged at 1000×g for 1 minute. Blood samples were diluted 1:3 in 
RPMI 1640 (Gibco, Life Technology, Paisley, UK) supplemented with 1% v/v penicillin and 
streptomycin, and 1% v/v ITS (RPMI 1640 p/s ITS+) and layered on the top of filter. The 
samples were centrifuged at 1000×g for 10 minutes. The mononuclear cell layer is found just 
above the filter in spin filter tubes. Plasma was removed and mononuclear cells were collected 
into a clean 50 ml tube. To wash mononuclear cells, they were resuspended 1:5 in RPMI 1640 
p/s ITS+ and centrifuged at 374×g for 10 minutes. Supernatant was removed. Mononuclear 
cells were resuspended in 5 ml RPMI 1640 p/s ITS+ and centrifuged at 249×g for 10 minutes. 
The last wash step was repeated twice. After the last wash, cells were resuspended in 20 ml 
RPMI 1640 p/s ITS+ and the number of mononuclear cells was counted using a 
haemocytometer. Samples were centrifuged at 1500 rpm for 5 minutes and supernatant was 
removed. 
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Figure 2.2 Cord blood sample processing and CD34
+ve
 sorting, where CMdep is rNDK 
depleted conditioned media. 
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2.3.2 Sorting of CD34+ve cells from primary mononuclear cells 
Mononuclear cells were washed in 5 ml cold (6°C - 12°C) magnetic activated cell 
sorting (MACS) buffer (see Appendix) and centrifuged at 374×g for 5 minutes. CD34
+ve
 cells 
were sorted from mononuclear cells using indirect CD34 Microbead kit (Miltenyi Biotec, 
Surrey, UK) following manufacturer‟s instructions. Briefly, every 108 mononuclear cells were 
resuspended in 300 μl MACS buffer, 100 μl FcR Blocking Reagent and 100 μl CD34 Hapten-
Antibody were added, then mixed and incubated for 15 minutes at 6°C - 12°C. Mononuclear 
cells incubated with CD34 Hapten-Antibody were washed with 10 ml MACS buffer and 
centrifuged at 1500 rpm for 5 minutes. Supernatant was removed and cells were resuspended 
in 400 μl MACS buffer. Anti-Hapten MicroBeads (100 μl) were added, mixed and incubated 
at 6°C - 12°C for 15 minutes. After incubation with Anti-Hapten MicroBeads mononuclear 
cells were washed with 10 ml MACS buffer and centrifuged at 1500 rpm for 5 minutes. 
Supernatant was removed and cells were resuspended in 500 μl MACS buffer. 
CD34
+ve
 cells were sorted using MS column for < 2×10
8
 mononuclear cells or LS 
Column for < 2×10
9
 mononuclear cells. Briefly, MS column was placed into a magnet and 
washed with 500 μl MACs buffer. Mononuclear cells stained with CD34 Hapten-Antibody 
and Anti-Hapten MicroBeads were applied to the MS column and washed with 500 μl MACS 
buffer three times. CD34
-ve
 cells were collected in the unbound fraction. The column was 
removed from the magnet and placed on the top of a clean tube. CD34
+ve
 cells were eluted 
with 1 ml MACS buffer by using the plunger supplied with the column. To increase purity of 
eluted CD34
+ve
 cells collected CD34
+ve
 cell fraction was applied to a new MS column. MS 
column was prepared as described above. CD34
+ve
 cell were eluted with 500 μl MACS buffer. 
CD34
+ve
 and CD34
-ve
 eluted fractions were centrifuged at 1500 rpm for 5 minutes and 
supernatant was removed. CD34
-ve
 cells were resuspended in RPMI 1640 p/s ITS+ as 10
6
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cells per 1 ml. CD34
+ve
 cells were resuspended in 2 ml RPMI 1640 p/s ITS+ and kept at 4°C 
overnight.  
The percentage of CD34
+ve
 cells in mononuclear cell fraction (pre CD34
+ve
 sort 
sample) and the purity of eluted CD34
+ve
 cells were analyzed by flow cytometer. 
2.3.3 CD34-ve cell treatments 
Resuspended CD34
-ve
 cells in RPMI 1640 p/s ITS+ (500 μl) were seeded as 0.5×106 
cells per well into a 48 well plate. For each treatment with each rNDK protein or elution 
buffer (EB) (Novagen) CD34
-ve
 cells were seeded into two wells. Seeded CD34
-ve
 cultures 
were treated with 1 μg/ml or 2 μg/ml rNDK proteins or EB as a negative control. CD34-ve cell 
cultures of CB12 sample were supplemented with 1.25 μg/ml polymyxin B sulfate salt (PMB) 
(Sigma). One of the CD34
-ve
 cultures for the same treatment was incubated for 20 hours, the 
other for seven days. From samples incubated for 20 hours conditioned media (CM) were 
removed and from collected CM rNDK were depleted. Samples of CD34
-ve
 incubated for 
seven days were collected for flow cytometry analysis and Jenner Giemsa staining. 
2.3.4 CD34+ve cell treatments 
Only twice sorted CD34
+ve
 cells were used for treatments. Overnight stored CD34
+ve
 
cells were count using a haemocytometer on the second day after the CD34 sorting. CD34
+ve
 
cells were spin at 2000 rpm for 5 minutes and supernatant was removed. CD34
+ve
 cells were 
resuspended as 1×10
6
 cells per 1 ml in rNDK protein depleted CM (CMdep), seeded as 
0.15×10
6
 or 0.1×10
6
 cells per well into a 96 well plate and incubated for 7 days. On the day 7 
samples of treated CD34
+ve
 cells were collected for flow cytometry analysis and Jenner 
Giemsa staining. 
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2.4 COLONY PCR 
The integrity of bacterial colonies was verified for the overnight cultures by colony 
PCR amplification of the rNDK gene cloned in the pET-15b expression vector using bacterial 
NDK specific primers. PCR using NM23-H1 specific primer was run on all colonies.  
PCR mix (see Appendix) was prepared. Overnight culture (5 μl) was diluted in 5 μl 
dH2O and by heating the mix at 90°C for 10 minutes cDNA was released. 1×PCR mix, 2 μl 
10 μM forward primer (see Appendix) and 2 μl 10 μM reverse primer (see Appendix) was 
added to prepared cDNA. cDNAs were amplified in the PCR cycle: 
94°C for 10 minutes 
94°C for 15 seconds 
56°C for 15 seconds         40 cycles 
72°C for 40 seconds 
72°C for 10 minutes 
 Each PCR product (10 μl) was mixed with 10 μl 5×DNA gel loading buffer (Bioline, 
London, UK). Samples were load on 1% agarose gel (see Appendix) containing 0.3 μg/ml 
ethidium bromide (Sigma). Agarose gel electrophoreses was performed in 1×TBE buffer (see 
Appendix) at 125 V for 1 hour. 
2.5 THE DETERMINATION OF rNDK PROTEIN CONCENTRATION  
The determination of rNDK protein concentration was performed using DC Protein 
Assay kit (BioRad, Hemel Hempstead, UK) following manufacturer‟s instructions. Briefly, 
reagent A‟ was prepared by mixing 20 µl reagent S with 1 ml reagent A. Each purified rNDK 
protein fraction (2 µl) and 2 µl standard at varied concentrations (bovine serum albumin 
(BSA) diluted in RIPA buffer (see Appendix) as 0, 0.6, 1.25, 2.5, 5.0 and 10.0 mg/ml) were 
pipetted into a 98 well plate. Reagent A‟ (25 µl) and 200 µl reagent B was added to each well 
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and left incubating for 15 minutes. The intensity of each well was read using plate reader. 
Measured standard values were used to draw a standard curve. Concentrations of rNDK 
proteins were calculated using standard curve. 
2.6 PROTEIN DEPLETION FROM CM 
Treated CD34
-ve
 cultures were collected in ependorfs as 500 µl after 20 hours 
incubation at 37ºC. Collected cultures were spin at 15,000 rpm for 15 seconds and pellet free 
CMs were collected in new ependorfs. HIS-Select
TM
 Nickel affinity gel (Sigma) is used as 
100 µl per 1 ml of CM to deplete rNDK protein. For example, for rNDK protein depletion 
from 3 ml of CM (6 cultures each 500 µl) 300 µl HIS-Select
TM
 Nickel affinity gel is needed. 
HIS-Select
TM
 Nickel affinity gel (300 µl) was placed in ependorf, spin at 15,000 rpm and 
supernatant was removed. HIS-Select
TM
 Nickel affinity gel was washed with 1 ml dH2O and 
was spin at 15,000 rpm. Supernatant was removed. Then HIS-Select
TM
 Nickel affinity gel was 
resuspend in 1 ml equilibration buffer (see Apendix) and split equally into 6 ependorfs. To 
each ependorf with HIS-Select
TM
 Nickel affinity gel 500 µl CM was added and incubated at 
4°C with shaking for 20 minutes. After incubation CM and gel were spin at 15,000 rpm for 
2.5 minutes. CMdep was removed and filter sterilized.  
2.7 SDS–PAGE 
2.7.1 Sample preparation 
Eluted rNDK protein fractions (Paragraph 2.1.3), supernatants collected from bacteria 
cultures (Paragraph 2.2) CM and CMdep (Paragraph 2.3.3) were diluted 3:4 in 4×gel loading 
buffer (GLB) (see Appendix). For Western blot analysis the second eluted fractions of rNDK 
(Paragraph 2.1.3) were diluted 1:10 in 1×GLB and as 1mg/ml. 
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Prepared samples were boiled for 10 minutes. Each sample (10 μl) was load on to 
SDS-polyacrylamide gel. Coomassie blue staining was performed to check purity of eluted 
rNDK fractions. Western blot was performed to check rNDK depletion in CM and to check 
the second eluted fraction for rNDK proteins. 
2.7.2 SDS – polyacrylamide gel preparation 
Recombinant NDK proteins were separated by SDS–PAGE on 1.5 mm 12.5% SDS–
polyacrylamide gels. SDS–polyacrylamide gel consist of two layers: resolving gel (see 
Appendix) on the bottom and stacking gel (see Appendix) on the top. Resolving gel (8 ml) 
was pipetted in-between glass plates. Water (1 ml) was pipetted on the top of the gel and 
resolving gel was left to polymerize for 30 minutes. Water layer was removed and prepared 
stacking gel was pipetted on the top of resolving gel layer. A 10 well comb was inserted and 
stacking gel was left to polymerize for next 30 minutes.  
Two prepared SDS–polyacrylamide gels were placed into a box. Running buffer (see 
appendix) was added in between two gels and into the box to cover the bottom of both gels. 
Prepared samples and protein ladder were loaded on SDS–polyacrylamide gel. Gels were 
electrophoresed at 120 V for approximately 1 hour. 
2.8 COOMASSIE BLUE STAINING  
After SDS–PAGE gels were stained with Coomassie stain (see Appendix) with 
shaking at 20 rpm for 2 hours. Coomassie stain was removed; gels were placed in Destain (see 
Appendix) and shaken at 20 rpm until gels are transparent. Stained proteins on SDS–
polyacrylamide gels were analyzed using a GeneFlash transluminator (Geneflow, 
Staffordshire, UK).  
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2.9 WESTERN BLOT ANALYSIS 
Polyvinilidene difluoride (PVDF) membrane (Millipore Corp, Bedford, MA, USA) 
was soaked in 100% methanol for 10 seconds, and then washed in transfer buffer (see 
Appendix). Filter papers (12 pieces per gel) were soaked in transfer buffer. Protein transfer 
from SDS-polyacrylamide gel to PVDF membrane was set up as follows: 6 pieces of filter 
paper on the bottom, PVDF membrane, gel and 6 pieces of filter paper on the top. Protein 
transfer was performed at 25 V for 1 hour. 
After transfer PVDF membrane was washed in TBS-T (see Appendix) with shaking at 
60 rpm for 5 minutes, three times. NM23-H1 (C-20) rabbit polyclonal primary antibodies 
(Santa Cruzm, Wembley, UK) were diluted 1:5000 in 10 ml 5% Blotto, but His-probe (H-15) 
rabbit polyclonal primary antibodies (Santa Cruz) were diluted 1:2500 in 10 ml 5% Blotto. 
Anti-rabbit secondary antibodies (Sigma) were diluted 1:1000 in 10 ml 5 % Blotto. To 
prevent non-specific antibody binding PVDF membrane was soaked in 30 ml 5% Blotto (see 
Appendix) with shaking at 20 rpm for 30 minutes. Blotto was poured, off and membrane was 
incubated with diluted primary antibodies at 4°C with shaking at 20 rpm, overnight. The 
excess of primary antibodies was removed by washing PVDF membrane in TBS-T with 
shaking at 60 rpm for 10 minutes, three times. Then PVDF membrane was incubated with 
diluted secondary antibodies with shaking at 20 rpm, for 1 hour. The excess of secondary 
antibodies was removed by washing PVDF membrane in TBS-T with shaking at 60 rpm for 
10 minutes, three times. 
SuperSignal West Pico Chemiluminiscent Substrate or SuperSignal West Dura 
Chemiluminiscent Substrate (Thermo Scientific, Waltham, UK) was used. Stable peroxide 
solution and Luminal/Enhancer solution were mixed as 1:1 in total volume 2 ml for 1 
membrane. PVDF membrane was incubated in 2 ml of the prepared solution for 5 minutes. 
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The excess of solution was drained off. PVDF membrane was wrapped in cling film and taped 
down into a film cassette. Prepared membrane was exposed to a photographic film (Kodak, 
Rochester, NY, USA) for a varied time and developed using AGFA Curix 60 developer 
(AGFA, Mortsel, Belgium).  
2.10 rNDK PROTEIN MASS CALCULATION  
Expected protein masses were calculated from rNDK protein sequences. Secreted 
rNDK protein masses were calculated from photographs of SDS-polyacrylamide gels stained 
with Coomassie blue. Firstly, a curve for protein ladder with respect to protein run distance 
was drawn. Mass of each secreted rNDK protein was determined from the equation of the 
trend line for the drawn curve. 
2.11 FLOW CYTOMETRY 
2.11.1 CD34+ve cell staining 
CD34
+ve
 pre-sorted cells, CD34
+ve
 cells after first and second sort and CD34
+ve
 cells 
incubated in CM were collected as 50 - 100 µl. To the collected samples 5 µl FcR blocking 
reagent (Miltenyi Biotech) and 2 µl CD34 FITC (BD Bioscience, Oxford, UK) or 1 μl CD34 
APC antibody (BD Bioscience) were added. Control samples were stained with the same 
amount of FITC (BD Bioscience) or APC isotype control antibody (BD Bioscience). All 
samples were incubated for 10 minutes, washed with 2 ml PBS (PAA Laboratories, Gmbh, 
Yevil Sommerst, UK) then spin at 1500 rpm for 5 min. Supernatant was removed, and cells 
were resuspended in 200 µl FACS fix (see Appendix). Microbeads (CytoCount
TM
, Alere Ltd., 
Stockport, UK) (10 μl) were added to the samples. Prepared samples were analyzed using BD 
LSRII machine with FACS DIVA software (BD Bioscience), collecting 100,000 viable cells 
for CD34
+ve
 pre-sorted samples and 10,000 viable cells for CD34
+ve
 sorted samples. 
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2.11.2 CD34-ve cell staining 
Treated CD34
-ve
 cells were collected as 100 - 200 µl. To the collected samples 5 µl 
FcR blocking reagent and 1 µl CD34 APC and 2 µl CD11b PE* antibodies (BD Bioscience) 
were added. Control samples were stained with the same amount of APC and PE* isotype 
control antibodies (BD Bioscience). Samples were incubated for 10 minutes, washed in 2 ml 
PBS, then spin at 1500 rpm for 5 min. Supernatant was removed, and cells were resuspended 
in 200 µl FACS fix. Prepared samples were analyzed using BD LSRII machine with FACS 
DIVA software, collecting 20,000 viable cells.  
2.12 JENNER GIEMSA STAINING 
Giemsa Buffer (see Appendix) was diluted 1:25 in dH2O. Jenner stain (RAYMOND A 
LAMB Ltd., Eastbourne, UK) was diluted 1:3 in diluted Giemsa buffer. Giemsa‟s staining 
solution (BDH, VWR International Ltd., Poole, UK) was diluted 1:20 in diluted Giemsa 
buffer. To produce slides 75μl of cell culture were cytospined at 500 rpm for 3 min using 
Cytospin 3 (Shannon, UK). Prepared slides were air dried. Cells on the slides were fixed in 
methanol for 5 minutes and air dried. Slides were stained in diluted Jenner stain for 5 minutes 
then washed with water. Then slides were stained in dilute Giemsa stain for 10 minutes. 
Slides were washed, and air dried. Stained slides were mounted with DePex mounting 
medium (BDH, VWR International Ltd., Poole, UK). Cells were visualized using microscope. 
Photographs were taken at ×400 magnification. 
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3 RESULTS 
3.1 PRODUCTION OF HIS-TAGGED rNDK PROTEINS 
Glycerol stocks of BL21 (DE3) with the pET-15b expression vector containing NDK 
coding gene were streaked out and regrown on LB agar plates. Single colonies were picked 
and cultured overnight. Overnight cultures were diluted, and rNDK protein expression was 
induced with IPTG as described in materials and methods. 
3.1.1 Integrity of the rNDK protein producing system 
The integrity of bacterial colonies was verified for the overnight cultures by colony 
PCR amplification of the NDK gene cloned in the pET-15b expression vector using bacterial 
NDK specific primers. PCR using NM23-H1 specific primers was run on all colonies. PCR 
products were separated by agarose gels electrophoresis. The correct sized PCR products for 
each bacterial NDK strain and no NM23-H1 contamination were observed for all BL21 (DE3) 
colonies (Data not shown due to the suitable image of the gel was not captured) indicating 
that the rNDK colonies contained the correct plasmid sequence. 
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3.1.2 Purification of rNDK proteins 
Recombinant NDK proteins were purified using Ni-NTA His-Bind resin from the 
IPTG induced cultures as described in materials and methods. Briefly, BL21 (DE3) rNDK 
protein producing cells were lysed, and pellets were discarded. Total lysate was added to the 
Ni-NTA His-Bind resin column, and unbound fractions were collected. rNDK proteins were 
eluted in 6 fractions as 1 ml. Purified proteins were separated by SDS-PAGE on 12.5% gels 
and stained with Coomassie blue (Figure 3.1). E.coli and S.pneumoniae rNDK proteins were 
eluted in the second and third fractions. S.aureus rNDK and rNM23-H1 proteins were eluted 
in the first three fractions, whilst K.pneumoniae rNDK was eluted in the first four fractions. 
For the first three fractions protein concentration was determined (Figure 3.2). The highest 
concentration of rNDK proteins is in the second eluted fraction. Therefore, the second 
fractions were diluted in RPMI 1640 p/s ITS+ to a final concentration of 100 µg/ml. 
Verification of rNDK proteins in the second eluted fractions was performed using 
Western blot. There are no commercially available antibodies for bacterial NDK proteins so 
we tested anti-NM23 antibodies for their cross-reactivity against bacterial NDK proteins. In 
the first Western blot analysis NM23-H1 antibody was used (Figure 3.3). Bands were 
observed for rNM23-H1, S.aureus rNDK and their dimers. NM23-H1 antibody is rNM23-H1 
specific, thus when protein fractions are diluted as 1:10 in 1×GLB and loaded on a SDS-
polyacrylamide gel, photo bleaching of rNM23-H1 was observed. Bands of K.pneumoniae 
and E.coli rNDK usually were observed, when membrane was incubated in strong ECL and 
exposed to a film for a longer time. No band for S.pneumoniae rNDK was observed. 
Therefore, alignment of bacterial NDK protein sequences with NM23-H1 was produced 
(Figure 3.4). 
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Figure 3.1 Purification of rNDK proteins. Coomassie blue stained SDS-polyacrylamide gels. For each rNDK protein samples of total 
cell lysate, unbound fraction and six eluted rNDK protein fractions (F#1 –F#6) were loaded on a gel. 
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NM23-H1 antibody binds to the 20 amino acid long C-terminal NM23-H1 
sequence. Sequence similarities between NM23-H1 and E.coli, K.Pneumoniae, 
S.pneumoniae, S.aureus NDK proteins are 15%, 15%, 5% and 8 amino acids 40% 
(Figure 3.3). This explains observed band intensity and absence of S.pneumoniae rNDK 
band. To overcome the problem, in further Western blot analysis His-probe antibody 
was used. 
The second eluted fractions of rNDK proteins were diluted as 1 mg/ml and 
loaded as 10 µl on a SDS-polyacrylamide gel. His-probe antibody binding to all rNDK 
proteins was observed (Figure 3.3). Weak binding of His-probe antibody to 
S.pneumonia rNDK was observed. His-probe antibody binds stronger to E.coli, 
K.Pneumoniae, S.aureus rNDK and rNM23-H1 proteins. For rNM23-H1 and E.coli, 
S.aureus rNDK were observed two bands – mono and dimer form of rNDK.  
 
 
Protein 
Concentration 
of F#1, mg/ml 
Concentration 
of F#2, mg/ml 
Concentration 
of F#3, mg/ml 
rNM23-H1 0.71  2.57  0.69  
E.coli rNDK 0.00  2.30  0.92  
K.pneumonia rNDK 2.35  4.15  2.47  
S.pneumoniae rNDK 0.49  4.30  2.00  
S.aureus rNDK 0.27  3.46  1.13  
 
Figure 3.2 Concentration of rNDK proteins in the first three fractions, where F#1, 
F#2 and F#3 are fractions 1-3.  
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Figure 3.3 Purification of rNDK proteins. Verification of rNDK proteins using 
Western blot. The second eluted fraction of each rNDK protein was diluted 1:10 in 
1×GLB (for PVDF membrane incubation in NM23-H1 antibody) and 1mg/ml in GLB 
(for PVDF membrane incubation in His-probe antibody) and loaded on SDS-
polyacrylamide gel. Proteins separated by SDS-PAGE were transferred from SDS-
polyacrylamide gel onto PVDF membrane and membrane was incubated in NM23-H1 
or His-probe antibody.  
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 1    5     10     15     20     25     30   
NM23-H1 M A N C E R T F I A I K P D G V Q R G L V G E I I K R F E Q K G 
E.coli ● ● I - ● ● ● ● S I ● ● ● N A ● A K N V I ● N ● F A ● ● ● A A ● 
K.Pneumoniae ● ● ○ - ● ● ● ● ○ ○ ● ● ● ○ ○ ● ○ ○ ○ ○ ○ ● S ● ○ S ● ● ● ○ ○ ● 
S.aureus ● - - - ● ● ● ● L M ● ● ● ● ○ ● ● ● ○ ● ○ ● ● V ● S ● I ● R ● ● 
S.pneumonia ● - - - ● Q ● ● F ○ ● ● ● ● ● ● K ● ● ● ● ● ● V L ● ● I ● ● R ● 
   35     40      45     50     55     60    
NM23-H1 F R L V G L K F M - Q A S E D L L K E H Y V D L K D R P F F A G 
E.coli ● K I ● ● T ● - ● L H L T V E Q A R G F ● A E H D G K ● ● ● D ● 
K.Pneumoniae ● ○ - ● ● ○ ● - ● ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ○ ○ E ○ ● ● ● ● ○ ● 
S.aureus L ○ ● ● ● G ● L ● - ● V P M ○ ● ○ E T ● ● G ○ ○ Q ○ ○ ● ● Y N D 
S.pneumonia ● T ○ E K ● E ● R S ● V ● ● ○ ● I D Q ● ● Q ● ● V ○ Q S ● Y P P 
  65     70     75     80     85     90     95 
NM23-H1 L V K Y M H S G P V V A M V W E G L N V V K T G R V M L G E T N 
E.coli ● ● E F ● T ● ● ● I ● V S ● L ● ● E ● A ● Q R H ● D L ● ● A ● ● 
K.Pneumoniae ● ● ○ ● ● ○ ● ● ● ○ ● ○ ○ ● ○ ● ● ○ ● ○ ● ○ ○ ○ ● ○ ○ ● ● ○ ● ● 
S.aureus ● I S ● I ○ ● A ● ● F ● ● ● V ● ● ○ D ○ ● N V S ● H I I ● S ● ● 
S.pneumonia I R ○ ● ● ○ ● ● ● ● L ○ G ● I S ● P K ● I E ● W ● T ● M ● ○ ● R 
     100     105 
 
   110     115 
 
        120   
NM23-H1 P A D S K P G T I R G D F C I Q V G R N - I I - - - - H G S D S 
E.coli ● ● N A L A ● ● L ● A ● Y A D S L T E ● - G T - - - - ● ● ● ● ● 
K.Pneumoniae ● ● ○ ○ ○ ○ ● ● ○ ● ○ ● ○ ○ ○ ○ F ○ ○ ● - ○ ○ - - - - ● ● ● ● ● 
S.aureus ● S E ○ S ● ● S ● ● ● ● L G L T ● ● ● ● - ● ● - - - - ● ● ● ● ● 
S.pneumonia ● E E ○ ○ ● ● T ● ● ● ● ● ○ K A A ● ○ ● E ● ● Q N V V ● ● ● ● ● 
   125    130     135     140     145     150      
NM23-H1 V E S A E K E I G L W F H P E E L V D Y T S C A Q N W I Y E   
E.coli ● ● ● ● A R ● ● A Y F ● G E G ● V C P R ● R           
K.Pneumoniae ● ● ● ● ○ ○ ● ● ○ F ○ ● A ○ ○ ● ○ ○ ○ ○ ● ○           
S.aureus L ● ● ● ● ○ ● ● N ● ● ● N ○ N ● I T S ● A ● P R D A ● L ● ●   
S.pneumonia E ● ● ● K ○ ● ● ○ ● ●                      
                                 
 ●  The same amino acids as in NM23-H1 protein    The same amino acids found in K.Pneumoniae and S.aureus NDK proteins 
                                 
 ○  The same amino acids as in NDK protein from E.coli  
 
 The same amino acids found in S.aureus and S.Pneumoniae NDK proteins 
 
Figure 3.4 Alignment of NM23-H1 and E.coli, K.Pneumoniae, S.pneumoniae, S.aureus NDK protein sequences. NM23-H1 protein C-
20 amino acid sequence with which NM23-H1 protein binds to NM23-H1 antibody is shown in yellow. Bacterial NDK protein similarity 
with NM23-H1 protein C-20 sequence is shown in grey. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 150 of 190 
 
3.2 BL21 (DE3) BACTERIA SECRETE rNDK PROTEINS  
To check if BL21 (DE3) bacteria secrete rNDK proteins overnight cultures were 
diluted and rNDK protein expression was induced by IPTG. Samples were collected shortly 
before IPTG induction (zero time point) and every 24 hours for six days. IPTG non-induced 
culture was monitored as a control. Secreted proteins were separated by SDS-PAGE on 12.5% 
gels and stained with Coomassie blue (Figure 3.5). 
For each rNDK protein curves of protein ladder mass with respect to their run distance 
were drawn. Secreted protein masses were determined from the trend line equation of the 
curve (Figure 3.6). Verification of rNDK proteins was performed by calculation of masses for 
observed proteins on Coomassie blue stained SDS-polyacrylamide gels and comparison to the 
predicted masses. Calculated masses were found as similar to predicted ones. 
No rNDK secretion in IPTG non-induced cultures was observed (Data not shown). 
Secretion of rNDK proteins in IPTG induced cultures was observed from the first day (Figure 
3.5). The intensity of observed rNDK protein bands allow to suggest that secretion of 
K.pneumoniae, S.aureus and S.pneumoniae rNDK stays unchanged for 6 days, while secretion 
of rNM23-H1 and E.coli rNDK decreases. Moreover, E.coli rNDK secretion is weak and is 
observed only for the first three days.  
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rNM23-H1  S.pneumoniae 
 
 
 
   
   
   
E.coli  S.aureus 
 
 
 
 
 
 
K.pneumoniae 
 
 
Day post IPTG induction 
 
 
Figure 3.5 Time course experiment: BL21 (DE3) bacteria secrete rNDK proteins. 
Coomassie blue staining of SDS-polyacrylamide gels. Overnight cultures were diluted 1:50 
and rNDK protein expression was induced by IPTG. Samples were collected before ITPG 
induction (zero time point) and every 24 hours for six days. Prepared samples of supernatants 
were loaded on SDS-PAGE gels. 
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(b) 
Protein Predicted mass, kDa Calculated mass, kDa 
rNM23-H1 19.78 22.26 
E.coli rNDK 18.69 20.92 
K.pneumoniae rNDK 18.72 20.05 
S.pneumoniae rNDK 18.01 19.21 
S.aureus rNDK 19.26 19.94 
 
Figure 3.6 Time course experiment: BL21 (DE3) bacteria secrete rNDK proteins. 
Verification of secreted rNDK proteins. (a) Curves and trend lines of protein ladder mass 
with respect to their run distance (b) rNDK protein masses calculated from trend line equation 
and predicted from protein sequences. 
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3.3 THE OPTIMIZATION OF CD34+ve CELL PURIFICATION 
CB samples were sorted for mononuclear cells (pre CD34
+ve
 sorted cells). Further 
mononuclear cells were sorted for CD34
+ve
 cells as described in materials and methods. Pre 
and post CD34
+ve
 sorted samples were stained with CD34 FITC (CB2-CB11) or CD34 APC 
(CB12) antibodies as described in materials and methods and analysed by flow cytometry.  
An example of flow cytometry data for pre and post CD34
+ve
 sorted cells is shown for 
CB7 sample (Figure 3.7). CB7 sample was double sorted for CD34
+ve
 cells. Flow cytometry 
data for each sample: CD34
+ve
 pre-sorted, CD34
+ve
 after 1
st
 and 2
nd
 sort are shown as two 
plots. The first one compares the forward and side scatter of all collected events (Figure 3.7, 
Column 1). An increase in forward scatter indicates an increase in event size. Whereas an 
increase in side scatter indicates an increase in granulation of cell cytoplasm, thus indicates 
more mature cells. Gate R1 enclose all viable cells, while dead cell and debris are found in the 
bottom left corner. Microbeads form a line in the top left corner. For the pre CD34
+ve
 cell 
sample was collected 100,000 R1 gated events, for the CD34
+ve
 sorted samples 10,000 R1 
gated events. Analysing data of CD34
+ve
 once and twice sorted cells viable cells are situated 
on the bottom of the plot (Figure 3.7, Column 1). Viable cells of pre CD34
+ve
 sorted sample 
are more distribute towards the increase in side scatter. The second plot represents all viable 
cells (R1 gated events) and it compares the side scatter and CD34 FITC stained cells (Figure 
3.7, Column 2). Gate R2 enclose CD34
+ve
 cells. In pre CD34
+ve
 sorted sample amount of 
CD34
+ve
 cells is negligible, it increase with each CD34
+ve
 sort (Figure 3.7, Column 2). 
Amount of CD34
+ve
 cells in pre and post CD34
+ve
 cell sort samples was calculated from 
the ratio between microbeads and R2 gated events (Figure 3.7, Column 2). CD34
+ve
 cells are 
found as 0.5 – 1.7% of mononuclear cells (Figure 3.8a). Percentage of CD34+ve cell for CB2 
and CB3 after single sort is 42.1% and 35.1%, respectively. To increase the purity of CD34
+ve
 
cells temperature (6°C - 12°C) of MACS buffer was monitored and CD34
+ve
 cell purity 
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increased to 47.1 - 65.6% (CB4-CB7). Although, monitoring temperature of MACS buffer an 
increase in purity of CD34
+ve
 cells was observed, the purity of CD34
+ve
 cells is unsatisfactory. 
Therefore, double sort was performed and an increase in CD34
+ve
 purity 75.8 – 88.9% is 
observed (Figure 3.8 b).  
To visualize diversity of sorted cells, Jenner Giemsa staining was performed (Figure 
3.9). Jenner Giemsa stains nuclei blue violet, erythrocytes – weak red, platelets - light pale 
pink, lymphocyte cytoplasm - sky blue, monocyte cytoplasm – greyish blue, granules in 
granulocytes – dark violet and stem cells (CD34+ve) – violet. Mononuclear layer consist of 
cells with round nucleus, such as lymphocytes, monocytes or macrophages. In CD34
-ve
 cell 
sample lymphocytes (dark blue nuclei with a narrow rim of cytoplasm), monocytes (greyish 
blue) and stem cells (perfectly round and violet) are distinguished. In CD34
+ve
 cell sample 
most of cells are stem cells (CD34
+ve
) (Figure 3.9).  
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Figure 3.7 CD34
+ve
 cell purification. Flow cytometry data. Pre CD34
+ve
 sorted cells and 
CD34
+ve
 cells after 1
st
 and 2
nd
 sort (CB7). Total collected events are observed in column 1 
plots. Gate R1 enclose viable cells and gate R2 CD34
+
 cells.  
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Figure 3.8 CD34
+ve
 cell purification. Percentage of CD34
+ve
 cells. (a) Percentage of 
CD34
+ve
cells in pre CD34
+
 sort cells (b) Percentage of CD34
+ve
cells in CD34
+ve
 cells after 1
st
 
and 2
nd
 sort. 
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Figure 3.9 CD34
+ve
 cell purification. Post sorted CD34
-ve
 and CD34
+ve
 cell Jenner Giemsa 
staining (CB2). Pictures are taken at ×400 magnification. 
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3.4 VIABILITY OF CD34-ve CELLS TREATED WITH rNDK PROTEINS 
After CD34 sorting CD34
-ve
 cells were diluted as 0.5×106 cells per ml in RPMI 1640 p/s 
ITS+ and seeded as 500 µl in a 48 well plate. CD34
-ve
 cells were treated with 1µg/ml (CB8-
CB10) or 2µg/ml (CB11 and CB12) rNM23-H1 or E.coli, K.Pneumoniae, S.pneumonia, 
S.aureus rNDK protein (rNDK-EC, rNDK-KP, rNDK-SP and rNDK-SA) or EB. CB12 
samples were supplemented with 1.25 µg/ml PMB. Treated CD34
-ve
 cells were incubated at 
37°C for 7 day. Treated cells were stained with CD34 APC and CD11b PE* antibodies as 
described in materials and methods and analysed by flow cytometry.  
An example of flow cytometry data for treated CD34
-ve
 cell cultures incubated for 7 
days is shown for CB11 sample as two plots for each rNDK or EB treatment (Figure 3.10). 
The first plot of side scatter against forward scatter shows all collected events (Figure 3.10, 
Column 1). The gate R1 encloses viable cells. The second plot of CD34 APC against CD11b 
PE
*
 is R1 gated, thus represents all viable cells (Figure 3.10, Column 2). Gate R2 encloses 
CD11b
+ve
 cells, whilst gate R3 encloses CD34
+ve
 cells. Plots in column 2 shows that CD34
+ve
 
and CD11b
+ve
 cells are present in the treated CD34
-ve
 cell cultures. The amount of CD34
+ve
 
cells is 0.1-4.0%, although it was expected to be close to 0. Amount of CD11b
+ve
 cells is 
higher 5.3–40.1% (Figure 3.11). The amount of CD11b+ve cells increases about two times in 
the sample supplemented with PMB (CB12) (Figure 3.11). Otherwise there is no consistency 
in the levels of CD11b
+ve
 and CD34
+ve
 cells in treated CD34
-ve
 cells cultures (Figure 3.11) 
Figure 3.12 represents viability of treated CD34
-ve
 cells. Total concentration of viable 
CD34
-ve
 cells decreases from initial concentration 10
6
 cells per ml (day 0) to 1.83±0.53×10
5
 
(EB), 1.21±0.32×10
5
 (rNM23-H1), 1.10±0.26×10
5
 (rNDK-EC), 1.74±0.38×10
5
 (rNDK-KP), 
0.99±0.20×10
5
 (rNDK-SP), 1.59±0.45×10
5
 (rNDK-SA) cells per  ml. Total cell concentration 
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is higher in EB treated samples (negative control) than in rNM23-H1 treated samples (positive 
control) for all CB samples indicating that positive control failed to work. 
CD34
-ve
 cell differentiation was observed for all treated CB samples. CD34
-ve
 cell 
culture photographs were taken on day 7 (Figure 3.13). CD34
-ve
 cells treated with EB are less 
differentiated, whilst all rNDK proteins promoted macrophage and fibroblast formation. 
Cluster formation in CD34
-ve
 cell cultures treated with rNDK was observed only for CB1 and 
CB11. Cells treated with EB did not form cluster or they were present in smaller amount. 
Presence and absence of clusters in CD34
-ve
 cell cultures treated with rNM23-1 and EB, 
respectively, is shown in photographs of Jenner Giemsa stained CD34
-ve
 cells (Figure 3.14). 
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Figure 3.10 Differentiation of CD34
-ve
 cells. Flow cytometry data. CD34
-ve
 cells were seeded as 0.5×106 cells per well in a 48 well plate 
as 500 µl. Seeded cells were treated with 2 µg/ml rNDK protein or EB and incubated at 37ºC for 7 days (CB11). Gate R1 enclose viable 
cells, gate R2 CD11b
+ve
 cells and gate R3 CD34
+ve
 cells. 
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Figure 3.11 CD34
-ve
 cell differentiation. Percentage of CD34
+ve
 and CD11b
+ve
 in treated 
CD34
-ve
 cell cultures. CD34
-ve
 cells were seeded as 0.5×106 cells per well in a 48 well plate 
as 500 µl. Seeded cells were treated with 1µg/ml (CB8 - CB10) or 2 µg/ml (CB11 and CB12) 
rNDK protein or EB and incubated at 37ºC for 7 days (CB11). CB12 was treated with 1.25 
µg/ml PMB.  
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Figure 3.12 CD34
-ve
 cell viability (CD11b
+ve 
cell concentration per ml is represented in 
red, total cell concentration is sum of blue and red). CD34
-ve
 cells were seeded as 0.5×106 
cells per well in a 48 well plate as 500 µl. Seeded cells were treated with 1µg/ml (CB8 - 
CB10) or 2 µg/ml (CB11 and CB12) rNDK protein or EB and incubated at 37ºC for 7 days 
(CB11). CB12 was treated with 1.25 µg/ml PMB.  
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Figure 3.13 CD34
-ve
 cell viability. CD34
-ve
 cells were seeded as 0.5×106 cells per well in a 48 
well plate as 500 µl. Seeded cells were treated with 2 µg/ml (CB11) rNDK protein or EB and 
incubated at 37ºC (CB11) for 7 days. Photographs were taken at x400 magnification. 
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Figure 3.14 CD34
-ve
 cell viability. Photographs of Jenner Giemsa stained CD34
-ve
 cell 
treated with rNM23-H1 or EB. CD34
-ve
 cells were seeded as 0.5×106 cells per well in a 48 
well plate as 500 µl. Seeded cells were treated with 2 µg/ml (CB1) rNm23-H1 protein or EB 
and incubated at 37ºC for 7 days (CB1). Collected cells were cytospined and stained in Jenner 
Giemsa stain. Photographs were taken at x400 magnification. 
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3.5 VIABILITY OF CD34+ve CELLS TREATED WITH CM 
From CD34
-ve
 cell cultures treated with rNM23-H1 or E.coli, K.Pneumoniae, 
S.pneumonia, S.aureus rNDK protein or EB and incubated for 20 hours CM (CM-NM, CM-
EC, CM-KP, CM-SP, CM-SA or CM-EB) was collected. Recombinant NDK proteins were 
depleted from collected CM as described in materials and methods. Protein depletion was 
verified by Western blot (Figure 3.15). 
CD34
+ve
 sorted cells were left overnight at 4ºC. On the next day CD34
+ve
 cells were 
counted and diluted as 10
6
 cells per ml in CMdep. Resuspended cells were seeded as 150 µl 
(CB8) and as 100 µl (CB9-CB12) in a 96 well plate and incubated at 37ºC for 7 days. Treated 
cells were stained with CD34 FITC (CB8-CB11) or CD34 APC (CB12) antibodies as 
described in materials and methods and analysed by flow cytometry.  
An example of flow cytometry data for treated CD34
+ve
 cell cultures incubated for 7 
days is shown for CB8 sample as two plots for each CMdep-NDK and CMdep-EB treatment 
(Figure 3.16). The first plot of side scatter against forward scatter shows all collected events 
(Figure 3.16, Column 1). Gate R1 encloses viable cells. Amount of viable cells in CD34
+ve
 
resuspended in CMEB (CD34
+ve
/CMdep-EB) is smaller than in CD34
+ve
/CMdep-NM. The 
second plot of side scatter against CD34 FITC is R1 gated, thus all events represents all viable 
cells (Figure 3.16, Column 2). Gate R2 encloses CD34
+ve
 cells. Amount of CD34
+ve
 cells in 
CD34
+ve
/CMdep-EB is smaller than in CD34
+ve
/CMdep-NM (Figure 3.16, Column 2). 
Figure 3.17 represents viability of treated CD34
+ve
 cell cultures. CD34
+ve
 cell culture 
were seeded at total cell concentration 10
6
 cells per ml. CD34
+ve
 cell purity
 
for CB8, CB9, 
CB10, CB11 and CB12 is 82.6%, 85.7%, 85.4%, 75.8% and 83.5%, respectively. Therefore, 
genuine concentration of CD34
+ve
 cells in seeded samples is 8.26×10
5
 (CB8), 8.57×10
5 
(CB9), 
8.54×10
5
(CB10), 7.58×10
5
(CB11) and 8.35×10
5
(CB12) cell per ml. Total concentration of all, 
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including CD34
+ve
 cells, from initial concentration 10
6
 cells per ml decreases to 
1.45±0.52×105 (CMdep-EB), 2.38±0.73×10
5
 (CMdep-NM), 2.46±0.87×10
5
 (CMdep-EC), 
2.18±1.25×105 (CMdep-KP), 4.04±3.64×10
5
 (CMdep-SP) and 2.75±0.68×10
5
 cells per ml 
(CMdep-SA). Whereas concentration of CD34
+ve
 cells only from initial concentration 
8.26±0.16×105 cells per ml decreases to 0.59±0.12×105 (CMdep-EB), 1.16±0.37×10
5
 (CMdep-
NM), 1.18±0.50×105 (CMdep-EC), 1.33±0.78×10
5
 (CMdep-KP), 2.51±1.91×10
5
 (CMdep-SP), 
1.44±0.43×105 (CMdep-SA)   Moreover, percentage of CD34
+ve
 cells in treated cultures 
decreases from 75.8-85.7% to 58.3 - 78.7% (CB8), 45.4 - 50.0% (CB9), 47.3 - 59.0% (CB10), 
19.6 - 27.4% (CB11) and 60.1 - 70.7% (CB12). CD34
+ve
 cell viability is not consistent. 
Comparing viability of CD34
+ve
 cells treated with positive (CMdep-NM) and negative control 
(CMdep-EB) only in samples CB8, CB11 and CB12 CD34
+ve
 cell concentration  is higher in 
CD34
+ve
/CMdep-NM cells. In CB9 sample concentration of CD34
+ve
 cells treated with CMdep-
NM or CMdep-EB are similar, while in sample CB10 CD34
+ve
 cell concentration is higher for 
CMdep-EB. 
Photographs of the treated CD34
+ve
 cell cultures were taken on day 7 (Figure 3.18). In 
CD34
+ve
/CMdep-EB sample there are fewer cells, whilst in CD34
+ve
/CMdep-NDK are more 
cells. CD34
+ve
/CMdep-NDK cells are tending to form clusters, whilst in CD34
+ve
/CMdep-EB no 
cluster or less in comparison to CD34
+ve
/CMdep-NDK is observed. This tendency is observed 
even when amount of the total cells is very small (CB9 and CB10). Lack and presence of 
clusters in CD34
+ve
/CMdep-EB and CD34
+ve
/CMdep-NM is observed in Jenner Giemsa stained 
CD34
+ve
 cell cultures (Figure 3.19). 
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Figure 3.15 Verification of rNDK protein depletion in CM. Western blot analysis 
(CB12). 
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Figure 3.16 CD34
+ve
 cell viability. Flow cytometry data. CD34
+ve
 cells were diluted as 10
6
 cells per ml in 150 µl CMdep-NDK or CMdep-
EB and seeded in a 96 well plate. Treated CD34
+ve
 cell cultures were incubated at 37ºC for 7 days (CB8). Gate R1 enclose viable cells, gate 
R2 CD34
+ve
 cells. 
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Figure 3.17 CD34
+ve
 cell viability (CD34
+ve
 cell concentration per ml is represented in 
blue, total cell concentration is in sum of blue and red). CD34
+ve
 cells were diluted as 10
6
 
cells per ml in 150 µl (CB8) or 100 µl (CB9 – CB12) CMdep-NDK or CMdep-EB and seeded in 
a 96 well plate. Treated CD34
+ve
 cell cultures were incubated at 37ºC for 7 days.  
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Figure 3.18 CD34
+ve
 cell viability. Photographs of treated CD34
+ve
 cell cultures. CD34
+ve
 
cells were diluted as 10
6
 cells per 1 ml in 100 µl of CMdep-NDK or CMdep-EB and seeded in a 
96 well plate. Treated CD34
+ve
 cell were incubated at 37ºC for 7 days (CB11). Photographs 
were taken at x400 magnification.  
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Figure 3.19 Photographs of Jenner Giemsa stained CD34
+ve
 cell treated with CMdep-NM 
or CMdep-EB (CB1). CD34
+ve
 cells were diluted as 10
6
 cells per 1 ml in 200 µl CMdep-NM or 
CMdep-EB and seeded in a 96 well plate. Treated CD34
+ve
 cell cultures were incubated at 37ºC 
(CB11) for 7 days. Collected cells were cytospined and stained in Jenner Giemsa stain. 
Photographs were taken at x400 magnification. 
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4 DISCUSSION 
4.1 BL21 (DE3) BACTERIA SECRETE rNDK PROTEINS 
It is known that several pathogenic bacterial taxa such as P.gingivalis (Yilmaz et al., 
2008), L.amazonensis (Kolli et al., 2008), M. tuberculosis (Zhao et al., 2007), P.aeruginosa 
(Zaborina et al., 1999), V.cholera and S.typhimurium (Dar et al., 2011), secrete NDK proteins. 
The exact mechanism of protein secretion remains hitherto unknown, yet it has been 
suggested that NDK protein secretion is promoted by the type I mechanism (Kamath et al., 
2000). The DXXX (X is predominantly hydrophobic amino acid) motif in the C-terminal 
region of NDK proteins seems to play a crucial role in NDK protein secretion.  
In this project, we could show that E.coli BL21 (DE3) secretes rNM23-H1, E.coli, K. 
pneumoniae, S.pneumoniae and S.aureus rNDK proteins. All these rNDK proteins possess the 
sequences DSVE (rNM23-H1, E.coli and K.pneumoniae), DSLE (S.aureus), DSEE 
(S.pneumoniae) or DYTS (rNM23-H1) in the C-terminal end, which might be responsible for 
their secretion. The secretion mechanism itself was not investigated, as it was not the purpose 
of this study. An important fact here is that rNDK proteins were secreted from the same E.coli 
BL21 (DE3) strain. Thus, it might be that K. pneumoniae, S. pneumonia and S. aureus 
bacteria do secrete NDK proteins expressed by themselves, an observation that should be 
investigated further. 
NM23-H1 and NM23-H2 are secreted by blood cells (Yokoyama et al., 1996, Willems 
et al., 1998, Okado-Kabe et al., 2002), as they are found in both healthy and in AML patient 
plasma (Niitsu et al., 2000, Willems et al., 1998, Okado-Kabe et al., 2002). The levels of 
NM23-H1 and NM23-H2 are increased in leukaemia patients (Niitsu et al., 2000) and 
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elevated levels of NM23-H1 and NM23-H2 might be just a result of the disease. However, 
they may as well play a role in the development of leukaemia.  
Extracellular expression of NM23-H1 was observed for myeloid and some erythroid 
cancer cell lines and was not observed for lymphoid cell lines (Okabe-Kado et al., 2002, 
Willems et al., 1998). Moreover, extracellular levels of NM23-H1 decrease with cell 
differentiation (Okabe-Kado et al., 2002). Thus, it is possible that by expression of NM23-H1, 
immature cells affect the functional activity of more mature cells. 
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4.2 ADDITIONAL rNDK PROTEIN PROMOTES CELL SURVIVAL 
Willems et al. (2002) showed that additional NM23-H1, NM23-H2 and NM23-H3 did 
not affect differentiation of CD34
+ve
/CD38
-ve
 primary cell culture grown in the presence of 
IL-1, IL-3, IL-6, kit-ligand and FL cytokines differentiation. Additional NM23 proteins 
altered differentiation of more mature CD34
+ve
/CD38
+ve
 cells. It is supported by the findings 
where additional rNM23-H1 binds better to more mature cells CD34
lo
/CD11b
+ve
 then to 
immature CD34
+ve
 (Lilly et al., 2011, Lilly, 2012). An observation of this study is that 
additional rNM23-H1 protein promoted the survival of both cell populations, although 
rNM23-H1 predominantly binds to more mature populations. This leads us to suggest that 
additional rNM23-H1 indirectly promotes immature cell survival. The suggestion was 
confirmed by an experiment using AML samples. Recombinant NM23-H1 protein indirectly 
promoted survival of immature CD34
+ve
/CD117
+ve
. 
Bacterial and eukaryotic NDK protein structural similarities (Hama et al., 1991, Chen 
et al., 2002, Dumas et al., 1992) may mean that NDK proteins are functionally similar. E.coli, 
K. pneumoniae, S. pneumoniae and Staphylococcus aureus NDK proteins possess 43 - 53% 
sequence similarity with NM23-H1. Thus, it might be that bacterial NDK proteins promote 
AML stem cell survival and proliferation, as shown for rNM23-H1 (Lilly et al., 2011, Lilly, 
2012). Bacterial NDK proteins may become a potential target to lessen or eliminate AML. 
Therefore, it is relevant to test if rNDK proteins are able to promote survival of healthy and 
cancer blood stem cells. 
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4.2.1 Direct influence of rNDK proteins on CD34-ve cells 
In this part of the project we tested if E.coli, K. pneumoniae, S. pneumoniae, S.aureus 
rNDK proteins promote CD34
-ve
 cell survival. In all experiments, EB was used as a negative 
control and rNM23-H1 as a positive control. Incubated for 7 days CD34
-ve
 cell were seeded at 
concentration 10
6
 cells per 1 ml after incubating for 7 days the concentration decreased to to 
1.83±0.53×10
5
 (EB), 1.21±0.32×10
5
 (rNM23-H1), 1.10±0.26×10
5
 (rNDK-EC), 
1.74±0.38×10
5
 (rNDK-KP), 0.99±0.20×10
5
 (rNDK-SP), 1.59±0.45×10
5
 (rNDK-SA) cells per 
ml. Our positive control treated cells did not survive and did not proliferate, as it was shown 
by Lilly (2012). Moreover, total cell concentration was higher when CD34
-ve
 cultures were 
treated with EB in comparison to treatment with rNM23-H1. Unfortunately, due to a failure of 
our controls, no suggestions can be made about how bacterial rNDK proteins effect CD34
-ve
 
cultures. Flow cytometry analysis shows that treated CD34
-ve
 cultures in the presence of EB 
or rNDK proteins for 7 days have CD34
+ve
 cells (0.1 – 4.0%). The percentage of CD34+ve 
cells in the CD34
-ve
 fractions was not determined after CD34 sorting. However, the amount of 
CD34
+ve
 cells in pre CD34
+ve
 sorted cells is about 0.5 – 1.7%. Thus, after CD34 sorting, the 
percentage of CD34
+ve
 cells in CD34
-ve
 cell fractions should be negligible. The percentage of 
CD34
+ve
 cells found in CD34
-ve
 cultures is higher than it was determined in pre CD34
+ve
 sort
 
sample, suggesting that CD34
+ve
 cells have proliferated in treated samples. Nevertheless, the 
CD34
+ve
 cell concentration in treated CD34
-ve
 cultures is just 1.73±0.60×10
3
 (EB), 
1.84±0.71×10
3
 (rNM23-H1), 1.27±0.43×10
3
 (rNDK-EC), 2.04±0.90×10
3
 (rNDK-KP), 
1.87±0.47×10
3
 (rNDK-SP), 3.43±0.24×10
3
 (rNDK-SA) cells per ml indicating that CD34
+ve
 
cells proliferation is putative. It can be assumed that CD34
+ve
 cells left in post sorted CD34
-ve
 
sample survived in treated CD34
-ve
 cultures while CD34
-ve
 cells died.  
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Differentiation of treated CD34
-ve
 cells culture into macrophages and fibroblastic cells 
for all CB samples was observed. Cell differentiation was confirmed by flow cytometry 
analysis. We observed that treated CD34
-ve
 cell cultures possess CD11b
+ve
 cells. CD11b
+ve
 
cells are found as 5.3 – 40.1% of CD34–ve cell cultures. The amount of CD11b+ve cells 
increased about two times when CD34
-ve
 cultures were supplemented with PMB (CB12). 
PMB is used to protect treated cells from bacterial lipopolysaccharides (endotoxins) which 
could be present in purified rNDK protein fractions. It might be assumed that PMB protects 
CD34
-ve
 cells from endotoxins, thus allowing cells to differentiate more than it was seen in 
PMB non-supplemented CB samples. Only one CB sample was supplemented with PMB, so 
it cannot be suggested if the increased amount of CD11b
+ve
 cells is due to individual 
properties of CB sample or due to supplemented PMB.  
4.2.2  Indirect influence of rNDK protein on CD34+ve cells 
Total concentration of all, including CD34
+ve
 cells, from initial concentration 10
6
 cells 
per ml decreases to 1.45±0.52×105 (CMdep-EB), 2.38±0.73×10
5
 (CMdep-NM). Whereas 
concentration of CD34
+ve
 cells only from initial concentration 8.26±0.16×105 cells per ml 
decreases to 0.59±0.12×105 (CMdep-EB), 1.16±0.37×10
5
 (CMdep-NM).Although average 
CD34
+ve
 cells only are higher for the CD34
+ve
/CMdep-NM than it is for CD34
+ve
/CMdep-EB 
cells, for the CB9 sample was observed the opposite. Higher concentrations of 
CD34
+ve
/CMdep-NM than of CD34
+ve
/CMdep-EB was observed for samples CB8, CB11 and 
CB12, whereas for CB10 sample CD34
+ve
/CMdep-EB cells survived just slightly better. 
CD34
+ve
 cell cultures resuspended in CMdep-NM (positive control) and incubated for 
7days do not survive and do not proliferate as it was shown by Lilly et al (2012). Moreover, 
comparing the negative control with the positive control our results are not consistent. . As 
mentioned above our control experiments did not work for CD34
-ve
 cell cultures. CD34
-ve
 cell 
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cultures did not show the expected survival. Therefore, CD34
-ve
 cell cultures may secrete not 
enough active components (cytokines), which could cause the expected CD34
+ve
 cell survival 
and even cell proliferation. 
Lilly (2012) previously showed that rNM23-H1 indirectly promotes healthy and 
leukaemia stem cell (CD34
+ve
) survival. In our experiments, both total cell concentration 
including CD34
+ve
 cells and concentration of CD34
+ve
 cells only decreased, yet also the 
percentage of CD34
+ve
 cell in treated CD34
+ve
 cultures decreased. It was expected that even if 
the total cell concentration decreases, the percentage of CD34
+ve 
cells would stay unchanged 
or even increased. Nevertheless, the percentage of CD34
+ve
 cells in treated CD34
+ve
 cell 
cultures decreased from 82.6% to 58.3 - 78.7% (CB8), from 85.7% to 45.4 - 50.0% (CB9), 
from 85.4% to 47.3 - 59.0% (CB10), from 75.8% to 19.6 - 27.4% (CB11) and from 83.5% to 
60.1 - 70.7% (CB12). The highest decrease in CD34
+ve
 cell percentage was observed for 
CB11. Processed CB11 sample had the smallest purity sorted CD34
+ve
 cells in sorted CD34
+ve
 
fraction. It might be that contamination >20% of non CD34
+ve
 cells in CD34
+ve
 seeded cells 
affected high decrease in CD34
+ve
 cells. 
CD34
+ve
 cells resuspended in CMdep-NM and incubated for 7 days tended to form 
clusters. Treated CD34
+ve
/CMdep-EB cells usually did not form clusters or formed less in 
comparison to treated CD34
+ve
/CMdep-NM. Cluster formation may indicate that cells are 
dividing, but cells might just be sticking together. The amount of total cells is decreased. If 
cells are dividing the speed of new cell formation is much smaller than cell death.  
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4.2.3 Suggestions why our positive control failed to work 
The protocol of cord blood storage used for CB samples by Lilly (2012) was altered in 
our study. This change could affect CD34
-ve
 and/or CD34
+ve
 cell activity. If CD34
-ve
 cell do 
not possess their genuine activity, they are not able to release the same amount of cytokines or 
they may release even different ones.  
The fail of positive control can be explained by possible rNM23-H1 activity loss. 
Aggregation of NDK proteins was observed in the purified NDK protein fractions. It might be 
that the protein aggregation had changed their active form. Thus, even when proteins are 
diluted in RPMI 1640 p/s ITS+ to the final concentration of 100 µg/ml, they do not form their 
native structure. Both suggestions require checking. 
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4.3 FUTHER STUDIES 
Firstly, the reason of the positive control fail requires investigation. When the problem 
is solved, treatments of CD34
-ve
 and CD34
+ve
 cells purified from CB samples can be 
performed. If the effect of bacterial rNDK proteins on the survival of healthy CD34
-ve
 and 
CD34
+ve
 cells has been shown, the bacterial rNDK protein effect on leukaemia stem cells can 
be better understood. 
Lilly et al (2011) reported that CD34
-ve
/CD117
-ve
 cell cultures treated with rNM23-H1 
secrete IL-1β and IL-6 cytokines stronger then CD34-ve/CD117-ve cell cultures treated with 
EB. Thus, CD34
+ve
/CD117
+ve
 proliferation can be due to cell response on these cytokines. 
Similar to findings IL-1β promoted CD34+ve cell proliferation (Ezaki et al., 1995) and IL-6 
accompanied with GM-CSF or IL-3 promoted proliferation of normal haemopoietic cell from 
bone marrow and proliferation of leukaemia myeloid cell (Hoang et al., 1988). Therefore, it 
should be further investigated if bacterial rNDK proteins will promote cytokine secretion 
from CD34
-ve
 cell cultures treated with bacterial rNDK proteins and indirect CD34
+ve
 cell 
survival and proliferation. 
If rNDK proteins promote indirect CD34
+ve
 cell survival and proliferation through 
rNDK protein binding to more mature CD34
-ve
 cells, the most intriguing future direction 
would be to target these rNDK proteins with the aim of preventing their binding to leukaemia 
CD34
-ve
 cells, thus preventing cytokine release and leukaemia CD34
+ve
 cell survival. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 180 of 190 
 
5 REFERENCES 
 
BACKER, J. M., MENDOLA, C. E., KOVESDI, I., FAIRHURST, J. L., O'HARA, B., 
EDDY, R. L., JR., SHOWS, T. B., MATHEW, S., MURTY, V. V. & CHAGANTI, R. 
S. (1993) Chromosomal localization and nucleoside diphosphate kinase activity of 
human metastasis-suppressor genes NM23-1 and NM23-2. Oncogene, 8, 497-502. 
BERG, J. M., TYMOCZKO, J. L. & STRYER, L. (2002) Biochemistry, WH Freeman and 
Company. 
BILITOU, A., WATSON, J., GARTNER, A. & OHNUMA, S. (2009) The NM23 family in 
development. Mol Cell Biochem, 329, 17-33. 
BOURS, M. J., SWENNEN, E. L., DI VIRGILIO, F., CRONSTEIN, B. N. & DAGNELIE, P. 
C. (2006) Adenosine 5'-triphosphate and adenosine as endogenous signaling 
molecules in immunity and inflammation. Pharmacol Ther, 112, 358-404. 
BUCANEVE, G., CASTAGNOLA, E., VISCOLI, C., LEIBOVICI, L. & MENICHETTI, F. 
(2007) Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic 
patients. Ejc Supplements, 5, 5-12. 
BURNETT, A. K., GOLDSTONE, A. H., STEVENS R. M. F., HANN, I. M., REES, J. K. H., 
GRAY, R. G. & WHEATLEY K. (1998) Randomised comparison of addition of 
autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid 
leukaemia in first remission: results of MRC AML 10 trial. Lancet, 351, 700-708. 
BUSKE, C., FEURING-BUSKE, M., ABRAMOVICH, C., SPIEKERMANN, K., EAVES, C. 
J., COULOMBEL, L., SAUVAGEAU, G., HOGGE, D. E. & HUMPHRIES, R. K. 
(2002) Deregulated expression of HOXB4 enhances the primitive growth activity of 
human hematopoietic cells. Blood, 100, 862-868. 
CHAKRABARTY, A. M. (1998) Nucleoside diphosphate kinase: role in bacterial growth, 
virulence, cell signalling and polysaccharide synthesis. Mol Microbiol, 28, 875-882. 
CHANG, C. L., ZHU, X. X., THORAVAL, D. H., UNGAR, D., RAWWAS, J., HORA, N., 
STRAHLER, J. R., HANASH, S. M. & RADANY, E. (1994) Nm23-H1 mutation in 
neuroblastoma. Nature, 370, 335-336. 
CHEN, Y., GALLOIS-MONTBRUN, S., SCHNEIDER, B., VERON, M., MORERA, S., 
DEVILLE-BONNE, D. & JANIN, J. (2003) Nucleotide binding to nucleoside 
diphosphate kinases: X-ray structure of human NDPK-A in complex with ADP and 
comparison to protein kinases. J Mol Biol, 332, 915-926. 
CHEN, Y., MORERA, S., MOCAN, J., LASCU, I. & JANIN, J. (2002) X-ray structure of 
Mycobacterium tuberculosis nucleoside diphosphate kinase. Proteins, 47, 556-557. 
COULOMBEL, L. (2004) Identification of hematopoietic stem/progenitor cells: strength and 
drawbacks of functional assays. Oncogene, 23, 7210-7222. 
DAR, H. H., PRASAD, D., VARSHNEY, G. C. & CHAKRABORTI, P. K. (2011) Secretory 
nucleoside diphosphate kinases from both intra- and extracellular pathogenic bacteria 
are functionally indistinguishable. Microbiology, 157, 3024-3035. 
DICK, J. E. (2008) Stem cell concepts renew cancer research. Blood, 112, 4793-4807.  
DUMAS, C., LASCU, I., MORERA, S., GLASER, P., FOURME, R., WALLET, V., 
LACOMBE, M. L., VERON, M. & JANIN, J. (1992) X-ray structure of nucleoside 
diphosphate kinase. Embo J, 11, 3203-3208.  
FRITSCHE, T. R., HORN, M., SEYEDIRASHTI, S., GAUTOM, R. K., SCHLEIFER, K.-H. 
& WAGNER, M. (1999) In Situ Detection of Novel Bacterial Endosymbionts of 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 181 of 190 
 
Acanthamoeba spp. Phylogenetically Related to Members of the Order Rickettsiales. 
Appl Environ Microbiol, 65, 206–212. 
GOMEZ, L., GARAU, J., ESTRADA, C., MARQUEZ, M., DALMAU, D., XERCAVINS 
M., MARTI, J. M. & ESTANY, C. (2003) Ciprofloxacin prophylaxis in patients with 
acute leukemia and granulocytopenia in an area with a high prevalence of 
ciprofloxacin-resistant Escherichia coli. Cancer, 97, 419-424. 
GRIGORIADIS, A. E., KENNEDY, M., BOZEC, A., BRUNTON, F., STENBECK, G., 
PARK, I.H., WAGNER, E.F. & KELLER, G.M. (2010) Directed differentiation of 
hematopoietic precursors and functional osteoclasts from human ES and iPS cells. 
Blood, 14, 2769-2776. 
JANEWAY, C. A. Jr., TRVERS, P., WALPORT, M. & SHLOMCHIK, M. J. (2001) 
Immunobiology: The immune system in health and disease, Fifth ed., New York, 
Garland Science. 
HELMS, M., VASTRUP, P., GERNER-SMIDT, P. & MOLBAK, K. (2002) Excess mortality 
associated with antimicrobial drug-resistant Salmonella Typhimurium. Emerg Infect 
Dis, 8, 490-495. 
HEMERRICH, S., YARDEN, Y. & PECHT, I. (1992) A chromoglycate binding protein from 
rat mast cells of a leukemia line is a nucleoside diphosphate kinase. Biochemistry, 31, 
4574-4579. 
HEPPNER, G. H. & MILLER, B. E (1983) Tumor heterogeneity biological implications and 
therapeutic consequences. Cancer Metast Rev, 2, 5-23. 
HOFFBRAND, A. V., MOSS, P. A. H. & PETTIT, J. E. (2008) Essential Haematology, 
Oxford, Blackwell Publishing Ltd. 
HOFFMAN, R., BENZ, E. J., SHATTIL, S. J., FURIE, B., SILBERSTEIN, L. E., 
MCGLAVE, P. & HESLOP, H. (2009) Haematology: Basic Principles and Practice, 
Philadelphia, Churchill Livingstone Elsevier. 
HUANG, J. Y., CHANG, T., CHANG, C. Y. & CHEN, C. J. (2005) Crystal structure of 
nucleoside diphosphate kinase required for coleoptile elongation in rice (Oryza sativa 
L.). J Struct Biol, 150, 309-318. 
KAMATH, S., CHEN, M. L. & CHAKRABARTY, A. M. (2000) Secretion of nucleoside 
diphosphate kinase by mucoid Pseudomonas aeruginosa 8821: involvement of a 
carboxy-terminal motif in secretion. J Bacteriol, 182, 3826-3831. 
KANG, C.-I., KIM, S.-H., KIM, H.-B., PARK, S.-W., CHOE, Y.-J., OH, M.-D., KIM, E.-C. 
& CHOE K.-W. (2003) Pseudomonas aeruginosa bacteremia: Risk factors for 
mortality and inﬂuence of delayed receipt of effective antimicrobial therapy on clinical 
outcome. Clin Infect Dis, 37, 745-751. 
KERN, W. V., KLOSE, K., JELLEN-RITTER, A. S., OETHINGER, M., BOHNERT, J., 
KERN, P., REUTER S., VON BAUM, H. & MARRE, R. (2005) Fluoroquinolone 
resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects 
of discontinuing prophylactic fluoroquinolone use in neutropenic patients with 
leukemia. Eur J Clin Microbiol, 24, 111-118.KOLLI, B. K., KOSTAL, J., 
ZABORINA, O., CHAKRABARTY, A. M. & CHANG, K. P. (2008) Leishmania-
released nucleoside diphosphate kinase prevents ATP-mediated cytolysis of 
macrophages. Mol Biochem Parasitol, 158, 163-175. 
LAU, H. Y., CLEGG, S. & MOORE, T. A. (2007) Identification of Klebsiella pneumoniae 
genes uniquely expressed in a strain virulent using a murine model of bacterial 
pneumonia. Microb Pathog, 42, 148-55. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 182 of 190 
 
LEUNG, S.-M. & HIGHTOWER, L. E. A 16-kDa protein functions as a new regulatory 
protein for Hsc70 molecular chaperone and is identified as a member of the 
Nm23/nucleoside diphosphate kinase family. J Biol Chem, 272, 2607-2614. 
LILLY, A. J. (2012) The significance of extracellular Nm23-H1 protein in acute myeloid 
leukaemia and its role in regulating haemopoietic stem cell behaviour. School of 
Biosciences. Birmingham, University of Birmingham. 
LILLY, A. J., KHANIM, F. L., HAYDEN, R. E., LUONG, Q. T., DRAYSON, M. T. & 
BUNCE, C. M. (2011) Nm23-h1 indirectly promotes the survival of acute myeloid 
leukemia blast cells by binding to more mature components of the leukemic clone. 
Cancer Res, 71, 1177-1186. 
LILLY, A., JOHNSON, W. E. & BUNCE C. M. (2011) The haematopoietic stem cell niche: 
new insights into the mechanisms regulating haematopoietic stem cell behaviour. Stem 
Cells Int, 1-10. 
LISTER, M. F., SHARKEY, J., SAWATZKY, D. A., HODGKISS, J. P., DAVIDSON, D. J., 
ROSSI, A. G. & FINLAYSON, K. (2007) The role of the purinergic P2X7 receptor in 
inflammation. J Inflamm (Lond), 4, 5. 
LOWY, F. D. (2000) Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol, 
8, 341-343. 
MA, D., XING, Z., LIU, B., PEDIGO, N. G., ZIMMER, S. G., BAI, Z., POSTEL, E. H. & 
KAETZEL, D. M. (2002) NM23-H1 and NM23-H2 repress transcriptional activities 
of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter. 
J Biol Chem, 277, 1560-1567. 
MADANI, T. A. (2000) Clinical infections and bloodstream isolates associated with fever in 
patients undergoing chemotherapy for acute myeloid leukemia. Infection, 28, 367-374. 
MANDAI, M., KONISHI, I., KOSHIYAMA, M., MORI, T., ARAO, S., TASHIRO, H., 
OKAMURA, H., NOMURA, H., HIAI, H. & FUKUMOTO, M. (1994) Expression of 
metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation 
with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor 
expression. Cancer Res, 54, 1825-1830. 
MARTINEZ, J. A., PREVOT, S., NORDLINGER, B., NGUYEN, T. M., LACARRIERE, Y., 
MUNIER, A., LASCU, I., VAILLANT, J. C., CAPEAU, J. & LACOMBE, M. L. 
(1995) Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and 
loss of nm23-H1 expression in advanced tumour stages. Gut, 37, 712-720. 
MARTNER, A., DAHLGREN, C., PATON, J. C. & WOLD, A. E. (2008) Pneumolysin 
released during Streptococcus pneumoniae autolysis is a potent activator of 
intracellular oxygen radical production in neutrophils. Infect Immun, 76, 4079-4087. 
MARTY, F., YEH, W. W., WENNERSTEN, C. B., VENKATARAMAN, L., ALBANO, E., 
ALYEA, E. P., GOLD, H. S., BADEN, L. R. & PILLAI, S. K. (2006) Emergence of a 
clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of 
methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J 
Microbiol, 44, 595-597. 
MEHUS, J. G., DELOUKAS, P. & LAMBETH, D. O. (1999) NME6: a new member of the 
nm23/nucleoside diphosphate kinase gene family located on human chromosome 
3p21.3. Hum Genet, 104, 454-459. 
MILEO, A.M., PIOMBINO, E., SEVERINO, A., TRITARELLI, A., PAGGI, M. G. & 
LOMBARDI, D. (2006) Multiple interference of the human papillomavirus-16 E7 
oncoprotein with the functional role of the metastasis suppressor Nm23-H1 protein. J 
Bioenerg Biomembr, 38, 215-225. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 183 of 190 
 
MILLER, D. M., THOMAS, S. D., ISLAM, A., MUENCH, D. & SEDORIS, K. (2011) c-
Myc and cancer metabolism. Clin Cancer Res, 18, 5546-5553. 
MOREAU, A., HILL, M., THEBAULT, P., DESCHAMPS, J. Y., CHIFOLEAU, E., 
CHAUVEAU, C., MOULLIER, P., ANEGON, I., ALLIOT-LICHT, B. & CUTURI, 
M. C. (2009) Tolerogenic dendritic cells actively inhibit T cells through heme 
oxygenase-1 in rodents and in nonhuman primates. FASEB J, 23, 3070-
3077.MUNOZ-DORADO, J., ALMAULA, N., INOUYE, S. & INOUYE, M. (1993) 
Autophosphorylation of nucleoside diphosphate kinase from Myxococcus xanthus. J 
Bacteriol, 175, 1176-1181. 
MURAKAMI, M., KAUL, R., KUMAR, P. & ROBERTSON, E. S. (2009) Nucleoside 
diphosphate kinase/Nm23 and Epstein-Barr virus. Mol Cell Biochem, 329, 131-139. 
NAZARETH, H., GENAGON, S. A. & RUSSO, T. A. (2007) Extraintestinal pathogenic 
Escherichia coli survives within neutrophils. Infect Immun, 75, 2776-2785. 
NIITSU, N., OKABE-KADO, J., NAKAYAMA, M., WAKIMOTO, N., SAKASHITA, A., 
MASEKI, N., MOTOYOSHI, K., UMEDA, M. & HONMA, Y. (2000) Plasma levels 
of the differentiation inhibitory factor nm23-H1 protein and their clinical implications 
in acute myelogenous leukemia. Blood, 96, 1080-1086. 
OKABE-KADO, J., KASUKABE, T. & HONMA, Y. (2002) Expression of cell surface 
NM23 proteins of human leukemia cell lines of various cellular lineage and 
differentiation stages. Leuk Res, 26, 569-576. 
OKABE-KADO, J., KASUKABE, T., HONMA, Y., HAYASHI, M., HENZEL, W. J. & 
HOZUMI, M. (1992) Identity of a differentiation inhibiting factor for mouse myeloid 
leukemia cells with NM23/nucleoside diphosphate kinase. Biochem Biophys Res 
Commun, 182, 987-994. 
OKABE-KADO, J., KASUKABE, T., HONMA, Y., HAYASHI, M. & HOZUMI, M. (1988) 
Purification of a factor inhibiting differentiation from conditioned medium of 
nondifferentiating mouse myeloid leukemia cells. J Biol Chem, 263, 10994-10999. 
OKABE-KADO, J., KASUKABE, T., HONMA, Y., KOBAYASHI, H., MASEKI, N. & 
KANEKO, Y. (2009) Extracellular NM23 protein promotes the growth and survival of 
primary cultured human acute myelogenous leukemia cells. Cancer Sci, 100, 1885-
1894. 
OKABE-KADO, J., KASUKABE, T., HOZUMI, M., HONMA, Y., KIMURA, N., BABA, 
H., URANO, T. & SHIKU, H. (1995) A new function of Nm23/NDP kinase as a 
differentiation inhibitory factor, which does not require it's kinase activity. FEBS Lett, 
363, 311-315. 
OTERO, A. S. (2000) NM23/nucleoside diphosphate kinase and signal transduction. J 
Bioenerg Biomembr, 32, 269-275. 
PEDRA, J. H., CASSEL, S. L. & SUTTERWALA, F. S. (2009) Sensing pathogens and 
danger signals by the inflammasome. Curr Opin Immunol, 21, 10-16. 
POSTEL, E. H., BERBERICH, S. J., FLINT, S. J. & FERRONE, C. A. (1993) Human c-myc 
transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a 
candidate suppressor of tumor metastasis. Science, 261, 478-480. 
POSTEL, E. H. & FERRONE, C. A. (1994) Nucleoside diphosphate kinase enzyme activity 
of NM23-H2/PuF is not required for its DNA binding and in vitro transcriptional 
functions. J Biol Chem, 269, 8627-8630. 
QIN, Z., DAI, L., TOOLE, B., ROBERTSON, E.S. & PARSONS, C. (2011) Regulation of 
Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus. J Virol, 
85, 3596-3606. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 184 of 190 
 
ROWE, J.M. (2002) Therapy of secondary leukemia. Leukemia, 16, 748-750. 
SAHA, A. & ROBERTSON, E. S. (2011) Functional modulation of the metastatic suppressor 
Nm23-H1 by oncogenic viruses. FEBS Lett, 585, 3174-3184. 
SCHIMPFF, S. C., GREENE, F. A. C. P. W. H., YOUNG, V. M., FORTNER, C. L., 
JEPSEN, L., CUSACK, R. N. N., BLOCK, J. B. & WIERNIK, P. H. (1975) Infection 
Prevention in Acute Nonlymphocytic Leukemia Laminar Air Flow Room Reverse 
Isolation with Oral, Nonabsorbable Antibiotic Prophylaxis. Ann Intern Med, 82, 351-
358. 
SCHLICTMAN, D., KUBO, M., SHANKAR, S. & CHAKRABARTY, A. M. (1995) 
Regulation of nucleoside diphosphate kinase and secretable virulence factors in 
Pseudomonas aeruginosa: roles of algR2 and algH. J Bacteriol, 177, 2469-2474. 
SEHL, M. E., SINSHEIMER, J. S., ZHOU, H. & LANGE, K. L. (2009) Differential 
destruction of stem cells implications for targeted cancer stem cell therapy. Cancer 
Res, 69, 948-949. 
SHIZURU, J. A., NEGRIN, R. S. & WEISSMAN, I. L. (2005) Hematopoietic stem and 
progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. 
Annu Rev Med, 56, 509-538. 
SPOONER, R. & YILMAZ, O. (2012) Nucleoside-diphosphate-kinase: a pleiotropic effector 
in microbial colonization under interdisciplinary characterization. Microbes Infect, 14, 
228-237. 
TANCREDE, C. H. & ANDREMONT, A. O. (1985) Bacterial Translocation and Gram-
Negative Bacteremia in Patients with Hematological Malignancies. J Infect Diss, 152, 
99-103. 
WANG, J. C. & DICK, J. E. (2005) Cancer stem cells: lessons from leukemia. Trends Cell 
Biol, 15, 494-501. 
WANG, X., SHOOK, J., EDINGER, M., WARNER, N. & BUSH-DONOVAN, C. (2012) 
Multiparametric Immunophenotyping of Human Hematopoietic Stem Cells and 
Progenitor Cells by Flow Cytometry. BD Bioscience, 1-16. 
WILLEMS, R., SLEGERS, H., RODRIGUS, I., MOULIJN, A. C., LENJOU, M., NIJS, G., 
BERNEMAN, Z. N. & VAN BOCKSTAELE, D. R. (2002) Extracellular nucleoside 
diphosphate kinase NM23/NDPK modulates normal hematopoietic differentiation. 
Exp Hematol, 30, 640-648. 
WILLEMS, R., VAN BOCKSTAELE, D. R., LARDON, F., LENJOU, M., NIJS, G., 
SNOECK, H. W., BERNEMAN, Z. N. & SLEGERS, H. (1998) Decrease in 
nucleoside diphosphate kinase (NDPK/nm23) expression during hematopoietic 
maturation. J Biol Chem, 273, 13663-13668. 
WILSON, A. & TRUMPP, A. (2006) Bone-marrow haematopoietic-stem-cell niches. Nat Rev 
Immunol, 6, 93-106. 
WOGNUM, A.W. & SZILVASSY, S.J. (2013) Hematopoietic stem and progenitor cells. 
Stem Cell Technologies, Mini Rev, 1-8. 
YAMAGUCHI, A., URANO, T., GOI, T., TAKEUCHI, K., NIIMOTO, S., 
NAKAGAWARA, G., FURUKAWA, K. & SHIKU, H. (1994) Expression of human 
nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer, 73, 2280-2284. 
YOKOTA, T., ORITANI, K., BUTZ, S., EWERS, S., VESTWEBER, D. & KANAKURA, Y. 
(2012) Markers for Hematopoietic Stem Cells: Histories and Recent Achievements, 
Advances in Hematopoietic Stem Cell Research. IN PELAYO, R. (Ed.) Advances in 
Hematopoietic Stem Cell Research. Rikeja, In Tech. 
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 185 of 190 
 
YOKOYAMA, A., OKABE-KADO, J., SAKASHITA, A., MASEKI, N., KANEKO, Y., 
HINO, K., TOMOYASU, S., TSURUOKA, N., KASUKABE, T. & HONMA, Y. 
(1996) Differentiation inhibitory factor nm23 as a new prognostic factor in acute 
monocytic leukemia. Blood, 88, 3555-3561. 
ZABORINA, O., MISRA, N., KOSTAL, J., KAMATH, S., KAPATRAL, V., EL-IDRISSI, 
M. E., PRABHAKAR, B. S. & CHAKRABARTY, A. M. (1999) P2Z-Independent 
and P2Z receptor-mediated macrophage killing by Pseudomonas aeruginosa isolated 
from cystic fibrosis patients. Infect Immun, 67, 5231-5242. 
ZHAO, Q., LOGOTHETIS, D. E., & SEGUELA, P. Regulation of ATP-gated P2X receptors 
by phosphoinositides. Pflugers Arch, 455, 181-185. 
 
PUBMED PROTEIN DATABASE (no date) RecName: Full=Nucleoside diphosphate kinase 
3; Short=NDK 3; Short=NDP kinase 3; AltName: Full=DR-nm23; AltName: 
Full=Nucleoside diphosphate kinase C; Short=NDPKC; AltName: Full=nm23-H3. 
Available at: http://www.ncbi.nlm.nih.gov/protein/Q13232.2 (Accessed 18
th
 
September 2013).  
PUBMED PROTEIN DATABASE (no date) nm23-H7 [Homo sapiens] Available at: 
http://www.ncbi.nlm.nih.gov/protein/AAD34622.1 (Accessed 18
th
 September 2013).  
PUBMED PROTEIN DATABASE (no date) NM23-H8 [Homo sapiens]. Available at: 
http://www.ncbi.nlm.nih.gov/protein/AAF20909.2 (Accessed 18
th
 September 2013).  
PUBMED PROTEIN DATABASE (no date) Thioredoxin domain-containing protein 6 
[Homo sapiens]. Available at: http://www.ncbi.nlm.nih.gov/protein/NP_835231.1 
(Accessed 18
th
 September 2013). 
  
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 186 of 190 
 
6  APPENDIX 
6.1 BACTERIAL GROWTH MEDIA 
6.1.1 LB 
20 g dissolve in up to 1 liter dH2O 
6.1.2 LB agar  
1.2% agar in 1 liter of LB-Broth 
6.2 PCR 
6.2.1 1×PCR mix (50 μl) contained:  
27 μl dH2O,  
5 μl 10×PCR buffer (Bioline) , 
1.5 μl 50mM MgCl2 (Bioline), 
1 μl Tag polymerase (Bioline), 
1.5 μl 10 mM dNTPs. 
6.2.2 The sequence of the used primers (Sigma):  
5‟TAATACGACTCACTATAGGG3‟ (T7 forward primer),  
5‟GGCCCGTCTTCACCACAT3‟ (NM23-H1 reverse primer),  
5‟GTAGGGATCCTTATTAACGGGTGCGCGGGCACAC3‟ (E.coli rNDK reverse primer),  
„5GTAGGGATCCGATTAGCGAGTGCGGGCAAACC3‟ (K.pneumonia rNDK reverse 
primer),  
5‟GTAGGGATCCCTCTTAAAACCAAAGAGCAATTTC3‟ (S.pneumoniae rNDK reverse 
primer),  
5‟GTAGGGATCCATTTTATTCATATAACCATGCATC3‟ (S.aureus rNDK reverse 
primer).  
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6.3 AGAROSE GEL ELECTROPHORESIS 
6.3.1 1% agarose gel 
1 g agarose dissolve in 100ml 1×TBE buffer heating the mix. When mix cooled add 3 μl 
ethidium bromide 
6.3.2 1×TBE buffer 
10.8 g Tris 
5.5 g Boric acid 
4 ml 5 M EDTA pH 8.0 
Make up to 1 liter H2O 
6.4 SDS-PAGE ELECTROPHORESIS 
6.4.1 10×runing buffer 
30 g Tris (250 mM) 
144 g Glycine (1.92 M) 
10 g SDS (1%)  
Dissolve in up to 1 liter dH2O 
6.4.2 Resolving gel 12.5% (for one gel) 
3.2 ml dH2O 
2.5 ml 1.5 M Tris HCl pH 8.8 
4.2 ml ProtoGel (30% (w/v) acrylamide: 0.8% (w/v) Bis-acrylamide stack solution (37.5:1) 
100 μl 10% SDS 
50 μl 10% Ammonium persulphate 
3.3 μl N,N,N‟,N‟-tetramethyl-ethylenediamine (TEMED) 
6.4.3 Stacking gel (for one gel) 
2.03 ml dH2O 
830 μl 0.5 M Tris HCl pH 6.8 
440 μl ProtoGel (30% (w/v) acrylamide: 0.8% (w/v) Bis-acrylamide stack solution (37.5:1) 
66 μl 10% SDS 
16.7 μl 10% Ammonium persulphate 
1.7 μl TEMED 
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6.4.4 4×GLB 
3.7 ml dH2O 
1.25 ml 0.5 M Tris HCl pH 6.8 (62.5 mM) 
2.5 ml glycerol (40%) 
2.0 ml 10% SDS (2%) 
0.5 ml 2-β-mercaptoethanol 
Brilliant blue 
6.4.5 1.5 M Tris (pH 8.8) 
90.8 g Tris 
Dissolve in 400 ml, adjust pH to 8.8 
Make up to 500 ml in dH2O 
6.4.6 0.5 M Tris (pH 6.8) 
30.3 g Tris 
Dissolve in 400 ml, adjust pH to 6.8 
Make up to 500 ml in dH2O 
6.5 WESTERN BLOT 
6.5.1 Transfer buffer 
7.575 g TRis (25 mM) 
36 g glycine (192 mM) 
500 ml methanol (20%) 
Make up to 2.5 liters with dH2O 
6.5.2 TBS-T 
40 ml 1.0 M tris HCl pH 7.6 
16 g NaCl 
2 ml Tween20 
Make up to 2 liters dH2O 
6.5.3 5% Blotto (one membrane) 
2 g dried skimmed milk (5% w/v) 
40 ml TBS-T 
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6.6 COOMASSIE STAINING 
6.6.1 Coomassie stain: 
50% (v/v) methanol 
10% (v/v) acetic acid 
0.05% (w/v) Coomassie Brilliant blue 
6.6.2 Destain 
7% (v/v) acetic acid 
5% (v/v) methanol 
6.7 OTHERS 
6.7.1 Equilibration buffer 
50mM sodium phosphate (pH8) 
0.3M sodium chloride,  
10mM imidazole in H2O 
6.7.2 FACS Fix 
1% formaldehyde (v/v) 
2% FBS (v/v) 
in 500 ml PBS 
6.7.3 Giemsa buffer 
8 mM KH2PO4 
6 mM Na2HPO4 
Adjust to pH 7.0. 
6.7.4 MACS buffer 
2 mM EDTA 
1% FBS  
in PBS 
  
 MRes in Molecular and Cellular Biology 
Inara Liepina 
 
Page 190 of 190 
 
6.7.5 RIPA buffer 
1% v/v NP40 (IGEPAL) 
0.5% w/v sodium deoxycholate 0.5g 
0.1% w/v 10% SDS 1ml 
Make up to 100 ml in dH2O 
 
 
